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Following the discovery of the DISC1 gene in 2000, subsequent research has led to 
DISC1 becoming one of the most promising candidate genes for psychiatric disorders.  
Acting as a scaffold protein, DISC1 has a large number of interacting proteins and is 
involved in a series of intracellular signalling pathways.  Amongst these binding proteins 
are two enzymes, PDE4 and GSK3β, that were originally implicated in psychiatric 
disease by virtue of their inhibition by psychoactive drugs.  PDE4 enzymes are inhibited 
by rolipram, which possesses anti-depressant and anti-psychotic activity, while GSK3β 
is one of the major targets of lithium, a potent mood stabiliser.  Both these enzymes are 
intricately involved in the PI3K/AKT, cAMP, and MAPK signalling pathways, all of 
which have a number of downstream outcomes with potential relevance to psychiatric 
disorders.  The Millar and Porteous laboratory had established that DISC1 modulates 
PDE4 activity, but this predated awareness of GSK3β as another DISC1 interactor 
whose binding site overlapped with that of PDE4.  Since cAMP is a key regulator of 
signalling pathways in the brain, I hypothesised that not only DISC1, but also GSK3β 
may be involved in the regulation of PDE4 activity to control local cAMP levels and 
gradients.   
 
To investigate this hypothesis, I characterised SHSY5Y cells as a model for measuring 
PDE4 activity, and performed a series of genetic and pharmacological manipulations on 
this system.  Inhibition of GSK3β resulted in a decrease of basal PDE4 activity that was 
amplified by DISC1 overexpression.  Wild type cells that were treated with forskolin 
exhibited a significant increase in PDE4 activity, which was suppressed by GSK3β 
inhibition and both overexpression and knockdown of DISC1.  Further experiments 
confirmed that none of these changes were a result of differences in PDE4 mRNA or 
protein expression.  Thus I have provided evidence that suggests tonic activation of 
PDE4 by GSK3β and evidence for modulation of PDE4 activity by DISC1.  I provide 
evidence for the localisation of PDE4B & PDE4D with key psychiatric associated 
 vi 
receptors in structures resembling developing dendritic spines; furthermore, agonism of 
NMDA receptors results in a significant increase in PDE4 activity in primary neurons. 
 
These results are a simple demonstration of an emerging principle in psychiatric 
research: that none of the signalling pathways implicated in psychiatric disease are 
acting in isolation.  There are likely to be multiple points of integration between these 
pathways, with the demonstrated DISC1-GSK3β-PDE4 interaction forming one of these 
points.    My results add an important new element to the understanding of how the 
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1.1 Introduction to Schizophrenia 
 
Schizophrenia is a severe chronic psychiatric disorder with a lifetime risk of 1% (for a 
comprehensive review see Owen et al., 2005), carrying a total cost to English society 
estimated at £6.7 billion per year.  £2 billion of this figure accounts for direct treatment 
and care by the NHS (Mangalore R, 2007).  The incidence of the disease is increased in 
minority migrant populations and urban areas (McGrath et al., 2004).  Prevalence of the 
disease is believed to be greater in males than females throughout most of adulthood, 
with rates equalising by the end of the disease risk period, though this may be due to 
diagnostic bias (Aleman et al., 2003).   The disease is characterised by two forms of 
symptoms, which can be loosely classified as “positive,” including hallucinations, 
delusions and formal thought disorder, and “negative” symptoms of withdrawal, loss of 
volition, affective flattening and poverty of speech.  Underlying these deficits and 
predating their onset is a persistent “core” cognitive disorder (Rund, 1998) which 
correlates with daily living deficits in 50% of Scottish cases studied (Jablensky, 2006).  
These cognitive deficits affect working memory, short term and episodic memory, 
attention, and executive function, and do not alter in magnitude during psychotic 
episodes or periods of remission.  A subgroup of first degree relatives demonstrate a 
similar pattern of cognitive deficits to their affected relatives, marking these measurable 
traits as possible intermediate traits or “endophenotypes” (Asarnow et al., 2002) to aid 
genetic analysis, the rationale being that these “simpler” quantitative phenotypes may 
prove easier to link to genetic variation then the heterogenic entity of schizophrenia 
(Gottesman and Gould, 2003).   
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The aetiology of schizophrenia is still largely unknown, since it is a complex disorder 
with multiple potential susceptibility genes and environmental risk factors.  Although 
schizophrenia is highly heritable, the genetic architecture is complex, with no simple 
pattern of inheritance and no common genes of major effect (Sullivan et al., 2003).  
Despite a clear genetic influence, concordance in monozygotic twins is still only 50%, 
suggesting an important interaction of underlying genetic susceptibility with 
environmental factors (Sullivan et al., 2003).Where the balance lies between rare 
mutations of large effect and common variants of small effect is the subject of active 
debate (McClellan et al., 2007, Craddock et al., 2007), which will only be resolved by 
experimental evidence from candidate gene studies, high resolution linkage studies in 
high risk families, genome wide studies of single nucleotide polymorphisms 
(Consortium, 2009) and copy number variation (Sklar and Consortium, 2008, St Clair, 
2008) with follow-through gene resequencing and functional studies.  Indeed, several 
studies have now shown that affected individuals are more likely to harbour rare 
structural DNA variants than healthy controls (Xu et al., 2008, Walsh et al., 2008).  The 
process by which an association with a disease can be confidently proven was originally 
defined by A.B. Hill, with reference to epidemiological studies of environment and 
disease (Hill, 1965), but can be applied to modern genetics studies.  An undoubtable 
association must be strong and consistent across studies, be specific to the disease, 
expressed at the appropriate time, possess a biological gradient of effect, have biological 
plausibility that does not contradict established knowledge, and finally, show effects 
consistent with association in experimental situations (Hill, 1965).  Despite any single 
causative factor in psychiatric genetics that can fulfil all of these traditional criteria,  the 
appearance of multiple candidate genes over the last decade has led to biological 
pathways of interest for the disease, which will be crucial to advance our full 
understanding of this highly complex disorder (Porteous, 2008).   
 
With significant advances in ascertaining genes of interest in relation to schizophrenia in 
the last 20 years, the old question of the Kraepelinian divide has been re-addressed.  In 
the early 20
th
 century, Emil Kraepelin posited that dementia praecox, (which evolved 
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into the entities we know today as psychosis and schizophrenia), and manic depression 
(bipolar disorder), were two distinct diseases (Craddock and Owen, 2005).  Bipolar 
disorder is a disease characterised by the experience of one or more manic episodes, 
during which patients can experience an excess of energy, a lack of need for sleep, 
inflated self esteem, and an increased participation in potentially risky behaviour.  These 
manic episodes are interspersed with periods of depression (hypomania), where a patient 
can experience a range of symptoms including anhedonia, fatigue, insomnia, weight loss 
and a diminished ability to concentrate (DSM IV diagnostic criteria).  Despite the fact 
that the symptoms of these two conditions often overlap, and can be different to 
confidently diagnose, the notion of this diagnostic divide has continued.  It is only in the 
last 10 years, with the availability of information about the genetics underlying the 
susceptibility to these two conditions, that the aetiology increasingly appears to share 
common features.  In a large Scottish family, covered in greater detail below, where 
disruption of the gene DISC1 is believed to be a causal event, there are cases of not only 
bipolar disorder and schizophrenia, but also major depression (Blackwood et al., 2004).  
Association studies on this same gene have shown multiple associations with bipolar 
disorder and schizophrenia in different populations (see Chubb et al., 2008 for a detailed 
review).  Whole genome scans of both disorders highlight some common chromosomal 
regions of susceptibility (Ferreira et al., 2008, Green et al., 2009), while standard 
association studies reveal that the D-amino oxidase activator gene and NRG1 are 
associated with both disorders (reviewed Craddock et al., 2005).  A spectacularly large 
Swedish family study using registries encompassing the entire Swedish population finds 
that first degree relatives of probands with schizophrenia have an increased risk of 
developing bipolar disorder, and vice versa (Lichtenstein et al., 2009).  This landmark 
study not only suggests some shared genetic aetiology for the diseases, but also suggests 
a small impact of shared environmental features.  With this rapidly progressing 
evidence, there is a large movement to start viewing psychiatric disorders as a spectrum, 
perhaps with multiple dimensions.  Where a patient is placed on this spectrum may be 
dictated by the particular combination of risk alleles they possess, and their exposure to 
environmental sources of risk.  This concept will be revisited throughout this thesis, as 
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evidence from studies of bipolar disorder treatment, schizophrenia genetics, and basic 
molecular biology are combined to try and further dissect signalling pathways that may 
go awry in these conditions. 
 
1.2 Introduction to DISC1 
1.2.1 DISC1 – The Initial Discovery 
The story of DISC1, one of the strongest candidate susceptibility gene for schizophrenia 
began 20 years ago, with the report of a large Scottish family (Stclair et al., 1990) 
carrying a balanced translocation at (1;11)(q42;q14.3) which associates with various 
major psychiatric disorders, including schizophrenia (Blackwood et al., 2001).  Of the 
87 karyotyped family members, 37 carry the translocation, and 29 of these carriers has a 
psychiatric diagnosis.  In the most recent study of this family, 7 of these carriers were 
diagnosed with schizophrenia, 10 with recurrent major depression, and one with bipolar 
disorder.  There was also one case each of anxiety, alcoholism and minor depression, 
and two cases of adolescent conduct disorder.  Linkage studies gave a maximum LOD 
score of 7.1 for segregration of the translocation with a broad clinical phenotype 
encompassing schizophrenia, recurrent major depression and bipolar disorder.  All tested 
carriers of the translocation exhibit a reduced P300 event related potential, a 
measurement of attention dependant information processing impaired in non 
translocation carrying schizophrenics (Blackwood et al., 2001).  Thus, inheritance of the 
translocation results in functional brain deficits in all carriers.  The translocation 
breakpoints were cloned and the gene named Disrupted in Schizophrenia-1 identified as 
directly disrupted by the breakpoint on chromosome 1 (Millar et al., 2000).  Also 
interrupted by the translocation is a non coding RNA gene located antisense to DISC1, 
named Disrupted in Schizophrenia 2 (Millar et al., 2000). 
 
1.2.2 An overview of DISC1 genetic studies 
Studies in the wider population have so far failed to reach a consensus as to a single 
causative SNP or haplotype in the DISC1 gene, but an ever increasing number of 
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positive findings in genetic linkage and association studies suggest a role for DISC1 
allelic heterogeneity in not only schizophrenia, but also in a wider spectrum of 
psychiatric diagnoses including bipolar disorder and major depressive disorder 
(Reviewed in Chubb et al., 2008).  It is important to state there have also been negative 
association findings (Devon et al., 2001, Kockelkorn et al., 2004, Zhang et al., 2005). 
Since this review, the first round of the CATIE (Clinical Antipsychotic Trials of 
Intervention Effectiveness, a large scale and multi-faceted schizophrenia study funded 
by the National Institute of Mental Health and co-ordinated by the University of North 
Carolina) schizophrenia Genome Wide Association Study (GWAS) shows a trend 
towards positive results for DISC1, but this result does not reach genome wide 
significance (Sullivan et al., 2008).  There are also positive findings in a GWAS for late 
onset Alzheimer disease (Beecham et al., 2009).  Other GWAS results have proved 
negative with respect to DISC1 (O’Donovan et al., 2009).  Despite this, the weight of 
positive evidence in favour of DISC1 variants conferring susceptibility to psychiatric 
disorders in the general population is increasingly convincing.    
 
Association studies concerning neurophenotypes outwith psychiatric disorders are also 
interesting, suggesting a more generalised role for DISC1 in disease with cognitive 
deficits or a potential neurodevelopmental component.  A Finnish group report evidence 
that associates a DISC1 haplotype and microsatellite within intron 9 previously 
associated with schizophrenia, with males with autistic spectrum disorders and Asperger 
syndrome (Kilpinen et al., 2007).  Given the core cognitive disorder present in 
schizophrenic cases, other groups are working to find potential effects of DISC1 on 
subclinical measures of cognitive ability.  Again this is well reviewed by Chubb et al, 
2008, but as a short summary, various studies report linkage or association between 
DISC1 variants and impaired cognitive function in both schizophrenic and normal 
individuals.  Most notably, the HEP haplotypes originally introduced by Hennah 
(Hennah et al., 2003) are variably associated with reduced pre frontal cortex grey matter, 
impaired long term memory and impaired working spatial memory (Cannon et al., 
2005).   
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A lot of focus thus far has been on the DISC1 Ser704Cys polymorphism, which 
associates with schizophrenia, schizoaffective disorder and major depression in various 
populations (Callicott et al., 2005, Hashimoto et al., 2006, Qu M and Tang F, 2007).  
Healthy subjects carrying the Cys allele show decreased hippocampal grey matter 
volume in a North American population (Callicott et al., 2005), and an Italian population  
(Di Giorgio, 2008)an increased volume of medial superior frontal gyrus and short insular 
cortex in one Japanese population (Takahashi et al., 2009).  A further Japanese 
population shows decreased grey matter volume in the cingulate cortex, cingulate and 
posterior gyrus, with reduced white matter integrity in PFC (Hashimoto et al., 2006).  
Interestingly, this study also reports lower extracellular signal relate kinase (ERK) 
activity associated with the Cys allele (Hashimoto et al., 2006).  In the former Japanese 
study, schizophrenic Cys carriers have a smaller supramarginal gyrus, and the volume of 
the right medial superior frontal gyrus correlates with neuroleptic dosage in Ser 
homozygotes (Takahashi et al., 2009).  Finally, the Italian study, in attempting to 
connect structural differences to function, found that Ser homozygotes show increased 
hippocampal activity, with enhanced connectivity between the formation and the right 
middle frontal gyrus during a memory encoding task, despite there being no genotype 
associated difference in task performance (Di Giorgio, 2008).  There are relatively weak 
indications of a detrimental effect of this allele on normal cognitive ageing in females in 
a Scottish cohort of subjects (Thomson et al., 2005).  It is not yet clear whether this 
variant is significant in itself, or whether it acts to tag a haplotype responsible for the 
phenotypes observed. 
 
Recently, the theory that variation in multiple schizophrenia susceptibility genes may 
interact to heighten the risk of schizophrenia in an individual has become popular.  To 
this end, combinatorial studies involving DISC1 have begun, focusing originally on 
NDE1 and NDEL1, two well established protein binding partners.  The first of these 
studies shows genome wide linkage to schizophrenia with a marker close to NDE1, 
when data is conditioned on a background of the previously identified HEP3 DISC1 risk 
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haplotype.  Further study of 4 tagging SNPs within NDE1 produces 2 SNPs with a 
putative association, but these fail to survive Bonferroni correction (Hennah et al., 
2007).  In a different approach, a hypothesis driven study finds two major NDEL1 
haplotypes, one of which is more commonly transmitted in healthy controls.  On 
conditioning on a background of DISC1 risk (hetero or homozygosity for the Cys allele), 
there is a significant effect of NDEL1 haplotype (via a tagging SNP, rs1391768) on 
schizophrenia risk in Ser homozygotes.  Conversely, the genotype at rs3784859 in 
NDE1 shows a putative effect on schizophrenia risk only in combination with a Cys 
carrying background.  This leads to the hypothesis that NDE1/NDEL1 genotype may 
effect the efficacy of protein binding to DISC1 (Burdick et al., 2008).  Finally, an 
interaction between NRG1 and DISC1 SNPs has been observed: the T/T genotype of 
rs2793092 in DISC1 only shows an association with increased lateral ventricle volume 
in schizophrenic patients on a background of their also carrying the T allele of 
rs6994992 in NRG1 (Mata et al., 2009).   
 
Functional studies of the Ser704Cys SNP suggest that the Cys variant increases the 
propensity of DISC1 to form oligomers (Leliveld et al., 2009).  The variant lies within 
the oligomerisation region of residues 668-747 as defined by Leliveld et al, 2009.  
Overexpression of the Cys variant results in a subtle decrease of NDEL1 binding in 
human neuroblastoma cultures in comparison to Ser variant overexpression (Leliveld et 
al., 2009).  This result is in agreement with earlier work which suggested that the Cys 
variant of DISC1 interacts more strongly with NDEL1 in yeast-2-hybrid screening, and 
shows a mild trend towards a decreased DISC1-NDEL interaction as measured by co-
immunoprecipitation (Kamiya et al., 2006).  Thus, a DISC1 variant that is related to 
psychiatric disease by genetic association may affect both DISC1 function, and the 
function of a different, interacting protein.  This finding may begin to explain the 
interplay between SNPs in these proteins.       
 
There are three more disparate pieces of evidence to add to the genetic association of 
DISC1 with psychiatric disease.  The first of these derives from a relatively new field of 
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genetic study: that of copy number variation (CNV).  These variations vary in size, and 
encompass deletions, insertions and duplications of sections of DNA.  The first major 
study published investigating this phenomenon reveals a gain of sequence in DISC1 in a 
mother and her child, but no psychiatric diagnosis is reported for these subjects (Redon 
et al., 2006).  Further evidence of the presence of CNVs is required to judge the 
significance of this kind of variation in DISC1.  The next piece of evidence is the 
presence of ultra rare structural variants in DISC1 that may lead to disease.  Deep 
sequencing was performed on likely regions of functional significance in DISC1 in 288 
schizophrenia patients and controls.  As well as detecting the common variants used in 
association studies, Q246R, S704C and L607F (the former two of which were weakly 
associated with schizophrenia in this cohort), six patients are found to carry ultra rare 
schizophrenia specific mutations (R37W, S90L, T603I, G14A and R418H) not present 
in a scan of 10,576 control alleles.  The authors attribute 2% of the risk for 
schizophrenia to these ultra rare variants (Song et al., 2008).   
 
The final piece of genetic evidence comes from a large body of work characterising the 
various isoforms of DISC1 (Nakata et al., 2009).  Over 50 full length DISC1 transcripts 
are identified from post mortem human brain using a combination of PCR, long range 
PCR and sequencing and 3 and 5’ RACE.  Expression of transcripts with deletions of 
exon 7 and 8, and a short variant transcript (Esv) is significantly increased in 
schizophrenic hippocampi.    Furthermore, the expression of the transcript lacking exon 
3 is significantly associated with the homozygous A allele at intronic SNP rs821597, and 
possession of the phenylalanine variant of L607F or homozygosity for the Cys variant of 
S704C leads to increased expression of the transcript lacking exons 7 and 8 (Nakata et 
al., 2009).  This experiment is exciting, as it links two previously unassociated DISC1 
risk SNPs to a potential mechanism, suggesting how structural changes may lead to 
differential DISC1 expression, and thus pathological physiology.  In their earlier study, 
possession of DISC1 risk variants (C at hCV219779, G at rs821597 and A at rs821616) 
led to significantly decreased mRNA expression of the DISC1 interacting proteins 
FEZ1, LIS1 and NUDEL in post mortem hippocampus (Lipska, 2006).  Independent of 
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genotype, mRNA was decreased for each of these three proteins in the hippocampus of 
schizophrenic patients, and showed a trend towards a mild decrease in the dorso-lateral 
prefrontal cortex (DLPFC) (Lipska, 2006).  
 
To summarise, the genetic evidence for the potential role of DISC1 in predisposition not 
only to schizophrenia, but to other major psychiatric and cognitive disorders is 
increasingly convincing.  Up to January 2009, 24 association studies of DISC1 and 
schizophrenia had been performed – 15 of these reported positive association (Lakhan 
and Kramer, 2009).  Genetic and phenotypic evidence (both from MRI and performance 
in behavioural tests) suggests a distinct role for DISC1 in normal hippocampal function.  
The fact that there has been no single causative and biologically explainable finding to 
account for the role of DISC1 in all patients suggests one of two prospects – either that 
there is allelic heterogeneity, with multiple variations within the gene resulting in 
susceptibility in different cases, or that the markers studied thus far are in high linkage 
disequilibrium with a true causative variant.  Evidence thus far, most strikingly the 
failure to narrow down the area of interest within the DISC1 gene to a specific region, 
and the new evidence for ultra rare causative variants, suggests that allelic heterogeneity 
is the more likely explanation.  This suggestion has yet to reach full acceptance in the 
psychiatric genetic community, but is seen in other conditions such as Cystic Fibrosis, 
where almost 1300 disease causing mutations have been reported in the CFTR gene (des 
Georges et al., 2004).  It is hoped that deep sequencing of DISC1 will add significantly 
to knowledge in this area. 
 
1.2.3 DISC1 splice variants 
The human DISC1 gene contains 13 exons which produce a full length transcript of 
7.5kb  (Millar et al., 2001).  The number of DISC1 isoforms reportedly produced by this 
transcriptionally complex locus is still under discussion.  There are 4 robustly confirmed 
human isoforms: “Long” (L), encoded by all 13 exons, “Long variant” (Lv) arising from 
an alternative splice site in exon 11, “Short” (S) arising from utilisation of an alternative 
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splice site in exon 9, and  “Extremely short” (Es) which skips the exon 3 donor splice 
site thus converting exon 3 into an alternative terminal exon (Chubb et al., 2008). A 
combination of PCR on mRNA extracted from human hippocampus and 3’ and 5’ 
RACE identified up to 54 different isoforms with a varying expression profile. (Nakata 
et al., 2009).  PCR with a series of primers produced five unpredicted products.  These 
fragments were sequenced to reveal two products skipping exon 3 and exons 7 and 8, 
and three that end with an alternate exon 3.  5’ RACE revealed products with first exons 
corresponding to the reported exon 1 of DISC1 or exon 1 of the adjacent Translin-
associated factor X gene (TSNAX).  3’ race gave rise to products with ten alternate final 
exons (Nakata et al., 2009).  Not all of these variants are predicted to result in protein 
expression, as many contain a premature stop codon. 
1.2.4 DISC1 Protein structure 
The initial predicted structure for DISC1 was consistent with the hypothesis that it acts 
as a scaffold protein, having a globular head domain and an α-helical tail domain with 
numerous coiled coil protein binding sites and localisation signals (Millar et al., 2000).  
Further multiple sequence alignment work shows that the C terminus is more conserved 
throughout species than the N terminus region (Taylor et al., 2003).  Despite this lack of 
conservation the N terminus domain is predicted to contain a nuclear localisation signal 
and an alpha helix.  The remainder of the N terminus has multiple areas of low sequence 
complexity, or “disorder”, which display a lack of folded structure with high flexibility 
(Figure 1.1, taken from Chubb et al, 2008).  Contrary to original beliefs on the subject of 
disorder, this characteristic may actually be intrinsic to the function of the protein, 
allowing it to adopt a more ordered conformation on binding of further proteins (Tompa, 
2002).  The C-terminus of DISC1 also contains several self association domains, 
allowing for the formation of stable dimers and more labile oligomers (Leliveld et al., 




Figure 1.1 is taken from Chubb et al 2008, and is a simple summary of the 
structure of DISC1.  The largely disordered N-terminal head domain contains a 
nuclear localisation signal, while the C terminal consists of a series of coiled coil 
domains implicated in protein binding and self association. 
 
1.2.5 DISC1 Tissue Expression 
DISC1 expression is not confined to the brain. Detailed discussion of mRNA and protein 
localisation in human and non human tissue can be found in Chubb et al 2008, thus this 
brief overview summarises mostly studies on human tissue.  Northern blots demonstrate 
strong DISC1 mRNA expression in adult heart, widespread brain regions, placenta, and 
weak expression in the kidney and pancreas (Millar et al. 2000).  RT-PCR demonstrates 
the expression of DISC1 in human foetal brain (Millar et al., 2000, James et al., 2004).  
Further work at the protein level confirms the presence of DISC1 in foetal brain, heart, 
limbs, kidney and lung (James et al., 2004).   
 
RNA-based studies demonstrate strong expression of DISC1 transcripts in numerous 
human brain regions, including the amygdala, caudate nucleus, corpus callosum, 
hippocampus, substantia nigra, sub thalamic nucleus, thalamus, cerebellum, cerebral 
cortex, medulla, spinal cord, occipital pole, frontal and temporal lobes and the putamen 
(Millar et al., 2000).  Despite the widespread expression of DISC1 with regards to brain 
regions, expression appears to be restricted to specific cell types within these areas 
(James et al., 2004).   
 
 12 
In mouse studies, robust expression of DISC1 mRNA and protein was found throughout 
the developing hippocampus from E14, the first stage at which the hippocampus 
becomes discernable (Meyer and Morris, 2008, Austin et al., 2004).  At E18 and P1 
there is high DISC1 protein expression in the developing dentate gyrus and granule cell 
precursors.  By P5 and P14 there is a well defined pattern of expression in Ammon’s 
Horn and the dentate gyrus, one of the regions where adult neurogenesis occurs.  In this 
neurogenic niche, DISC1 colocalises with Ki67, a marker of proliferation in the cells of 
the subgranular zone (Meyer and Morris, 2008).  DISC1 is also robustly expressed in the 
other area responsible for adult neurogenesis, the subventricular zone, where it 
colocalises with neural progenitors expressing nestin and Sox2 (Mao et al., 2009).  In the 
adult human, strong expression of DISC1 mRNA is observed in a subset of granule cells 
within the dentate gyrus, and weaker expression seen in hippocampal pyramidal cells in 
layers CA1-3 (James et al. 2004), both areas consistently associated with schizophrenia 
(Weinberger, 1999).  Thus, DISC1 is highly expressed in the hippocampus, one of two 
areas of the brain that continues to undergo neurogenesis in the adult brain.  
Neurogenesis has been strongly implicated in psychiatric disease, a topic which I shall 
briefly discuss later in this introduction. 
 
1.2.6 DISC1 developmental expression 
Quantitative western blotting of mouse cortical lysate shows abundant presence of a 
75kDa isoform of DISC1 throughout development.  A 75kDa isoform shows low 
expression neonatally, but expression is upregulated at P25 and remains high until the 
final timepoint tested (6 months).  A 105kDa isoform has continually low expression, 
whereas a 100kDa form has two peaks at E13.5 and P16.5.  Expression of the 100kDa 
form also remains high after this second peak (Schurov et al., 2004).  Interestingly, these 
peaks correspond to the occurrence of neurogenesis and neural migration and puberty in 
the mouse, both thought to be critical timepoints in schizophrenia pathogenesis (Lewis 
and Levitt, 2002).   This work in mouse broadly concurs with similar studies in rat 
(Ozeki et al., 2003).  In human dentate gyrus, prefrontal cortex and temporal cortex, a 
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riboprobe detecting exons 2-10 of DISC1 (and hence not the short forms) showed 
significantly increased expression from neonatal development to infancy, a marked 
decrease in expression by teenage years, and a more gradual decline of expression with 
age (Lipska et al., 2006).   In humans therefore, the postnatal increase in DISC1 
expression seems to come earlier than the corresponding timepoints in mouse: infancy 
versus puberty.   
 
The more recent work describing the 54 putative splice variants of DISC1 also suggests 
differential regulation of DISC1 mRNA transcripts throughout human development, as 
seen in murine studies of protein.  The transcripts skipping exons 3, 7 and 8 and the 
extra short variant are expressed more highly in the pre frontal cortex during gestation, 
and drop to continuously low levels throughout postnatal development and ageing 
(Nakata et al., 2009).  Expression of longer transcripts follows a similar pattern, but the 
decline in expression is less severe.  No peak in expression was seen postnatally.  There 
is an effect of genotype at the intronic SNP, rs821597, on expression of short transcripts, 
where A/A homozygotes showed no decrease in short transcript expression with age.  A 
similar but non significant trend was observed with variation at Ser704Cys (Nakata et 
al., 2009).   Although there are some inconsistencies in this work, it is evident that 
isoform specific temporal regulation of DISC1 occurs throughout development.  Further 
reconciliation of mRNA splice variants with putative protein products and their 
migration on gels will be required to reconcile these profiles into a complete 
developmental picture.  DISC1 is therefore expressed throughout the brain during key 
events in development, neural migration, neurogenesis and synaptic pruning in 





1.2.7 DISC1 subcellular localisation 
Light microscopy on post mortem human cortical samples shows prominent multi layer 
staining of pyramidal and non pyramidal neuronal cell bodies throughout the grey 
matter.  This pattern does not appear to vary specifically between the four Brodmann 
areas studied.  Electron microscopy shows frequent localisation of DISC1 to chromatin 
and ribosomes (Kirkpatrick et al., 2006).  Unlike other studies (James et al., 2004, Ozeki 
et al., 2003, Millar et al., 2005a, Brandon et al., 2005), this one shows no localisation of 
DISC1 to the mitochondria.  This difference may be important to note, Kirkpatrick et al, 
2006 uses an antibody which is not employed in further publications.  Light microscopy 
shows diffuse staining of the neuropil in both grey and white matter in these brain 
regions.  Visualisation of these areas by electron microscopy localises the majority of 
DISC1 to synaptic structures including the axon terminals, the post synaptic density and 
dendritic spines.  Staining is heterogenous, with only a proportion of the aforementioned 
structures expressing DISC1 (Kirkpatrick et al., 2006).  DISC1, PDE4B, and their 
interactors NDEL1 and LIS1 are all present in synapse related cellular fractions 
(Clapcote et al., 2007, Niethammer et al., 2000), and exogenous protein colocalises to 
some extent with PSD95 in primary hippocampal neurons (Bradshaw et al., 2008).  
Further fractionation experiments demonstrate the presence of a 200kDa DISC1 
immunoreactive protein in the core post synaptic density fraction, while a 75kDa band 
was found in large quantities in the synaptosome and vesicle enriched fraction 
(Bradshaw et al., 2008).  It is generally accepted that at least a proportion of the 
pathophysiology of schizophrenia arises from dysfunction of the synapse (Harrison et 
al., 2005).   
 
Subcellular expression of DISC1 protein varies between the cell types studied, and the 
antibodies used.  Generally, DISC1 is predominantly cytoplasmic, and colocalises with 
markers for the mitochondria, cytoskeleton and centrosome.  The major studies of 
DISC1 subcellular localisation in other cell types have been reviewed in great detail by 
Chubb et al, 2008.  In primary cortical neurons, there is endogenous centrosomal 
localisation of DISC1 (Kamiya et al., 2005).  In fact, DISC1 has been implicated in the 
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maintenance of the NUDEL/LIS1/Dynein complex at the centrosome, playing an 
important role in neural migration (Kamiya et al., 2005).  Endogenous DISC1 is also 
present in a perinuclear distribution in primary cortical neurons (Brandon et al., 2005), 
and distributed in a punctate fashion with significant colocalisation with the 
mitochondrial marker HSP70.  Overlap of expression with microtubular markers (MAP2 
and α-tubulin) and disturbance of mitochondrial localisation post depolymerisation 
treatment shows association of DISC1 with microtubules in mouse cortical neurons 
(Brandon et al., 2005), and in rat hippocampal neurons (Taya et al., 2007).  DISC1 is 
part of a molecular complex with KIF5A, LIS1, 14-3-3ε and NUDEL localised in the 
centre of axonal growth cones in d.i.v.3 rat hippocampal neurons.  Some signal occurs in 
the peripheral and transitional regions of the growth cone (Taya et al., 2007).  Finally, 
DISC1 has a conserved nuclear localisation signal (Brandon et al., 2005, Ma et al., 
2002), has been detected in P1 nuclear subcellular fractions from brain and neural 
derived cell lines (Sawamura et al., 2005, Ozeki et al., 2003, James et al., 2004) and 
visualised in the nucleus by immunocytochemistry in SHSY5Y cells (James et al., 
2004).  This multi-compartmentalisation of DISC within the cell suggests that it may 
perform different roles and bind different proteins in the different cellular components, 
and thus have roles in a number of cellular processes.  DISC1 dysfunction therefore, is 
likely to have multiple consequences for cellular function. 
 
1.3 DISC1 Biological Function 
Considering that next to nothing was known about the protein product of the DISC1 
gene when it was first cloned in the year 2000, the explosion of studies, including animal 
models, in vitro biochemistry and cell culture experiments has been immense.  As it 
stands in January 2010, over 250 papers are brought up by searching for “DISC1” on 
Pubmed, and in 2009 just over 1 paper per week was published on the subject.  It is 
therefore impossible to cover every aspect of DISC1 biology in this review.  As such, in 
this review I will focus on the evidence suggesting the potential for DISC1 to be 
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involved in modulation of intracellular signalling, referring to reviews and key pieces of 
work that fall outside this remit that can be consulted for further information.  
 
1.3.1 The DISC1 interactome 
Acknowledgement of the putative DISC1 structure as a scaffold protein led to multiple 
screens of various methods for potential protein interactors (Morris et al., 2003, 
Camargo, 2006, Miyoshi et al., 2004, Brandon et al., 2004, Millar et al., 2003, Ozeki et 
al., 2003, Shinoda et al., 2007 Taya, 2007 #221).   The majority of work has been done 
via yeast-2-hybrid screening, with Shinoda (Shinoda et al., 2007) and Taya (Taya et al., 
2007) publishing results from affinity chromatography and mass spectroscopy.  Several 
proteins have been replicated in two or more of these original screens, or followed up 
via co-localisation, co-immunoprecipitation and GST pulldowns. Notable amongst these 
replicated results are PDE4B, ATF4 and 5, KIAA1212 (also named Girdin, AKT 
phosphorylation enhancer) LIS1, NDEL1 and NDE1, dynactin, SMARCE1, AKAP9, 
14-4-3ε, Grb2, Spectrin, MIP-T3, SPTAN1 and EIF3.   The reported interactors fall into 
8 main gene ontology functional categories, namely; cell cycle regulation, RNA 
processing, transcription regulation, inter membrane and vesicle transport, cytoskeletal 
and membrane integrity, microtubule movement, and pertinently for this work, signal 
transduction and neural migration.  Since these protein binding screens, further 
functional investigation of DISC1 has revealed a series of other interactors, the most 
interesting in this respect being glycogen synthase kinase 3β (GSK3β)(Mao et al., 2009). 
 
These screens have raised an infinite number of future directions for research into the 
functions and potential role in the pathophysiology of schizophrenia of DISC1.  The 
remit of this project being to investigate the potential for DISC1 to be involved in 
intracellular signalling, I will focus two of the interactors already known to mediate such 
pathways: the phosphodiesterase-4 protein family and GSK3β.       
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1.3.2 The Phosphodiesterase-4 family as DISC1 interactors 
Yeast-2-hybrid screening with full length DISC1 demonstrates an interaction with 
PDE4B (Camargo, 2006),  one member of a large family of 20 PDEs (Smith and Scott, 
2006) which form the sole means of inactivating cAMP within the cell (Duman, 2002, 
Alberini et al., 1995).  Local sculpting, both spatially and temporally, of cAMP gradients 
is crucial for normal cellular function, having implications for downstream enzyme 
activation and gene expression (Houslay, 2010).  PDE4 is also the target of the 
prototypical antidepressant Rolipram (Dyke and Montana, 2002), and its significance in 
psychiatric disease pathophysiology will be covered in detail later in this introduction.  
PDE4 isoforms have the same basic structure, but contain unique N-terminal domains 
responsible for specific targeting to cellular locations, as detailed in Figure 1.2 (Houslay 
and Adams, 2003).  Conventional and confocal microscopy in SHSY5Y cells and rat 
primary hippocampal cells shows colocalisation of endogenous PDE4B and the 71kDa 
isoform of DISC1 (Millar et al., 2005b).  Exogenous FLAG tagged PDE4B colocalises 
with myc tagged DISC1 in dendritic spine structures when expressed in mature mouse 
neurons (Bradshaw et al., 2008).   
 
Figure 1.2, adapted from Burgin et al, 2010, shows the structure of a PDE4 long 
form.  Long forms of PDE4 consist of a unique N-terminus region responsible for 
cellular targeting, two upstream conserved regions (UCRs) which act to 
modulate access to the catalytic site, a catalytic domain and C-terminus.  Short 
forms may lack one of the UCR domains.  PDE4 long forms have both a PKA 






Co-immune precipitation experiments strengthen the evidence for an interaction between 
the PDE4s and DISC1, but have also complicated the matter.  All 4 human isoforms of 
PDE4 (A-D) precipitate with exogenous 100kDa full length DISC1 in HEK293 cells.  
On cAMP elevating treatment with IBMX (non specific PDE inhibitor) and forskolin 
(stimulates adenylate cyclase), PDE4C2 and PDE4D3 show a marked decrease in 
interaction with full length DISC1, releasing a PKA phosphorylated active PDE4 
enzyme (Murdoch et al., 2007).    This is in contrast to previous work on endogenous 
71kDa DISC1, where PKA phosphorylated active PDE4B is released from DISC1 upon 
the same treatment of SHSY5Y cells (Millar et al., 2005b).  Further investigation shows 
no release of long or short PDE4B isoforms from full length DISC1 upon cAMP 
elevation in HEK293 and SHSY5Y cells (Murdoch et al., 2007).  This clearly has 
implications for compartmentalised and tightly regulated signalling, as the presence of 
certain isoforms of DISC1 and PDE4 in varying cellular locations will have different 
outcomes for PDE4 activity. 
 
Early interaction experiments with deletion constructs implicated the N terminal head 
region of DISC1 and the UCR2 domain of PDE4B, as being sufficient for DISC1 
binding (Millar et al., 2005b).  Peptide array binding assays of 25mers of overlapping 
full length DISC1 sequence probed with MBP-PDE4B1 and MBP-PDE4D3 show 2 
binding sites common to both probes, corresponding to amino acids 190-230 and 611-
650.  The first probe region is within that previously identified by deletion constructs.  
The PDE4B1 and a further PDE4B2 probe interacts with three additional regions of 
DISC1, residues 31-65, 101-135 and 266-290 (Murdoch et al., 2007).  These results are 
confirmed in vitro using pull down of GST fusion proteins.  Probing of DISC1 arrays 
with regions of PDE4D3 led to confirmation of the UCR2 domain as the first of the 
common binding sites.  The catalytic unit of PDE4D3 identifies the second common site.  
Reciprocal arrays of PDE4D3 and PDE4B1 confirm these results as common DISC1 
binding sites between B and D isoforms, and, intriguingly, found an additional specific 
binding site in the catalytic site of both PDE4B1 and PDE4D3.  If the PDE4B specific 
 19 
DISC1 site is removed through N terminal truncation of PDE4B, cAMP dependant 
release from DISC1 occurs (Murdoch et al., 2007).   
 
An early model was proposed where DISC1 binds an inactive form of PDE4.  An 
increase in intracellular cAMP activates PKA, which phosphorylates PDE4, resulting in 
its release in an active form from DISC1 (Millar et al., 2005b). Of course, this model is 
now complicated by the fact that this cAMP dependant release appears to be isoform 
specific (Murdoch et al., 2007). Recent work has attempted to solve the crystal structure 
of PDE4B and PDE4D when bound to the PDE inhibitors RS25344 and PMNPQ.  The 
catalytic site of PDE4D7 contains a helical structure with a phenylalanine residue 
protruding from UCR2 into the active site.  In PDE4B the corresponding residue is a 
tyrosine.  This residue interacts with the inhibitors, suggesting an excellent target for 
subtype specific PDE4 inhibitors.  The position of the UCR2 domain appears to be vital 
for PDE4 activity changes: antibodies targeting UCR2 can inhibit PDE4 activity alone.  
There are multiple residues in the UCR2 domain capable of interacting with the groove 
of the catalytic site.  When these residues are mutated the affinity of the two inhibitors 
for PDE4 is decreased.  Full and partial PDE4 inhibitors seem to act by “closing” the 
UCR2 domain across the active site of PDE4 (Burgin et al., 2010).  DISC1 interacts with 
the UCR2 domain of PDE4B and PDE4D, and the catalytic domain of PDE4D 
(Murdoch et al., 2007).  It is thus possible that DISC1 acts to inhibit PDE4s in a similar 
fashion to pharmacological inhibitors, and that PKA phosphorylation is capable of 
disrupting this interaction.     This model does not however explain the varying 
susceptibility to release observed in biochemical experiments. 
 
1.3.3 GSK3β as a DISC1 interactor  
Unlike the previous three proteins, GSK3β was revealed as a DISC1 interactor by 
functional studies, not interaction screens.  Knowledge that DISC1 expression peaks at 
E14-E15 in mice (Schurov et al., 2004), a period which coincides with neurogenesis, led 
to investigations of a putative role for DISC1 in cell proliferation.  DISC1 knockdown 
 20 
decreases, and overexpression increases proliferation of hippocampal progenitor cells 
both in vitro and in vivo.  These effects are mediated via β-catenin and the Wnt 
signalling pathway, one of the major targets of the enzyme GSK3β (Mao et al., 2009).  
Indeed, DISC1 knockdown results in an increase in the activating autophosphorylation 
of GSK3β, while overexpression has the opposite effect.  GSK3β coimmunoprecipitates 
with DISC1 from E14 mouse brain lysate, and binds directly to fragments 1-120 and 
356-595 of DISC1 in a GST pulldown (Mao et al., 2009).  The first DISC1 fragment, 
when mixed with purified GSK3β, β-catenin and axin (2 substrates), potently inhibits 
GSK3β autophosphorylation and downstream phosphorylation of β-catenin and axin.  
Fragments 221-355 and 356-595 have the same effect, but only at higher concentrations.  
In fact, a smaller peptide encompassing the highly conserved DISC1 residues 195-238 
inhibits GSK3β autophosphorylation more potently than the commercial GSK3β peptide 
inhibitor L803-mts (Mao et al., 2009).  Thus, not only does DISC1 appear to bind 
GSK3β, but it also has functional effects on the activity level of the enzyme, suggesting 
implications for downstream signalling of GSK3β mediated pathways.  Indeed, DISC1 
knockdown decreased the proliferation rate in adult hippocampal progenitor cells in 
vitro and in vivo.  This effect was mediated via stabilisation of β-catenin, and rescued by 
overexpression of human DISC1 cDNA or pharmacological inhibition of GSK3β.  
Overexpression of DISC1 led to increased cell proliferation, again both in vivo and in 
vitro (Mao et al., 2009).   
 
1.4 Animal models of DISC1 function  
 
The validity of mouse models for such a uniquely human disease as schizophrenia has 
been discussed ad nauseum – how is it possible to model behaviour so intertwined with 
human senses and verbal communication in an animal?   Although this is presently 
addressed in animal studies using very well characterised behavioural paradigms, with a 
large battery of controls for sensory deficits and confounding emotive behaviour, there 
remain questions over the validity of directly relating mouse behaviour to components of 
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schizophrenia. The fact remains that however one chooses to model the behavioural 
aspects of the disease, rodent models are hugely valuable tools as they allow genetic 
manipulation, developmental studies, investigation of gene environment interactions and 
pharmacological interventions which are considered unethical in human subjects.  
Whilst the biological processes occurring in the rodent models may not be identical to 
those of humans, with regards to the DISC1 pathway the expression pattern of DISC1 is 
relatively well conserved, despite the relatively low sequence conservation between 
humans and rodents (Bord et al., 2006).  Conventional knock outs of DISC1 have proved 
difficult to produce, possible due to the transcriptional complexity of the DISC1 gene, 
and so various alternative approaches have been taken to assess DISC1 biology.  Once 
more, it is outside the scope of this review to cover every animal model involving 
DISC1, so I shall focus on those that show specific relevance to alterations in 
intracellular signalling pathways. 
 
1.4.1  DISC1 murine models 
Many groups have genetically altered DISC1 expression in mice, to assess the 
phenotypes resulting for these changes.  In this section I will attempt to write a concise 
summary of the other mouse models that have addressed the DISC1 phenotype, and 
allude towards possible signalling pathways that may be affected.  It has been reported 
that the 129s6/SvEv strain of mice harbour a naturally occurring deletion in DISC1, and 
this variant has been expressed on a C57BL/6 background to assess potential 
behavioural effects (Koike et al., 2006, Kvajo et al., 2008).  The two main avenues of 
investigation however, have been to over express truncated forms of DISC1 to mimic 
the potential protein product from the translocation family (though it is important to state 
that no biological evidence of this protein has been discovered in the family, simply a 
50% reduction of DISC1 protein, Millar et al., 2005b), and to knock down DISC1 using 
shRNA.  In essence, both approaches model a decrease in DISC1 expression, as the 
truncated product generally has a dominant negative effect on wild-type DISC1 
localisation through self association, and thus results in a decrease in DISC1 expression 
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at its normal locations.  A final investigation took the alternate approach of applying 
serial electrical stimuli to the rat amygdala in an attempt to model the effects of seizures.  
In this case DISC1 expression was tested retrospectively, and found it to be decreased in 
granule cells of the dentate gyrus (Fournier et al., 2009).   
 
A huge array of DISC1 phenotypes are reported in these animal models, but there are 
common themes that occur in many of the experiments.  These are summarised in Table 
1.1A and B.  The reported phenotypes include large scale architectural changes, such as 
enlargement or abnormal asymmetry of the lateral ventricles during at least one stage of 
mouse development (Shen et al., 2008, Hikida et al., 2007, Pletnikov et al., 2007, Ayhan 
et al., 2010), a phenomenon also reported in schizophrenic humans (McCarley et al., 
1999).  Three experiments report a decrease in neural progenitor proliferation, which 
Mao et al describe as a function of aberrant GSK3β and Wnt signalling (Kvajo et al., 
2008, Shen et al., 2008, Mao et al., 2009).   Abnormal neural migration and ectopic 
integration is a feature of most models (Kamiya et al., 2005, Kvajo et al., 2008, Duan et 
al., 2007, Meyer and Morris, 2009).  One experiment suggests that only the functionally 
diverse granule cells in the dentate gyrus, and not the excitatory pyramidal cells are 
affected by this phenotype (Meyer and Morris, 2009)  One experiment attempted to 
further characterise which extracellular signalling pathways may be affected by 
overexpression of truncated DISC1 by assessing levels of neurotransmitters and their 
metabolites.  There is a decrease in dopamine and the dopamine metabolite 3,4-
dihydroxyphenylaceticacid (DOPAC) in the frontal cortex of male mice expressing 
truncated DISC1, and a decrease in dopamine in the hippocampi of female mice with 
truncated DISC1 expressed post natally (Ayhan et al., 2010).  The dopamine hypothesis 
of schizophrenia, which is partly formulated on the concept of dopamine hypofunction 
in the pre frontal cortex, will be discussed in detail later in this introduction. 
 
Experiments on brain slices from DISC1 knockdown mice suggests an increased rate of 
synapse maturation on dendritic spines, (Duan et al., 2007), while one experiment 
showed decreased synaptic transmission but with intact long term potentiation (LTP)(Li 
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et al., 2007a).  Overexpression of truncated DISC1 results in a decrease in dendritic 
complexity (Pletnikov et al., 2007, Shen et al., 2008, Li et al., 2007a), while there is a 
variable effect on dendritic spine density (Kvajo et al., 2008, Ayhan et al., 2010, Shen et 
al., 2008, Fournier et al., 2009).  Dendritic complexity is thought to be a result of 
expression of specific combinations of transcription factors and actin remodelling in 
response to integration of a number of extracellular and intracellular signals (Gao, 2007, 
Tada and Sheng, 2006).  It is thus possible that DISC1 dependent changes in the activity 
of GSK3β or the PDE4s may lead to differential transcription from LEF/TCF and CREB 
binding elements, to alter dendritic complexity.  DISC1 also directly binds transcription 
factors (Camargo, 2006), and may act as a scaffold for assembly of transcriptional 
complexes and actin associated proteins (Tada and Sheng, 2006).  Indeed, transcriptional 
assays show an additive effect of DISC1 and ATF4 expression in CRE-driven luciferase 
assays, suggesting that DISC1 is responsible for recruiting transcriptional repressors to 
ATF4 containing transcriptional machinery.  ATF4 has been implicated in multiple brain 
functions, including a form of long term memory, as one of the CRE binding family of 
CREB transcription factors. (Sawamura et al., 2008). 
 
Finally, behavioural tests that recapitulate some of the features of psychiatric disease 
including depression (forced swim and tail suspension tests), hyperactivity (novelty 
induced locomotion), cognitive and sociability deficits were performed, and all show 
positive results in some experiments.  Table 1.1A and B summarise the results of these 
tests.  None of these models showed changes in anxiety related behaviour.  As can be 
seen from the table, three investigations report locomotor hyperactivity in the open field, 
while 3 report no effect on this paradigm.  Working memory is compromised in two 
models (Kvajo et al., 2008, Koike et al., 2006, Clapcote et al., 2007).  There are 
however, almost as many negative findings throughout these experiments as there are 
positive, the majority of papers failing to replicate an aspect of behaviour that other 
groups report.  There may be multiple reasons for this.  Although the protocols for these 
tests are relatively standard, the conditions, equipment and levels of attention the mice 
are kept in will all vary between institutions.  The exact expression pattern of DISC1, 
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both temporally and spatially, may well result in different behavioural phenotypes.  Two 
of the groups have already shown that the timing of DISC1 overexpression can 
significantly alter the magnitude of the phenotype observed (Ayhan et al., 2010, Li et al., 
2007a).  What is apparent is that changes to expression levels of DISC1 result in an 
array of behavioural phenotypes in mice, all of which can be related to aspects of human 
psychiatric disease.  This would seem to add evidence to the idea that specific 
psychiatric diseases are less defined than originally perceived, and that DISC1 may well 
act as a hub protein, whose specific mutation, presence or absence can leave one 
susceptible to a range of psychiatric conditions.  
 
1.4.2 DISC1 point mutations lead to “schizophrenic” and 
“depressive” like behaviour – a role for DISC1/PDE4 
interactions? 
Clapcote et al took the approach of screening a bank of ENU mutagenised sperm for 
missense mutations in the largest coding Disc1 exon, exon 2, and found two 
independently derived missense mutations, Q31L and L100P.  Although there are no 
genotype related differences in mouse viability, two phenotypes with central shared 
features are apparent from in depth testing of these animals.  Both homozygous mutants 
have decreased brain volumes in comparison to wild type mice, despite expressing 
normal levels of all measured isoforms of DISC1.  Both have decreased Prepulse 
Inhibition (PPI, a measure of information processing deficits, commonly subnormal in 
schizophrenic patients,  Gottesman and Gould, 2003) in comparison to wild type litter 
mates.  (Clapcote et al., 2007).  This deficit is more pronounced in L100P animals, and 
partially alleviated by the common antipsychotics haloperidol and clozapine. 
Interestingly, the deficit is abolished by rolipram in the L100P mouse and the 
antidepressant bupropion in Q31L animals.  Latent Inhibition, a measure of information 
processing when mice are pre exposed to a conditional stimuli, is also disrupted in both 
homozygous mutants and L100P heterozygotes, and abolished by clozapine in the 
L100P homozygotes.  Both Q31L and L100P heterozygotes show working memory 
deficits (Clapcote et al., 2007). 
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L100P mice display increased horizontal locomotion in the open field test which is not 
related to elevated anxiety.  This leads to a suggestion of “schizophrenic” type behaviour 
in L100P mice.  Q31L homozygous mutants display a quite different phenotype, 
including increased immobile floating time in the Forced Swim Test.  Both bupropion 
and rolipram decrease immobile time in wild type rats, but only bupropion was effective 
in Q31L mutants.  Q31L mutants also exhibit decreased social interactions and lower 
reward responsiveness.  This leads to the suggestion that these mice are behaving in a 
“depressive” like fashion, potentially due to the effect of the mutation on PDE4B 
binding to DISC1   Both DISC1 mutations fall within regions implicated in PDE4B 
specific binding via peptide array (Murdoch et al., 2007). Indeed, in vitro experiments 
demonstrate decreased binding of PDE4B to both mutant forms of DISC1, with the 
L100P mutation having the greatest effect.  Brains from Q31L homozygote animals also 
show a marked 50% decrease in PDE activity, despite their possessing an equal amount 
of protein to their wild type littermates.  This most likely explains their lack of 
sensitivity to rolipram treatment (Clapcote et al., 2007).  This exciting work clearly 
demonstrates how small structural changes in DISC1 can have a large impact, not only 
on the biochemistry of DISC1-PDE4 interactions, but that these changes are significant 
enough to be detected in behavioural paradigms, which respond differentially to drug 
treatment.  This implicates DISC1 and PDE4 in behaviour that relates to two different 
human psychiatric conditions, and increasingly suggests a role for both allelic 
















































promoter P7 E15 P. & P. Pre Post 
Brain volume ↓ ↓  NS  ↓ male  NS  NS NS ↓ NS 
Lateral ventricles      ↑  ↑  ↑ ↑ NS NS 
Cortical volume ↓ ↓  NS ↓ PFC ↓  NS  NS ↓ NS ↓ 
Neural proliferation   ↑  ↓ ↓        
Neurite outgrowth     ↓ ↓    ↓    
Parvalbumin in cortex     NS ↓  ↓   ↓ ↓ ↓ 
Open field locomotion NS ↑ NS NS  NS  ↑ NS ↑ male    
Aggressive behaviour          ↑ male ↑ m. NS ↑ m. 
Sociability ↓ NS      NS ↓ ↓ male    
Spatial learning/memory NS NS   NS   NS  ↓ female    
Working memory ↓ NS  ↓ ↓    ↓     
Prepulse inhibition ↓ ↓  NS    ↓  NS    
Latent inhibition ↓ ↓    ↓        
FST immobile time ↑ NS NS   ↑  ↑ ↑  NS NS ↑ f. 
Dendritic complexity     NS ↓   ↓ ↓    
Ectopic integration     ↑ ↑ ↑       
Dendritic spine density      ↓      ↑ ↑ NS 











Neural proliferation   ↓  
Open field locomotion   ↑  
FST immobile time   ↑  
Dendritic complexity  ↑ granular cells ↑  
Neural migration Defect Defect  Defect 
Ectopic integration    ↑ 
Dendritic spine maturation  ↑   
Synapse maturation  ↑   
 
Table 1.1A, adapted from Shen et al, 2008, on the previous page details the 
phenotypes observed in various mouse models of DISC1 function, including 
ENU mutant DISC1, overexpression of human full length DISC1, expression of 
truncated mouse DISC1 variants, and expression of truncated DISC1 to model 
the human translocation.  ↓ = reduced, ↑ = increased, NS = no statistically 
significant effect, and a blank box means this investigation was not reported on.  
Abbreviations used are: P. & P. = pre and post natal expression of inducible 
DISC1 construct, m. = male, f.= female, HP = hippocampus. Table 1.1B details 











1.4.3 Non Mammalian DISC1 models 
 
The transgenic approach of DISC1 study has recently been extended to non mammalian 
animals, including zebrafish and drosphila, despite there being no DISC1 fly orthologue 
(Bord et al., 2006).  Transgenic flies express full length human DISC1 in mushroom 
bodies, which are structures involved in cognition, associative learning, attention and 
sleep homeostasis.  Expression of full length human DISC1 causes a mild sleep related 
phenotype, where male flies spent increased time asleep per day (Sawamura et al., 
2008).  Disturbances such as these have been related to cAMP Response-element 
binding proteins (CREB), transcription factors which bind to cAMP responsive elements 
(CRE) (Hendricks et al., 2001), with evidence from non-mammalian experiments 
investigating PDE4 orthologues suggesting high cAMP leads to decreased sleep 
(Zimmerman et al., 2008, Drerup et al., 2009).   
 
Strikingly, DISC1 morphant zebrafish portrayed a similar phenotype to those of another 
schizophrenia susceptibility gene: neuregulin.  DISC1 morpholino-injected (an anti-
sense method of knock-down) embryos have numerous gross developmental 
abnormalities: failed swim bladder inflation, mis-shapen eyes and head, cartilaginous 
and pectoral fin abnormalities, oedema in the pericardium and possessed no articulated 
lower jaw.  Most of these changes are likely attributed to the absence of DISC1 in 
migrating cranial neural crest cells, which are reduced in the pharyngeal arches of 
morphants (Wood et al., 2008, Drerup et al., 2009).  Morphants express a dose 
dependent decreased population of oligodendrocyte precursor olig2 expressing cells, and 
more terminally differentiated Sox10 expressing cells in the hindbrain.  This change was 
specific to DISC1 knockdown, and not attributable to p53 induced apoptosis (Wood et 
al., 2008).  This is interesting as oligodendrocyte abnormalities, including decreased 
total cell counts (Hof et al., 2002), and cytological changes (Uranova et al., 2001) have 
been observed in schizophrenic post mortem tissue, and white matter integrity changes 
are commonly reported throughout psychiatric disease (White et al., 2008).  However, 
evidence from mouse models has failed to show such phenotypes in response to DISC1 
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manipulation – could it be that mammals have evolved greater redundancy in pathways 
responsible for myelination, due to the greater distance that neurons must migrate? 
 
1.5 DISC1 affects signalling pathways associated with major 
psychiatric disease 
 
As with all aspects of DISC1 research, there has been an almost exponential increase in 
in vitro studies of DISC1 over the past 5 years.  For this reason I will confine my 
introduction only to those studies that highlight effects of DISC1 on well established 
signal transduction pathways that have been associated with psychiatric disease, 
independent of their association with DISC1, including ERK1/2, AKT and GSK3β and 
cAMP.  While these three proteins find themselves in pathways that are canonically 
viewed as isolated, there is a large amount of cross talk and interaction which has been 
highlighted as important in mood disorders and schizophrenia.  Here I will focus on the 
pharmacological aspects of these associations.  
 
1.5.1 Neurotrophin signalling and mood disorders 
ERK1/2 is part of the ras-mitogen-activated protein kinase (MAPK) cascade, whose 
most well characterised role is to prevent cells from undergoing programmed cell death.  
AKT forms parts of the PI3K/AKT pathway, responsible for activating a multitude of 
downstream effectors, including AKT, in response to the formation of 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) from phosphatidylinositol 4,5-
bisphosphate by PI3K.  Both cascades are implicated in regulation of synaptic plasticity, 
formation of dendritic spines, and neuronal complexity, differentiation and survival by 
activation in response to neurotrophins such as brain derived neurotrophic factor 
(BDNF) and nerve growth factor (NGF) (Yuan et al., 2001, Riccio et al., 1999, Mai et 
al., 2002, Foulstone et al., 1999, Alonso et al., 2004, Atwal et al., 2000, Jaworski et al., 
2005 Jiang, 2005 #544).  BDNF is of particular interest in depression as mRNA is 
decreased in the hippocampus and dentate gyrus in rats undergoing chronic 
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immobilisation stress (Smith et al., 1995), an adaptation which is blocked by 
administration of antidepressants (Nibuya et al., 1995).  When administered centrally 
BDNF itself has antidepressant effects in at least two behavioural tests: the forced swim 
test and learned helplessness post shock (Siuciak et al., 1997).  Chronic administration 
of antidepressants increases BDNF mRNA in the hippocampus (Nibuya et al., 1995).  
Treatment of SHSY5Y cells with BDNF leads to a decrease in GSK3β activity via AKT 
mediated phosphorylation of Ser9 and results in increased phosphorylation of the cAMP 
response element binding protein (CREB), as does treatment of cells with lithium (Cross 
et al., 1995, Grimes and Jope, 2001a).   Overexpression of GSK3β blocks BDNF 
induced phosphorylation of CREB, except in the presence of lithium, which also causes 
a small increase in ERK1/2 and CREB phosphorylation in control (non-BDNF treated) 
cells (Mai et al., 2002).   
 
CREB is one of the major downstream effectors of neurotrophins, and has similar 
antidepressant effects to BDNF when expressed in the hippocampus (Chen AH et al., 
2001).  CREB is activated by chronic antidepressant treatment (Thome et al., 2000),  
ERK (via ribosomal S6 kinase) and PKA by phosphorylation at Ser133 (Mai et al., 2002, 
Coyle and Duman, 2003, Shaywitz and Greenberg, 1999) and negatively regulated by 
GSK3β at Ser 129 (Grimes and Jope, 2001b).   ERK and AKT signalling is activated by 
phosphorylation after chronic treatment with valproate, and short term treatment with 
carbamazepine enhances basal and BDNF stimulated ERK1/2 and CREB  
phosphorylation (Yuan et al., 2001, Mai et al., 2002).  Both of these drugs are commonly 
used mood stabilisers.  Phosphorylation of AKT in response to valproate treatment is 
accompanied by an increase in inhibitory phosphorylation at Ser9 of GSK3β, while 
lithium treatment has this same effect without an increase in AKT phosphorylation (De 
Sarno et al., 2002).  Chronic valproic acid treatment of SHSY5Y cells in serum free 
media leads to an ERK mediated increase in neurite formation and cell survival, and an 
increase in Bcl-2 protein (Yuan et al., 2001), whose promoter activity is regulated by 
CREB binding (Riccio et al., 1999).       
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This wealth of information leads to a central pathway inextricably linked to depression 
and bipolar disorder, by its outcomes (control of neuronal plasticity and survival), its 
modulation at various points by antidepressant and mood stabilising drugs, and by post 
mortem evidence from human disease.  Schizophrenic brains have 68% decreased levels 
of AKT protein in peripheral tissues, and decreased levels in post-mortem frontal cortex 
and hippocampus when compared to a control population (Emamian et al., 2004a).  
There are concomitant decreases in GSK-3 phosphorylation at Ser9 in the periphery and 
brain post mortem tissue (Emamian et al., 2004a).  Finally, post mortem frontal cortex 
shows an array of disturbances in the MAPK cascade with respect to psychiatric 
diagnoses, including a significant decrease in MEK1 (which acts upstream to activate 
ERK1/2) in bipolar disorder, major depression and schizophrenia, and decreased CREB 
in major depression and schizophrenia regardless of pre morbid use of medication.  
There were no changes in protein expression of ERK1/2, and unfortunately potential 
changes in phospho proteins as are observed in many of the animal models were not 
assessed (Yuan et al.).   
 
To summarise (and grossly simplify!), growth factors, particularly BDNF, bind to 
tyrosine kinase receptors and activate PI3K and MAPK cascades, resulting in 
phosphorylation of ERK1/2 and AKT.  Activation of ERK leads to activating 
phosphorylation of CREB, which binds to CRE response elements in multiple genes, 
resulting in transcription of neuronal plasticity and survival related genes including Bcl-
2.  Concomitant activation of AKT results in inhibition of GSK3β, removing the 
inhibitory effect of this enzyme on CREB.  This basic pathway can be stimulated by 
mood stabilising and antidepressant drugs either by direct inhibition of GSK3β or 
upstream activation of ERK and AKT (Coyle and Duman, 2003).  This pathway 
therefore has three major outcomes with implications for psychiatric disease: activity 
changes downstream of ERK, including CREB mediated gene transcription, activity 
changes downstream of AKT, including activation of mammalian target of rapamycin 
(mTOR) which phosphorylates eIF-4E binding protein to regulate translation (Jaworski 
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et al., 2005, for a comprehensive review see O'Donnell and Gould, 2007), and changes 
in GSK3β activity.  This process is summarised and simplified in figure 1.3. 
 
Figure 1.3 depicts a simplified version of a selection of the pathways involved in 
neurotrophin signalling, showing how signalling from growth factor receptors 





1.6 Lithium:mechanisms for mood stabilisation 
Lithium remains the most established treatment for bipolar disorder.  There have been a 
huge number of behavioural studies performed on wild type rodents to assess the effects 
of lithium treatment, which suggest antidepressant, anxiolytic, and anti-manic properties.  
Amongst the most well replicated of these experiments are decreased aggression, 
decreased amphetamine, reserpine and stress induced hyperactivity, decreased 
exploratory behaviour, decreased latency to enter light compartments, decreased 
immobile time in the forced swim test, and an increase in pilocarpine induced seizures 
on lithium treatment (Beaulieu et al., 2008, O'Donnell and Gould, 2007).  It is still 
unclear whether there is a definitive molecular mechanism by which lithium exerts its 
effects, and at present there are two major pathways implicated: disruption of inositol 
homeostasis and inhibition of GSK3β. These two mechanisms are by no means mutually 
exclusive.   
 
The inositol depletion hypothesis stemmed from the observation that exogenous inositol 
protected Xenopus embryos from lithium induced embryo malformation (Busa and 
Gimlich, 1989). It was later discovered that lithium inhibits the activity of two of the 
lipid phosphatase enzymes responsible for hydrolysing, and thus recycling, inositol-1,4,5 
trisphosphate (IP3). This leads to an effective depletion of inositol which is particularly 
apparent in the brain, due to the lack of permeability to inositol of the blood brain barrier 
(reviewed Berridge et al., 1989). IP3 is a major second messenger downstream from 
GPCRs, and is involved in releasing calcium from intracellular stores to activate calcium 
regulated proteins. As with cAMP and PDE enzymes, which act to rapidly regulate 
cAMP fluxes both spatially and temporally, lipid phosphatases are required to inactivate 
this IP3 signal. More recent behavioural work in mammals is increasingly critical of this 
hypothesis as an important function in the efficacy of lithium (reviewed Beaulieu and 
Caron, 2008).  The most striking of these investigations shows that mice with a mutated 
myo-inositol transporter, who have inositol depleted in the PFC and hippocampus to 
similar levels to those reported in humans and rodents after chronic lithium treatment 
(Beaulieu and Caron, 2008), fail to recapitulate any of the noted behavioural effects of 
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lithium treatment.  These mutant mice were not sensitive to pilocarpine induced 
seizures, and showed no difference in the forced swim test and amphetamine induced 
hyperactivity when compared to wild type mice (Shaldubina et al., 2007).   
 
GSK3β was originally proposed as a target of lithium after observations that the 
teratogenic effects lithium causes in Xenopus embryos were markedly similar to the 
effects resulting from disruption or inhibition of GSK3β and wingless (Wnt) signalling. 
Indeed, bacterially purified GSK3β was inhibited by lithium in vitro with an IC50 of 
2mM, meaning incomplete inhibition will occur within the therapeutic ratio of 0.5-
1.5mM lithium. In in vitro enzyme reaction studies however, LiCl became more potent 
at inhibiting GSK3β as Mg
2+
 concentration decreased.  This implies that the clinical 
effect of lithium could vary between tissues, dependent on their magnesium content, 
with the potential for lithium to be more potent in vivo than in in vitro studies (Ryves 
and Harwood, 2001).  This inhibition of GSK3β by lithium was shown to be 
uncompetitive (Klein and Melton, 1996). 2mM LiCl was ineffective against activity of 
other kinases tested, including JNK, MAPK and ERK 1 and 2. Activity of overexpressed 
GSK3β was then shown to be altered by lithium in COS1 cells, using phosphorylation of 
co-transfected Tau as a proxy for GSK3β activity. Finally, addition of lithium to S2 cells 
(cells of drosophila origin lacking the Frizzled receptor) and mammalian PC12 cells 
resulted in an accumulation of the drosophila β-catenin homologue Armadillo and β-
catenin respectively. This demonstrated that Gsk3 and lithium function downstream of 
Wnt receptor signalling (Stambolic et al., 1996).  
 
 
1.7 GSK3β: multiple pathways for psychiatric pathogenesis 
As discussed above, GSK3β is an enzyme strongly implicated in psychiatric illness by 
virtue of its inhibition by LiCl, a common mood stabiliser (Beaulieu and Caron, 2008) 
and primary treatment for Bipolar Disorder. GSK3β is a virtually ubiquitous protein with 
a huge number of putative substrates, some of which are detailed below.  Fine control of 
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this enzyme is therefore key to appropriate function, and can be achieved at a series of 
levels.  The first level is phosphorylation.  GSK3β is phosphorylated at the inhibitory 
Ser9 site by a number of proteins, including AKT and PKA (Brian et al., 1982, Cross et 
al., 1995).  GSK3β also possesses an activating phosphorylation site, but there is 
controversy over which kinases may act here, and whether GSK3β may 
autophosphorylate (Jope and Johnson, 2004, Grimes and Jope, 2001b).  The second level 
of GSK3β activity control is also related to phosphorylation.  Although GSK3β does not 
require a strict canonical motif in a substrate, priming phosphorylation of the substrate 
by a separate kinase is often required for efficient phosphorylation (Fiol et al., 1987).   
 
The third level of control lies in the presence of GSK3β in a larger complex.  For 
example, in the canonical Wnt signalling pathway, binding of Axin to GSK3β enhances 
phosphorylation of β-catenin by GSK3β (Ikeda et al., 1998).  In a completely separate 
complex, GSK3 binding protein (GBP) bind GSK3β to sterically inhibit the active site 
(Grimes and Jope, 2001b).  There is some evidence that binding of these protein 
complexes may be competitive (Farr et al., 2000).  This effect of protein complexes links 
with the fourth level of enzyme control: subcellular localisation.  GSK3β contains a 
highly conserved nuclear localisation signal, yet its expression is predominantly 
cytoplasmic.  However, the proportion of nuclear GSK3β increases during significant 
cellular events such as S phase of the cell cycle.  When GSK3β–HA is overexpressed, 
there is a 50% increase in the nuclear:cytoplasmic ratio of GSK3β, suggesting the 
presence of cytoplasmic anchoring proteins that are saturated by overexpression of 
GSK3β.  Indeed, if cells are chemically crosslinked, the majority of endogenous GSK3β 
can be found in complexes (Meares and Jope, 2007).  Thus GSK3β activity may also be 
regulated by control of subcellular localisation, mediated by cytoplasmic proteins who 
anchor it in specific cellular compartments.  These multiple levels of control allow for 
very specific GSK3β mediated actions from a largely ubiquitous enzyme.   
 
GSK3β is expressed in many tissues throughout the body, but particularly enriched in 
brain (Woodgett, 1990).  In the cortex, layers V and VI are the most immunoreactive, 
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and in the hippocampus the signal is strong in pyramidal neurons, while the granular 
neurons of the dentate gyrus are weakly labelled.  Immunocytochemistry shows GSK3β 
to be present throughout hippocampal neurons, in dendritic spines, and it is found in 
both the cytosolic and synaptosomal fractions prepared from hippocampal and cortical 
neurons (Peineau et al., 2007, Claudie et al., 2007).  Studies in rat brain suggest that 
though GSK3β expression is high throughout development, there is a peak of expression 
between embryonic day 18 and postnatal day 10, which corresponds to the major period 
of synapse formation and maturation (Leroy and Brion, 1999). 
 
Pharmacological and genetic manipulation of GSK3β related pathways has strengthened 
the case that inhibition of GSK3β is vital for neuroactive components of lithium 
treatment.  GSK3β heterozygous knock out mice recapitulate the behavioural effects of 
lithium treated wild types, demonstrating decreased immobile time in the forced swim 
test, decreased exploratory behaviour, decreased amphetamine induced hyperlocomotion 
(Beaulieu et al., 2004, Beaulieu and Caron, 2008, O'Brien et al., 2004).  Lithium 
treatment of GSK3β heterozygous knock out mice results in impeded locomotion, while 
GSK3β homozygous knock outs are embryonic lethal (O'Brien et al., 2004), suggesting 
that there is an optimal level of GSK3β inhibition for beneficial neuroactive effects.  
 
Pharmacological inhibition of GSK3β by specific inhibitors produces effects in mice 
very similar to those exhibited in response to lithium treatment.  Thiadazolidinone 
(TDZD-8) inhibits novelty induced locomotor activity, and decreases anxiety as 
measured by the latency to enter a light compartment (Beaulieu et al., 2008, Gould et al., 
2004).  In mice with the dopamine transporter DAT knocked out, LiCl antagonises 
dopamine dependant hyperactivity, as do the specific GSK3β inhibitors SB216763, 
sodium valproate and TDZD-8 (Beaulieu et al., 2004).  Finally, GSK3β specific 
inhibition also leads to decreased immobile time in the forced swim test (Kaidanovich-
Beilin et al., 2004, Gould et al., 2004), one of the most well replicated effects of lithium 
treatment (O'Donnell and Gould, 2007). 
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Brain specific expression of a constitutively active form of GSK3β results in decreased 
food intake and brain size (whilst rates of hippocampal and sub ventricular proliferation 
are maintained), increased locomotor activity with decreased habituation to novelty, 
hyper-responsiveness to acoustic startle and, somewhat counter intuitively, decreased 
immobility in the forced swim test (Prickaerts et al., 2006).  AKT expression is 
upregulated in the striatum of these mice, presumably to compensate for GSK3β over-
activation.  This hypothesis is strengthened by the presence of increased phosphorylation 
at Ser9 of endogenous GSK3β in the striatum of these mice (Prickaerts et al., 2006).  
 
In cell culture and post-mortem studies, treatment with antipsychotic drugs has effects 
on GSK3β activation.  Short term treatment of SHSY5Y cells with clozapine results in 
increased inhibitory phosphorylation of Ser9 of GSK3β, and hence an accumulation of 
β-catenin in the nucleus (Kang et al., 2004).  Acute risperidone and olanzapine treatment 
increases GSK3β Ser9 phosphorylation in the cortex, hippocampi, striatum and 
cerebellum of mice, but has no effect of levels of phosphor-AKT.  Clozapine has the 
same effect, but this is only significant in the cortex and hippocampus.  Interestingly, 
lower doses of risperidone have a greater effect on GSK3β phosphorylation than high 
doses.  In the same paradigm, haloperidol has no effect (Li et al., 2007b). 
1.7.1 Downstream effectors of GSK3β  
GSK3β has a large number of downstream effectors, the most well studied of which is β-
catenin, a scaffolding protein involved in cell adhesion and major player in the Wnt 
signalling pathway critical for controlling cell proliferation.  GSK3β inhibits the 
accumulation of β-catenin through phosphorylation leading to ubiquitination (Beaulieu 
and Caron, 2008), while DISC1 has been proven to stabilise β-catenin through an 
inhibitory effect on GSK3β (Mao et al., 2009).  β-catenin is also implicated in dendritic 
morphogenesis in a pathway independent of downstream Wnt signalling, with 
overexpression resulting in more complex dendritic arborisation with shorter branching.  
N-cadherin mediated sequestration of β-catenin resulted in a decrease in axon branching 
(Yu and Malenka, 2003).  This may go some way to explaining the changes in synaptic 
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complexity seen in DISC1 mutant mice.  Finally, β-catenin is potentially involved in 
synaptic plasticity through NMDA receptor activity dependent redistribution to neuronal 
spines (Murase et al., 2002).   
 
A large number of other substrates of GSK3β have been described and are summarised 
in Table 1 of an excellent review by Grimes and Jope (Grimes and Jope, 2001b).  
Amongst these is PKA (also known as cAMP dependent protein kinase) (Brian et al., 
1982), which is known to phosphorylate, and hence activate PDE4 long isoforms 
(MacKenzie et al., 2002).  Also of note, GSK3β phosphorylates numerous cytoskeletal 
and cell adhesion related proteins, suggesting it may play a crucial role in neuronal 
architecture, and a large collection of transcription factors, the key end points of many 
intracellular signalling pathways (Grimes and Jope, 2001b).   
 
Finally, more recent work has implicated GSK3β in two processes critical for synaptic 
plasticity, NMDA dependent long term potentiation and depression.  Induction of LTD 
resulted in an increase in GSK3β activity in CA1 of the hippocampus.  GSK3β inhibitors 
prevented the induction of LTD in in vivo recordings from 2 week old rat hippocampi 
(Peineau et al., 2007).  Conversely, LTP inhibits GSK3β activity in vivo and in vitro 
through inhibitory phosphorylation at Ser9 (Claudie et al., 2007, Peineau et al., 2007) 
while transgenic mice overexpressing GSK3β have significant deficits in LTP and 
spatial learning deficits that are rescued by lithium treatment (Claudie et al., 2007).  
Induction of LTP and LTD using electrical stimulation are common experimental 
paradigms used to model the chemical strengthening and weakening of synapses 
respectively.  These processes are believed to provide information about similar 
processes which occur during learning and the formation of memory (Malenka and Bear, 
2004).  It is as yet uncertain exactly what the role of GSK3β is in this process, how 
essential it is, whether it acts as an integrator of higher signals (Wnt, for example), or 
whether it has a closer association with NMDA and AMPA receptors and the process of 
internalisation.  Indeed, neither of these roles is mutually exclusive. 
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The evidence for GSK3β playing an important role in multiple psychiatric disorders is 
multi leveled and growing at an astounding rate.  Pharmacological evidence that began 
with lithium treatment in humans has led to an increasing repertoire of substrates this 
ubiquitous enzyme phosphorylates, and links it to multiple processes implicated in 
psychiatric disease: synaptic plasticity, CREB signalling, and Wnt signalling being the 
three attracting the most interest.  The finding that DISC1 interacts with and inhibits the 
activity of GSK3β (Mao et al., 2009), and the potential of a dynamic regulatory complex 
being formed with PDE4B, is highly exciting, and may begin to explain some of the 
phenotypic findings seen in DISC1 mutant mice.   
 
1.8 DISC1 and signal transduction  
siRNA knockdown of DISC1 in primary cortical cultures results in significantly 
decreased phosphorylation of ERK1/2 (pERK) and AKT (pAKT) (Hashimoto et al., 
2006).  Viral infection of both the Ser704 and Cys variants of DISC1 results in an 
increase in pERK1/2 and pAKT.  These effects are more significant when the Ser variant 
is overexpressed: the pAKT increase after overexpression of the Cys variant is non-
significant (Hashimoto et al., 2006).  In rescue experiments, overexpression of Ser 
DISC1 variant compensated for the decrease in pERK1/2 resulting from siRNA 
mediated DISC1 knockdown.  There was a non-significant return to basal pERK1/2 
levels when the Cys variant was overexpressed: a similar pattern was observed with 
pAKT (Hashimoto et al., 2006).  Thus, it seems that DISC1 plays a similar biological 
role to that of mood stabilisers in this paradigm, and is capable of enhancing ERK and 
AKT activation, with the potential to exert effects on synaptic plasticity and neuron 
survival as described earlier.   
 
Affinity chromatography, immunoprecipitation and in vitro binding assays demonstrate 
that DISC1 forms a ternary complex with Kinesin-1 and Grb2, an adaptor molecule 
linking neurotrophin binding at tyrosine kinase receptors to downstream effectors such 
as Ras by recruiting guanine-nucleotide exchange factors (Shinoda et al., 2007).  Ras 
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acts upstream of AKT and ERK in the MAPK and PI3K signalling pathways (Reichardt, 
2006).  DISC1 and Grb2 are partially colocalised along microtubules in the central 
region of primary rat hippocampal axon growth cones: DISC1 knock down prevents 
Grb2 from accumulating in this area.  Growth cone localisation of Grb2 is rescued by 
overexpression of wild type DISC1, but not by overexpression of DISC1 with a mutated 
SH3 binding domain (Shinoda et al., 2007).  However, unlike the observations described 
above in unstimulated neurons, knockdown of DISC1 has no effect on ERK2 
phosphorylation in neurotrophin-3 (NT-3) treated PC12 cells.  Knockdown of Grb2 
results in decreased pERK2.   The story in neurons is more complex: DISC1 knockdown 
causes decreased levels of pERK1/2 in response to NT-3 treatment, but only in the 
growth cone, not the cell body.  Under NT-3 stimulated conditions, DISC1 knock down 
results in an axon elongation defect which is not rescued by overexpression of the SH3 
domain mutated DISC1 (Shinoda et al., 2007).  Conversely, the axon elongation defect 
seen in non-NT-3 stimulated neurons is rescued by both wild type and mutated DISC1, 
suggesting that the DISC1/Grb2 interaction, and thus localisation of Grb2 to the growth 
cone, is only critical for NT-3 stimulated axon elongation (Shinoda et al., 2007).  This 
works suggests a possible pathway by which DISC1 may alter ERK and AKT 
phosphorylation, but there are some discrepancies between the two pieces of work which 
have yet to be resolved.  It may be that the differences between the effects of DISC1 
observed in unstimulated neurons arise from methodological differences (such as 
differences in cortical versus hippocampal neurons), or the situation may be more 
complex than is presently appreciated.  
 
Knockdown of DISC1 in the adult mouse brain results in a cellular phenotype very 
similar to that of PTEN suppressed mice (Kwon et al., 2006).  Adult born neurons in the 
dentate gyrus microinjected with a DISC1 shRNA containing oncoretrovirus have larger 
cell bodies, an increased number of ectopic primary dendrites, more complex dendritic 
arborisation and an accelerated rate of synapse formation (Duan et al., 2007).  Whereas 
adult born neurons normally integrate solely within the inner two thirds of the dentate 
gyrus granule cell layer, most DISC1 knockdown neurons had migrated to the outer 
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third of the granule cell layer by two weeks post injection, with some penetrating as far 
as the molecular layer.  At 4 weeks post injection, 50% of DISC1 knockdown neurons 
had reached the molecular layer whereas strikingly, no control cells were present in this 
layer (Duan et al., 2007).  In the PTEN mutant mice, knockdown was limited to post 
mitotic neurons, due to the NSE promoter used, but despite this a very similar cellular 
phenotype to DISC1 knockdown is observed.  PTEN negative dentate gyrus neurons 
have increased soma size, an increased number of ectopic processes which project across 
a larger area, and a highly significant increase in synapsinI staining and the number of 
presynaptic vesicles.  Importantly, cells with ectopic dendrites exhibited an increase in 
pAKT and phosphorylated GSK3β, whereas cells without ectopic dendrites had no 
pAKT changes (Kwon et al., 2006).    
 
This phenotypic similarity led to the hypothesis that DISC1 regulates the developmental 
of adult born neurons through activation of AKT signalling.  DISC1 directly binds 
KIAA1212, a protein which is expressed during differentiation of adult born neurons, 
and binds to AKT to potentiate AKT activation.  The mechanism by which KIAA1212 
achieves this remains unclear, but the protein exhibits no kinase activity (Anai et al., 
2005).  DISC1 single cell knockdown results in an increased immunostaining of pAKT 
in immature post mitotic neurons.  Concomitant elevation of pS6, a downstream marker 
of activated AKT signalling is also observed.  Treatment of HEK293 cells with insulin 
activates AKT signalling.  Overexpression of KIAA1212 in this system is sufficient to 
elevate levels of pAKT and pS6 without insulin stimulation.  Coexpression of DISC1 
and KIAA1212 decreases KIAA1212 phosphorylation resulting in decreased pAKT and 
pS6 in both experimental situations.  Overexpression of DISC1 alone had no effect on 
pAKT levels in either stimulated or unstimulated cells (Kim et al., 2009b).  This is in 
contrast to earlier observations in cortical neurons, where DISC1 overexpression in 
unstimulated cells resulted in an increase in pAKT (Hashimoto et al., 2006).  
Immunoprecipitation experiments suggest that coexpression of DISC1 and KIAA1212 
decreases the association of KIAA1212 with endogenous AKT, an association which is 
constant in the absence of excess DISC1, regardless of cell stimulation.  There is no 
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direct binding between DISC1 and AKT (Kim et al., 2009b).  KIAA1212 overexpressing 
neurons, (thus increasing AKT signalling) exhibit a cellular morphology and dendritic 
arborisation strikingly similar to PTEN and DISC1 knockdown neurons, as do neurons 
expressing a constitutively active form of AKT.  Both these neuron types exhibited a 
migration and integration phenotype, but less severe than is observed with DISC1 
knockdown (Kim et al., 2009b).  Rapamycin can be used to inhibit mTOR, a kinase 
enzyme that functions downstream of AKT.  mTOR regulates translation by 
phosphorylating eIF-4E.  Rapamycin application fully rescued the effects of DISC1 
knockdown or KIAA1212 overexpression in adult born neurons, whilst having no effect 
on S6 phosphorylation or morphology in control cells.  Application of SB216763, a 
specific inhibitor of GSK3β, had no significant rescue effect, implicating mTOR as the 
pathway of interest with respect to differentiation, growth and integration of adult born 
neurons (Kim et al., 2009b).   
 
1.8.1 DISC1 and adult neurogenesis: a brief summary 
Adult hippocampal neurogenesis arises from neural progenitor cells in the subgranular 
zone that give rise to functional granular neurons that fully integrate into the dentate 
gyrus.  This process is of great interest to the study of psychiatric disease, as various 
rodent models of major depression, stress and schizophrenia have all resulted in 
decreased proliferation of neural progenitors, and decreased survival of mature adult 
born neurons (DeCarolis and Eisch).  Treatment with a large range of psychoactive 
drugs (antidepressants, NMDA antagonists and neuroleptics: though there is more 
controversy over the precise effects of antipsychotics) and exercise generally has the 
opposite effect, resulting in an increased pool of amplifying progenitor cells, and an 
increased number of post mitotic neuroblasts and mature neurons.  In humans, major 
depression, post traumatic stress disorder, Alzheimer’s Disease and schizophrenia have 
all been linked to decreased hippocampal volume and aberrant function.  This decrease 
in volume however does not appear to relate directly to a loss of adult born neurons, and 
should be approached with some caution, particularly as it is unclear whether possessing 
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a smaller hippocampus is actually a risk factor for these diseases (for an introductory 
review of neurogenesis see DeCarolis and Eisch, Duman, 2002).  Studies of DISC1 add 
weight to the interest in this field.  As described above, DISC1 has a dual pronged effect 
on the various stages of neurogenesis.  DISC1 acts via regulation of GSK3β and Wnt 
signalling to have effects on proliferation of neural progenitor cells, while it functions 
upstream of AKT and mTOR signalling to regulate growth, morphology and integration 
of adult born neurons.  Once more, DISC1 appears to be involved in the integration of 
extracellular signals and fine control of signal transduction which is vital for normal 
neuronal location, connectivity and brain function.       
       
1.9 Phosphodiesterase-4  
 
The PDEs are a large family of enzymes which form the sole means of inactivating 
cAMP within the cell (Alberini et al., 1995, Duman, 2002), playing numerous roles in 
compartmentalised cellular signalling and signal transduction (Lynch et al., 2006, 
Houslay, 2010).   cAMP is the diffusible downstream signalling molecule of a wide 
variety of G-protein coupled receptors (GPCRs), and well controlled fluxes in cAMP 
distribution are vital for maintaining appropriate intracellular signalling (Lynch et al., 
2006).  A complex pattern of splicing leads to their being more than 20 PDE4 isoforms, 
all possessing unique N-termini (Houslay and Adams, 2003).  Some PDE4 subtypes, 
including PDE4B2 and one or both of PDE4D1/D2 have gene promoters which are 
responsive to local cAMP concentrations (D'Sa et al., 2002).  All PDE4 long forms have 
the same basic structure.  They possess a unique N-terminus involved in localisation of 
the enzyme, a regulatory module consisting of an upstream conserved regions 1 (UCR1) 
and UCR2 domain, whose organisation can be disrupted by PKA phosphorylation, and a 
catalytic domain.  All short forms lack UCR1.  PKA phosphorylation in the UCR1 
domain of long forms opens the PDE4 structure, increasing enzyme activity, while ERK 
is capable of phosphorylating UCR2 in PDE4B, C and D.  PDE4A lacks the ERK 
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consensus site.  Whether this phosphorylation is inhibitory or activating depends upon 
the PDE4 subtype (Baillie et al., 2000, MacKenzie et al., 2002, Burgin et al., 2010). 
 
PDE4s are highly expressed in the human brain.  PDE4A and PDE4D are moderately 
expressed in the frontal cortex.  PDE4B and PDE4C are detectable here, but at low 
levels.  Binding assays show a high density of rolipram binding sites throughout the 
cortex (Pérez-Torres et al., 2000).  In the hippocampus, PDE4A, PDE4B and PDE4D are 
expressed highly throughout the dentate gyrus and CA2, with PDE4A being decreased in 
CA1 and CA3.  Again, high rolipram binding is exhibited throughout.  Expression in the 
rodent is similar, with the major difference being that PDE4C expression is restricted to 
the olfactory bulb (Pérez-Torres et al., 2000).  As with DISC1, there are multiple levels 
of evidence implicating PDE4s in psychiatric disease, from genetic association with 
human disease to pharmacological and genetic models in rodents.   
 
1.9.1 Genetic evidence linking PDE4 to psychiatric disease 
Systematic screening of schizophrenia and bipolar disorder probands for cytogenetic 
rearrangements highlights PDE4B as an independent risk factor for schizophrenia. A 
schizophrenic Scottish proband and related cousin with a psychotic disorder carry a 
balanced translocation at t(1;16)(p31.2;q21), interrupting the gene coding for PDE4B, 
and predicted to affect production of the PDE4B1 isoform (Millar et al., 2005b).  
Association studies to be discussed below show some positive findings for the PDE4 
genes and schizophrenia, but as with DISC1, there are also some negative studies.  
However, two main regions of interest for psychiatric disease seem to be appearing in 
PDE4B: the central region of intron 3, and intron 7, which lies close to the PDE4B2 
splice site (Pickard et al., 2007, Fatemi et al., 2008). 
 
Positive association between a series of SNPs in PDE4B and schizophrenia is reported in 
a Caucasian population (Fatemi et al., 2008).  A haplotype based on two of these SNPs 
is also associated with schizophrenia in this population.  These SNPs are clustered in 
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intron 7 near the splice site for the PDE4B2 short isoform.  Positive associations within 
this region but with different SNPs are also seen in an African American population 
(Fatemi et al., 2008).  This region also holds significant association with schizophrenia 
in a Japanese population (Numata et al., 2008).  Decreases in PDE4B isoforms are found 
in post mortem cerebellar tissue from the Stanley foundation, but this decrease is only 
significant for the PDE4B4 and PDE4B2 isoforms (Fatemi et al., 2008).  A trend 
towards a similar decrease is reported from frontal cortex samples.  Tissue from bipolar 
patients also showed a significant decrease in cerebellar PDE4B3 (Fatemi et al., 2008).   
 
The presence of a protective 7 SNP haplotype found within intron 3 of PDE4B is also 
reported, which reaches significance in females only (Pickard et al., 2007).  A Finnish 
study also finds this region to be of interest, reporting a single risk SNP and the 
neighbouring haplotype block as having protective and risk forms (Tomppo et al., 2009).  
A Scandinavian study finds a cluster of SNPs near the PDE4B3 splice site that are 
nominally associated with schizophrenia and bipolar disorder, but fail to survive 
multiple testing (Kähler et al.)  However, post hoc analysis showed 4 of these SNPs do 
reach significance, but in females only, and 4 are related to positive symptoms of 
schizophrenia (Kähler et al.).  A further small study finds no evidence of association of 
PDE4B with schizophrenia, and no evidence of an interaction between PDE4B and 
DISC1 SNPs (Rastogi et al., 2009). 
 
It seems that fewer genetic studies have been performed on PDE4A and PDE4D, and I 
was only able to find one positive report.  This finds association with a single SNP and 
an associated haplotype in the final intron of PDE4D, which is over represented in 
schizophrenic individuals (Tomppo et al., 2009).  The is also weak GWAS evidence for 
association of a PDE4D SNP with a form of neuroticism (Shifman et al., 2007).  It is 
clear that further study is required to adequately assess the genetic risk of PDE4A and 
PDE4D to schizophrenia, but early results for PDE4B are promising. 
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1.9.2 Pharmacological evidence for an involvement of the PDE4s 
with psychiatric disease 
Carefully regulated distribution of cAMP is important in many processes in the brain, 
including memory and cognition, both processes which are altered in schizophrenics 
with respect to the general population.  First generation antipsychotics increase cAMP in 
vitro and in vivo, whereas second generation antipsychotics have differential effects, 
probably reflecting the profile of receptors they target (Molteni et al., 2009).  Chronic 
haloperidol treatment increases PKA activity in the striatum, but has no effect in the 
hippocampus or cortex.  Chronic clozapine decreases PKA activity in all three areas, and 
alters the expression of PKA subunits (Dwivedi et al., 2002). 
 
Few experiments have been performed to assess putative anti-psychotic or mood altering 
effects of PDE4 inhibition.  In wild type mice, treatment with chronic rolipram, a PDE4 
inhibitor, has anxiolytic and antidepressant effects.  Rolipram treated mice increase the 
time in, and number of entries to, open arms of the elevated plus maze, show decreased 
latency to enter a light compartment, and once there spend more time in the light.  These 
effects are markedly similar to those of the tranquilising benzodiazapine diazepam.  
Treated rodents also show significantly less immobile time in the forced swim and tail 
suspension tests (Li et al., 2009).  Rolipram increases cAMP concentration and 
phosphorylation of CREB in the hippocampus and PFC, and increases the rate of 
neurogenesis in the hippocampus.  The anxiolytic effects of chronic rolipram treatment 
are ablated by treatment with MAM, a DNA methylating agent that blocks neurogenesis 
(Li et al., 2009), suggesting PDE4 produces at least a subsection of its neurological 
effects by mediating neurogenesis. 
 
In mice, acute rolipram treatment antagonises hyperlocomotion induced by PCP and D-
amphetamine, in a similar way to the licensed anti-psychotics haloperidol and 
risperidone (Siuciak et al., 2007).  Chronic treatment of mice with antidepressants (the 
noradrenaline reuptake inhibitor Desipramine, serotonin reuptake inhibitors fluoxetine 
and sertraline, a monooxidase inhibitor and chronic electroconvulsive stimuli) leads to 
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changes in PDE4 subtype expression.  PDE4A and PDE4B mRNA and protein 
expression was increased in the frontal and parietal cortex, but not in the hippocampi.  
PDE4B mRNA and protein is increased in response to antidepressant treatment, and 
decreased by cocaine in the nucleus accumbens, an area associated with reward 
behaviour (Takahashi et al., 2009).  Chronic clozapine treatment in mice increases 
PDE4B2 and PDE4B4 mRNA and protein expression in striatal membrane preparations 
(Dlaboga et al., 2008).  
 
The majority of experiments performed using pharmacological manipulation of PDE4 
have been centred on cognitive function and memory, as opposed to antidepressant 
effects.  Reneerkens has written a highly detailed review on all such experiments 
performed thus far, so I will only summarise the recurring themes here (Reneerkens et 
al., 2009).  Acute treatment of wild type rodents with rolipram leads to improvements in 
memory consolidation and spatial working memory, even in aged mice.  Monkeys 
improve in executive function paradigms after a single dose 30 minutes before testing. 
(Reneerkens et al., 2009).  In aged monkeys however, rolipram actually has a negative 
effect on working memory, an opposite effect to that seen in young monkeys (Ramos et 
al., 2003). It is possible to induce memory deficits in rodent models through a wide 
range of protocols.  MEK/ERK inhibition, treatment with the muscarinic antagonist 
scopolamine and non competitive NMDA antagonist MK801 leads to two forms of 
deficit in spatial working memory as measured by the radial arm maze (Zhang and 
O'Donnell, 2000, Zhang et al., 2000, Zhang et al., 2004).  These treatments increase the 
number of working memory errors, so that mice re-enter arms of the maze they have 
already visited, and reference errors, where mice enter unbaited arms(Zhang et al., 
2000).  Forskolin treatment shows a trend towards reversal of the scopolamine induced 
deficit, but this effect was non-significant (Zhang and O'Donnell, 2000).  The drug 
induced increase in both these error types is attenuated by acute rolipram treatment 
(Zhang and O'Donnell, 2000).  This implies that the increase in cAMP resulting from 
PDE4 inhibition relates to specific areas of the brain.  A widescale increase resulting 
from forskolin treatment may be beneficial in some brain areas but disruptive in others.  
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Treatment of mice with MK801 also leads to deficits in long term memory leading to 
decreased latency in an inhibitory avoidance task which is rescued by rolipram 
administration (Zhang et al., 2000).   
 
Recent work by Vecsey et al focusses on sleep deprivation in mice, and demonstrates 
that two cAMP dependant LTP paradigms (spaced 4 train or theta burst) are impaired 
after 5 hours of sleep deprivation in mice.  Long term maintenance of LTP induced by 
forskolin treatment is also impaired in these mice, and brain slices show decreased levels 
of cAMP in CA1, both at baseline and after forskolin treatment, and decreased phospho-
CREB.  These deficits are rescued by treatment with IBMX, a non-specific PDE 
inhibitor, suggesting that PDE activity may be increased after sleep deprivation.  Indeed, 
PDE4 possesses increased activity after sleep deprivation, and the PDE4A5 isoform is 
upregulated in these mice.  Thus rolipram treatment successfully rescues the LTP deficit 
induced in these mice, and also rescues sleep deprived deficits in context specific 
memory in a fear conditioning paradigm (Vecsey et al., 2009). 
 
The beneficial effect of PDE4 inhibition extends to other conditions that also have a 
significant cognitive component, especially ones involving memory.  Mouse models of 
Rubenstein-Taybi syndrome, a rare disorder which results from heterozygous mutation 
of the CREB binding protein (CBP), have intact learning and short term memory, but 
defective long term memory as characterised by fear condition and object recognition 
paradigms.  A single infusion of rolipram into the hippocampi returns the 1 day memory 
of these CBP mutant mice to maximal levels (Bourtchouladze et al., 2003). 
 
One of the more common models of Alzheimer’s disease, a disease characterised by 
severe progressive memory loss involves expression of mutant amyloid precursor and 
presenilin-1 protein.  This model recapitulates aspects of Alzheimer’s memory loss, with 
impaired LTP and synapse function, and deficits in spatial working memory (Gong et 
al., 2004).  Acute rolipram treatment almost entirely rescues the LTP deficit in 
hippocampal slices from these mutant mice, and deficits in freezing behaviour but has 
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no effect on spatial working memory (Gong et al., 2004).  When rolipram was 
administered daily for 3 weeks, then withdrawn for 6-8 weeks, the benefits of rolipram 
were maintained, and improvement was also seen in the radial arm maze, a measure of 
spatial working memory.  These deficits may be due to a decrease in active CREB, 
thought to be required for LTP, as phospho-CREB is lower in the hippocampi of mutant 
mice.  This effect is also rescued by rolipram treatment (Gong et al., 2004).  Thus, 
inhibition of PDE4 is effective in treating memory disorders that are likely to have 
distinct etiological routes to schizophrenia, suggesting the potential for these routes to 
lead to a common pathway. 
 
 
1.9.3 Evidence from knockout rodent models – the contribution of 
specific isoforms to PDE4 function 
Due to the lack of PDE4 subtype specific inhibitors being available, some groups have 
produced knockdown mice to assess the contribution of PDE4 subtypes to the effects 
observed with rolipram.  Mice deficient in PDE4B display no gross abnormalities, but 
their weight diverges from that of wild type mice after 21 weeks of age.  In behavioural 
testing, knockout mice show decreased immobile time in the forced swim test (Siuciak 
et al., 2008, Zhang et al., 2008).  No change in memory related behaviour and the 
passive avoidance paradigm (suppression of preference to avoid shock) is apparent 
(Siuciak et al., 2008, Zhang et al., 2008).  However, PDE4B knockout mice show 
increased anxiety in an array of paradigms, including decreased head dips at the hole 
board, an increased latency to cross to a light compartment, decreased exploration in an 
open field and have increased serum levels of corticosterone (Zhang et al., 2008). Other 
phenotypes including an increased amplitude of startle response, PPI deficits, increased 
sensitivity to amphetamine stimulated hyperlocomotion are also reported (Siuciak et al., 
2007).  Biochemical measurements suggest PDE4B knockouts have a hypodopaminergic 
striatum (decreased dopamine, and decreased metabolites DOPAC and HVA) with 
decreased serotonin metabolites and turnover.  In the hippocampus however, 
serotonergic tone is increased with a decreased turnover (Siuciak et al., 2008).  These 
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experiments suggest that knocking out PDE4B has a mild antidepressant effect, a strong 
anxiogenic effect and significant effects on the information filtering. 
 
Conditioned Avoidance Responding (CAR) is a behavioural test commonly used to 
predict the efficacy of a putative antipsychotic.  In this somewhat counter intuitive 
paradigm, drugs possessing antipsychotic activity inhibit a trained rodent’s avoidance of 
a shock in response to a stimuli, but not the actual response.  Drugs without 
antipsychotic efficacy either have no effect, or suppress both the avoidance behaviour 
and the response to shock (Wadenberg and Hicks, 1999).  Treatment of wild type rats 
with rolipram dose-dependently inhibits CAR in rats.  However, PDE4B knockout mice 
are less sensitive to rolipram treatment in this paradigm than wild type mice (Siuciak et 
al., 2007), suggesting that PDE4B activity is required for mediating the putative 
antipsychotic effects of rolipram. 
 
PDE4D knockout mice have decreased total PDE4 activity in the cortex and 
hippocampus (Zhang et al., 2002), agreeing with the finding that PDE4A, PDE4B and 
PDE4D are all highly expressed in CA1 of the rat, while PDE4A and PDE4D alone are 
more moderately expressed in CA3 (Pérez-Torres et al., 2000).  This experiment 
suggests that the other PDE4s are not able to completely compensate for the loss of 
PDE4D in these mice.  Indeed, cAMP was found to be increased in cerebral cortical 
slices from knockout mice (Zhang et al., 2002).  PDE4D knockout mice behave as wild-
type mice treated with antidepressants, showing decreased immobile time in the tail 
suspension and forced swim tests.  Chronic treatment with rolipram also decreased 
immobile time in wild type mice, but not PDE4D knockouts.  Two antidepressants in 
clinical use, desipramine and fluoxetine however, still possessed full antidepressant 
activity in the knockout mice (Zhang et al., 2002).  This suggests that rolipram and the 
two clinically used anti depressants exert their effects through different mechanisms.  
PDE4D is required only for rolipram to exert its effects.  PDE4D knockout mice showed 
no difference to wild type mice in two anxiety related paradigms: the elevated plus maze 
and multi-compartment chamber (Zhang et al., 2002). 
 51 
 
In a separate experiment, PDE4D knockout mice show decreased freezing time when 
subject to fear conditioning paradigms.  Context and cue dependant fear conditioning is 
affected, suggesting impaired associative learning.  These deficits are only evident 24 
hours post training, not in the hour directly post training (Rutten et al., 2008).  
Recordings from single neurons of PDE4D knockout mice suggest that the loss of 
PDE4D has no effect on basal synaptic transmission or pre synaptic glutamate release.  
However, when subject to 2 different LTP inducing protocols, LTP recordings are 
enhanced, suggesting inappropriate chemical strengthening of synapses when PDE4D is 
absent.  No difference is obtained when LTD protocols are employed (Rutten et al., 
2008).   
 
When these genetic, pharmacological and behavioural experiments are taken as a whole, 
there seems to be no doubt that normal PDE4 function, particularly that of PDE4B and 
PDE4D, is of great importance to a series of processes key to psychiatric pathology.  It 
is also clear that the full picture is likely to be very complex, a tale of multiple isoforms, 
varying intracellular and regional localisation, and associating proteins.  Elucidating the 
precise isoforms involved with every aspect of PDE4 function will be a difficult task, 
but one that should reap huge rewards with regard to psychiatric illness.  Isoform 
specific inhibitors or even genetic knockout models are required.  The interaction 
between DISC1 and the PDE4 enzymes links two highly interesting risk proteins, and 
may provide insight into how alterations in such widespread proteins lead to such 





1.10 Strategies for treating psychiatric disease 
1.10.1 First and Second Generation Antipsychotics: The 
Dopamine Hypothesis of Schizophrenia 
The uniting aspect of all fully licensed antipsychotic drugs is that they possess activity at 
D2 type dopamine receptors.  Originally, neuroleptic activity of first generation 
antipsychotics was shown to correlate with the capacity to antagonise this receptor 
(Seeman et al., 1976).  Modern PET based binding studies of first episode 
schizophrenics treated with haloperidol suggest a wide range of DRD2 occupancy by the 
drug, from 38 to 87% occupancy of available receptors (Kapur et al., 2000).  Occupancy 
of DRD2 predicted the outcome of treatment, but also the likelihood of extra-pyramidal 
symptoms (parkinsonian symptoms and prolactin elevation).  Occupancy above 65% 
predicted a clinical response, whilst occupancy above 72% and 78% lead to 
hyperprolactinaemia and EPS respectively (Kapur et al., 2000).  Thus there is a rather 
narrow window for therapeutic efficacy of drugs antagonising DRD2 in schizophrenia.  
Indeed, many of the second generation antipsychotic drugs possess lower affinity for 
DRD2 receptors than first generation drugs (Talbot and Laruelle, 2002, Abi-Dargham, 
2005): in a study using fixed doses of risperidone and olanzapine, lower dose 
risperidone was found to be more potent than olanzapine, with DRD2 occupancies of 69 
and 55% respectively (Frankle et al., 2004).  Second generation antipsychotics tend to 
possess activity at a wide variety of other neural receptors, particularly 5-HT2A, which 
may be responsible for their varying efficacy and side effect profiles (Abi-Dargham and 
Laruelle, 2005). 
 
These findings form the basis of the dopamine hypothesis of schizophrenia, which 
remained the predominant theory of schizophrenia pathogenesis for many years.  Other 
strands of evidence also add weight to the idea that dopamine dysregulation may lead to 
schizophrenia, particularly the positive symptoms.  Early clinical studies found that the 
dopamine enhancing agents amphetamine, methylphenidate and L-dopa can all result in 
acute psychosis (for an introductory review see Abi-Dargham, 2005).  Repeated 
exposure to amphetamine can lead to paranoid psychosis, hallucinations, and progress to 
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thought disorder (Abi-Dargham, 2005).  All these are common features of a psychotic 
episode in schizophrenia.  Treatment with these substances leads to sensitisation to 
future dopamine release, leading to theories that schizophrenic patients may be 
endogenously dopamine super sensitive, perhaps through expression of high affinity 
DRD2 receptors (Philip Seeman, 2006).   
 
While dopamine hyperfunction in the striatum appears to correlate well with the positive 
symptoms of schizophrenia, these models fail to recapitulate the negative symptomology 
of the disease.  The PFC influences striatal dopamine through two functional 
connections: an activating glutamatergic pathway and an inhibitory GABAergic pathway 
(Weinberger and Laruelle, 2001). The full dopamine hypothesis is therefore two fold: 
that hyperactive subcortical mesolimbic projections lead to hyperstimulation of DRD2 in 
the striatum, resulting in positive symptoms, while dopamine hypoactivity in the PFC 
leads to hypostimulation of DRD1 in the PFC, causing negative and cognitive symptoms 
(Abi-Dargham, 2005).  In studies of DRD1 availability in the DLPFC, untreated 
schizophrenics showed increased DRD1 availability which correlated with poor 
performance in the N-back verbal working memory paradigm (Abi-Dargham et al., 
2002).   
 
Postmortem studies in this field have been wide ranging and controversial.  With these 
studies, adaptive changes long term use of neuroleptics must always be carefully 
considered as a confounding factor.  A significant number of studies have found 
increased striatal DRD2, while some hint at increased subcortical dopamine and 
metabolites in schizophrenia.  Studies generally report no changes in DRD1 or dopamine 
transporter expression (Abi-Dargham, 2005).  This area is clearly one that would benefit 
from a systematic meta-analysis.  Imaging studies in live patients have attempted to 
further address these questions.  In their large meta-analysis of all imaging and binding 
studies up to 2001, Weinberger and Laruelle found a series of replicated dopaminergic 
system alterations, the most striking being a small but significant 13% increase in DRD2 
receptors in the striatum in schizophrenic patients.  Patients also generally showed more 
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variability in DRD2 expression than healthy controls (Weinberger and Laruelle, 2001).  
Their literature review suggested increased accumulation of DOPA decarboxylase in the 
striatum of schizophrenic patients, and an enhanced amphetamine induced decrease in 
tracer binding.  This latter effect was exacerbated during periods of psychosis 
(Weinberger and Laruelle, 2001).  Schizophrenic patients have a higher DRD2 
occupancy, as assessed by depletion studies, and occupancy is predictive of a good 
therapeutic response to 6 weeks of antipsychotic treatment (Abi-Dargham et al., 2000).  
No consistent changes in DRD1 expression in schizophrenia have been reported, but 
there is a trend towards low PFC DRD1 expression being associated with negative 
symptoms and poor Wisconsin Card Sort Test performance (Weinberger and Laruelle, 
2001). 
 
Genetic studies have also shown some indication of dopaminergic dysfunction in 
schizophrenia.  The most highly studied of these is a non synonymous Val/Met SNP in 
catechol-O-methyl transferase, an enzyme involved in dopamine degradation, 
particularly in the PFC where there is low expression of the dopamine transporter 
protein (Goldberg and Weinberger, 2004, Williams et al., 2007).  Most work has 
focussed on this Val/Met SNP, which alters stability, and hence activity of the enzyme.  
Although a recent meta-analysis failed to show a significant association of either variant 
with schizophrenia (Williams et al., 2007), significant association is found between 
brain volume changes common in schizophrenia and cognitive ability (van Haren et al., 
2008).   In just one example, healthy subjects carrying two copies of the more stable 
higher activity Val allele perform less well in the Wisconsin Card Sort Test and the 
verbal N-back test (measures of working memory and executive function) than 
candidates possessing at least one Met allele (Goldberg and Weinberger, 2004).  fMRI 
shows a more “efficient” BOLD response to these tasks in Met allele carriers in normal 
conditions, but this deteriorated at high working memory loads when they were treated 
with amphetamine, suggesting that their higher basal dopamine was increased to 
disruptive levels by amphetamine.  Conversely, amphetamine enhanced efficiency in 
Val/Val individuals, suggesting that they have lower basal PFC dopamine, which is 
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enhanced to optimal levels by amphetamine treatment (Goldberg and Weinberger, 
2004).   
 
While evidence is consistently strong for an involvement of dopamine hyperactivity with 
the positive aspects of schizophrenia, the evidence for dopamine hypofunction in the 
PFC is mostly indirect and not yet totally convincing.  It is clear however, that 
dopaminergic tone in the PFC is intricately involved with cognitive function in healthy 
subjects, and thus may still be important for this complex disease.  In addition, first and 
second generation antispsychotics have an adverse side effect profile including weight 
gain, hyperporlactinaemia and extra pyramidal side effects, including Parkinsonian like 
tremors.  (Lieberman et al., 2005).  These side effects often lead to discontinuation of 
treatment.  In the CATIE trial designed to assess efficacy of first versus second 
generation antipsychotics, the most striking result is that 74% of the patients in this 
large, double blinded, multi centre study discontinued medication before the 18 month 
duration of the project was complete.  Olanzapine had the lowest discontinuation rate 
(64%), but was still associated with significant weight gain and altered metabolic 
measures.  The first generation antipsychotics, as expected from receptor affinity 
studies, had a greater rate of extra pyramidal symptoms (Lieberman et al., 2005).   From 
this side effect profile alone, it is clear that current treatment for schizophrenia is far 
from optimal.  To add to this, 40-50% of all schizophrenic patients are “treatment 
resistant,” being inadequately responsive to two or more antipsychotic drugs (Daskalakis 
and George, 2009).  In attempts to discover other targets for medication, and produce a 
pharmacological model of schizophrenia that more fully recapitulates all aspects of the 
disease, attention turned to glutamate, and a new theory was postulated. 
1.10.2 Metabotropic Glutamate agonists: The Glutamate 
Hypothesis 
The glutamate hypothesis of schizophrenia predates the first successful Phase II clinical 
trials with LY404039, a highly selective agonist of mGlu2/3 receptors in 2005 (Patil et 
al., 2007).  The excitatory functional connections between most brain regions implicated 
in schizophrenia: the PFC, hippocampus, limbic system, basal ganglia, thalamus and 
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striatum, are glutamatergic (Moghaddam, 2003).  NMDA receptors have been linked to 
important roles in axon guidance, synaptic pruning, and LTP: all factors which are have 
also shown abnormalities in models of schizophrenia (Meador-Woodruff and Healy, 
2000). 
 
Original evidence for this hypothesis derived from the study of the effects of non 
competitive NMDA antagonising drugs on human and animal behaviour.  In their 1991 
review, Javitt and Zukin describe many of these early experiments.  In healthy humans, 
acute PCP treatment induces a state lasting several hours that recapitulates many of the 
positive and negative features of schizophrenia.  Subjects become withdrawn, 
experience poverty of speech, and thought disorder, and have disrupted cognitive 
processes.  Measures of attention and information processing, such as paired learning 
and association tests show fronto-temporal and hippocampal functioning to be affected 
to a similar extent as is observed with schizophrenic patients (Javitt and Zukin, 1991).  A 
later study attempted to more rigorously define the cognitive effects of NMDA 
antagonism in humans.  This showed no deficits in a virtual Morris Water Maze 
paradigm, suggesting intact acquisition and retrieval of spatial memory.  In verbal tasks, 
ketamine treated individuals show impaired encoding of new words, and poor attention 
(Rowland et al., 2005).  At high doses, PCP administration results in a dissociation from 
the local environment, but not a loss of consciousness (Javitt and Zukin, 1991).  In stable 
schizophrenic subjects, PCP administration precipitates a psychosis encompassing many 
of the features of earlier “endogenous” episodes that may last for weeks (Javitt and 
Zukin, 1991).  Ketamine, another non competitive NMDA antagonist has the same effect 
in schizophrenic subjects (Lahti et al., 1995).  
 
Repeated administration of ketamine over 3 days to healthy human subjects results in a 
dose related increase in positive and negative symptoms, including altered self 
perception, hallucinations, paranoia and thought disorder, coupled with withdrawal, 
detachment and poor WCST performance (Krystal et al., 1994). Velvet monkeys treated 
with PCP for 14 days develop deficits in object retrieval paradigms, suggesting 
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compromised executive function (Jentsch et al., 1997).  These monkeys had decreased 
dopamine use in the DLPFC and prelimbic cortex, measured by decreased levels of 
homovanillic acid.  These deficits endured for at least 4 weeks post treatment 
withdrawal (Jentsch et al., 1997).  Mice, rats and cats acutely treated with PCP develop 
locomotor hyperactivity and stereotypical movements, and have inhibited spatial 
learning and associative learning (Javitt and Zukin, 1991). 
 
A series of individual trials of allosteric NMDA agonists which act at the glycine 
modulatory site of the NMDA receptor have shown efficacy in improving both positive 
and negative symptoms of schizophrenia, when used as an adjunct to established 
antipsychotic regimes.  D-serine shows efficacy as an adjunct in ameliorating positive 
and negative symptoms, as well as improving performance in the Wisconsin Card Sort 
Test (Tsai et al., 1998).  D-cycloserine showed no cognitive enhancement when used as 
an adjunct, but did successfully ameliorate negative symptoms in patients with deficit 
syndrome, a form of schizophrenia with primary, enduring negative symptoms (Goff et 
al., 1999, Heresco-Levy et al., 1999).  Glycine as an adjunct produced positive and 
negative symptom improvement in treatment resistant schizophrenia (Heresco-Levy et 
al., 1996, Heresco-Levy et al., 1999).  However, a more recent meta-analysis of these 
trials suggests that significant effects of allosteric NMDA enhancement are limited to a 
moderate amelioration of negative effects.  Glycine and D-serine, are the most effective 
of these treatments (Tuominen et al., 2005).   
 
Genetic association studies have highlighted a series of genes associated with 
glutamatergic function and the NMDA receptor in particular as risk genes for 
schizophrenia.  These are reviewed by Harrison (2003) and include D-amino acid 
oxidase (DAAO), which metabolises D-serine, and G72, which activated DAAO.  The 
association of neuregulin (NRG) with schizophrenia is one of the more established 
genetic findings, and NRG regulates NMDA receptor expression through the ErbB4 
receptor.  Regulator of G protein signalling 4 (RGS4) is a negative regulator of a series 
of GPCRs, including the metabotropic glutamate receptors, while dysbindin is involved 
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in the maintenance of synapses (Harrison and Owen, 2003).  Finally, a meta-analysis of 
association studies of the GRIN2B gene, which codes for the NR2B subject of the 
NMDA receptor, have shown a significant but small association of this gene with 
schizophrenia (Li and He, 2007). 
 
Postmortem studies describe decreased excitatory phosphorylation of the NR1 subunit of 
the NMDA receptor in the frontal cortex and hippocampus in schizophrenia, but no 
change in bipolar disorder or major depressive disorder (Emamian et al., 2004b).  
Phosphorylation at this residue was increased by treatment with haloperidol in rats in 
vivo and in striatal primary culture (Leveque et al., 2000).  There have been many 
studies of total NMDA receptor expression, but no consistent results in any brain region 
(Meador-Woodruff and Healy, 2000).  I was able to find no evidence of a meta-analysis 
of these results, as was performed for DRD2 receptor expression (Weinberger and 
Laruelle, 2001).  There does however, appear to be a consistent decrease in protein and 
mRNA expression of the gluR1 and gluR2 subunits of the AMPA receptor in 
schizophrenic hippocampi, with decreased tracer binding to this receptor (Meador-
Woodruff and Healy, 2000).  Tracers for in vivo binding assays of NMDA receptors 
have only recently been developed, but early studies show decreased NMDA receptor 
binding availability in the left hippocampus of medication free schizophrenics.  This 
deficit seems to be compensated for by antipsychotic treatment (Pilowsky et al., 2005). 
 
When all this evidence is brought together, a hypothesis of glutamatergic hypofunction 
in the PFC resulting in schizophrenia seems very sensible.  However, until recently, this 
rather convincing set of evidence had failed to come up with any great therapeutic 
benefit.  Allosteric modulators acting at the glycine modulatory site show a mild 
improvement in negative symptoms when used as an adjunct, but are still not in common 
use (Tuominen et al., 2005).  In 2005 however, an mGlu2/3 receptor agonist reached 
Phase II clinical trials.  Electron microscopy suggests varying expression of mGlu2/3 in 
the brain, including pre-synaptically on glutamatergic corticostriatal neurons (Petralia et 
al., 1996).  Activation of these receptors with mGlu2/3 agonists results in depression of 
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corticostriatal synapses through a decrease in cAMP (Lovinger and McCool, 1995), 
giving them an important inhibitory function in transmission in this pathway.   
 
LY404039, a highly specific mGlu2/3 agonist, and olanzapine, a second generation 
antipsychotic, inhibit PCP induced locomotion in wild type rats.  In mGlu2/3 knockout 
rats, LY404039 had no inhibitory effect, suggesting that mGlu2/3 agonists and 
olanzapine act through a different pathway to achieve these effects (Patil et al., 2007).  
In a randomised and double blinded placebo controlled Phase II trial, LY404039 proved 
to be safe and well tolerated, without inducing the extra pyramidal side effects or weight 
gain commonly seen with DRD2 antagonising antipsychotics.  Reported side effects 
were generally mild, including insomnia, nausea, headache and drowsiness (Patil et al., 
2007).  Patients treated with LY404039 showed significant improvements above placebo 
in positive and negative symptoms, that began after 1 week of treatment, and continued 
for at least 4 weeks (Patil et al., 2007).   
 
The agonist in question is likely to potentiate, and not activate the mGlu2/3  receptor 
(Johnson et al., 2005), which may be hypofunctional under conditions of a 
hypoglutamatergic PFC.  This produces a rather counter intuitive picture, where 
hypofunction of glutamate at the mGlu2/3 receptor in the PFC leads to increased 
glutamatergic output elsewhere in the brain.  Thus compartmentalisation of synapses and 
location of cortical connections are crucial in determining the functional outcome.  
Because the drug appears to potentiate activity at this receptor, and not stimulate activity 
without endogenous activation, a more endogenous approach to therapy is allowed 
(Johnson et al., 2005).  It will be interesting to see how this therapy compares with 
standard antipsychotic treatment in future trials. 
 
1.10.3 Bringing dopamine and glutamate together 
There is currently a chicken and egg style debate over which dysregulation, 
dopaminergic or glutamatergic, is the causative factor in schizophrenia.  While the 
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intricacies of this argument could fill a thesis alone, it is clear that the two pathways do 
not act in isolation.  Glutamatergic function in the PFC is intricately linked to dopamine 
transmission in the PFC and striatum.  Treatment of the contralateral PFC with 
tetrodotoxin, a general sodium channel blocking neurotoxin, leads to decreased 
dopamine release in the medial striatum (Mignon, 1996).  Blockade of the tonic 
GABAergic input to the striatum using bicuculline results in increased dopaminergic 
tone in the medial striatum (Mignon, 1996), suggesting the presence of both an 
excitatory and inhibitory input from the PFC to dopaminergic tone in the striatum (Abi-
Dargham, 2005).  Chronic users of ketamine have increased DRD1 availability in the 
dorso-lateral PFC (Narendran et al., 2005).  In healthy subjects, ketamine administration 
leads to a greater decrease in tracer binding on amphetamine treatment, implying 
enhanced dopamine release (Kegeles et al., 2000) 
 
The mGlu2/3 agonist allows for further insight into possible connections between these 
two theories.  As previously discussed, hypoglutamatergic conditions in the PFC may 
lead to hypofunction of presynaptic mGlu2/3 on corticostriatal afferent connections.  
This may lead to increased excitation of these connections, and thus aberrant excitation 
of dopaminergic tone in the striatum.  Further work is needed to truly establish the 
importance and the causation of dysfunction in these pathways in schizophrenia, and 
establish a hierarchy of effects.   
 
What is clear thus far, is that all these pathways are interconnected, that there is a 
potential role for numerous neurotransmitters (I have not covered serotoninergic and 
GABAergic connections in this review, both of whom have a large amount of literature 
linking them to psychiatric disorder) (Benes, 2002, Aghajanian and Marek, 2000),   and 
that a small malfunction in one component of their downstream circuitry may lead to 
more wide scale disarray, that manifests as psychiatric disorder.  For this reason, a more 
physiological target for psychiatric disease management may be the molecules that 
mediate the crosstalk between these pathways, allowing for activity dependant 
modulating of risk pathways, such as the mGlu2/3 receptor agonist, the PDE4s and 
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GSK3β.  As evidence for schizophrenia risk variants in genes increases, more of these 
mediating proteins and pathways may be highlighted.  This may allow a refinement of 
our approach to diagnosing psychiatric disease, being able to define subtypes of 
psychiatric disorder resulting from the actions of a combination of specific risk factors.  
The ultimate goal of redefining psychiatric disease through these principles lies in the 
potential for personalised medication, designed to correct specific deficits in a highly 
localised fashion, thus possessing a less damaging side effect profile and leading to 
better compliance than the drugs currently in use.  Approaches such as this are just 
beginning to show therapeutic value in other complex diseases such as breast cancer 
(Huber et al., 2009). 
 
1.10.4 Phosphodiesterase inhibition 
 
Phosphodiesterase inhibitors are already widely used therapeutically in treatment of 
vascular (Feldman and McNamara, 2002) and inflammatory diseases, as well as 
cognitive disorders (Rose et al., 2005).  The efficacy of highly successful subtype 
specific inhibitors has been demonstrated by the use of PDE5 inhibitors in the treatment 
of male erectile dysfunction (Burnett, 2005) and PDE3 inhibitors for the specific 
treatment of intermittent claudication (Doggrell and Doggrell, 2001).  Recent research 
by Menniti et al, 2007, has highlighted a possible role for specific inhibitors of the dual 
substrate PDE10A in the treatment of psychosis related to schizophrenia, which they 
attribute to alterations in cAMP mediated activity in medium spiny neurons in the basal 
ganglia pathways which form a “brake” for behaviour (Menniti et al., 2007).  They also 
cite potential positive effects on the cognitive component of schizophrenia after early 
mouse studies on PCP induced deficits in extra dimensional “set shifting” (a measure of 
attentional selection processes), which are attributed to improved corticostriatal 
neurotransmission on PDE10A inhibitor treatment (Rodefer et al., 2005).   The Authors 
suggest that PDE10A treatment could potentially have an effect on improving executive 
function in schizophrenic patients. 
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Rolipram is an antidepressant that specifically inhibits PDE4s via occupation of much of 
the cAMP binding site (Xu et al., 2004) which reached Phase II of Clinical Trials in 
1983 as an anti depressant. Little investigation has been done into its specific use as a 
treatment in schizophrenia, despite suggestions that people with schizophrenia have 
altered cAMP mediated signal transduction in platelets and post mortem brain fractions 
(Robichaud et al. 1999).  The lack of investigation is mainly due to the common side 
effects of Rolipram administration, the most limiting being emesis (Dyke and Montana, 
2002) and sedation (O'Donnell and Zhang, 2004).  The drug also has a narrow 
therapeutic window.  It is thought that these side effects are mediated at least partly 
centrally through the action of Rolipram on PDE4D, which is highly expressed in the 
squirrel monkey (a useful model as rats and mice do not vomit) in the area postrema and 
neurons of the nucleus tractus solitarius and locus coeruleus, areas involved in triggering 
emesis (Lamontagne et al., 2001).   
 
There are multiple challenges ahead for the search for clinically useful subtype specific 
PDE inhibitors.  There is still a huge lack of understanding over the subtle differences in 
expression pattern, localisation and function of not only the PDE4B and PDE4D 
isoforms, but also the long and short variably spliced subtypes of each isoform.  Where 
these complex patterns fit into the signalling pathways potentially mediating 
schizophrenia is another step beyond this.  With largely similar structures, refining 
compounds to specifically alter the activity of one isoform is difficult.  Finally, PDE4s 
are known to have two different states, the high and low-affinity rolipram binding states 
(termed HARBS and LARBS respectively).  The HARBS is almost exclusively found in 
the brain, particularly the hippocampus, frontal cortex and olfactory bulb.  The LARBS 
however is found in peripheral tissues as well as the brain (Zhao et al., 2003).  Initial 
results from recent experiments by Zhang et al suggest that the HARBS is most 
important in mediating the anti depressant effects resulting from Rolipram, with PDE4 
inhibitors CDP840, MEM1018 and MEM1091, which have a lower affinity for the 
HARBS conformation, requiring a five fold dosage to produce effects comparable to 
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Rolipram in the Forced Swim Test.  These inhibitors completely failed to produce an 
effect in the Differential Reinforcement of Low Rate 72-s operant schedule (Zhang et 
al., 2006).  Both these commonly used animal models are sensitive to antidepressant 
drugs.   
 
Recently, allosteric modulators that target the UCR2 domain of PDE4 have been 
developed.  In PDE4D, at residue 196, a phenylalanine protrudes from UCR2 and 
extends towards the active site.  This residue is a tyrosine residue in PDE4A, B, and C, 
and is important in binding of allosteric modulators.  This difference in charge can be 
capitalised on, and selective inhibitors developed with PDE4D selectivity .  To this end, 
an allosteric modulator has been developed with PDE4D selectivity (Burgin et al., 2010) 
that performs more potently than rolipram in augmenting long term memory and in 
rescuing a scopolamine induced deficit in spatial working memory.  Importantly, this 
inhibitor is 3000 times less emetic than Rolipram in beagle dogs, and 500 times less 
emetic in cynomolgus monkeys (Burgin et al., 2010).  
 
 
1.11 Aims of this PhD 
 
In this introduction I have detailed a number of pathways implicated in the development 
of not only schizophrenia, but also bipolar disorder and depression, including 
neurogenesis, neurotrophin, glutamatergic and dopaminergic signalling.  Central to all of 
these pathways is the integration of series of extracellular signals acting at neuronal 
receptors, to produce an output appropriate for the cellular context and intended purpose.  
cAMP acts as a key signalling molecule downstream of all of these receptors, and cAMP 
fluctuations are key for precise control of downstream effects, including gene expression 
and synaptic transmission.  DISC1 has also been linked to all of these conditions, 
through genetic, animal and in vitro studies, and seems likely to act as part of a common 
mechanism for susceptibility to psychiatric disease.  DISC1 interacts dynamically with 
the PDE4 enzyme family, two of whom are heavily linked to psychiatric disease by 
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genetic and pharmacological studies.  The PDE enzymes form the only means of 
inactivating cAMP fluxes within a cell.  There are also indications that DISC1 may bind 
and inhibit GSK3β, a further important signalling enzyme, perhaps as part of a complex 
involving PDE4.  The aim of my PhD therefore, is to investigate the hypothesis that 
DISC1 and GSK3β may be involved in regulating PDE4 activity, and thus play a role in 
modulating cAMP signalling downstream from GPCRs.  The thesis will therefore 
address these key points: 
 
It has been established that DISC1 binds PDE4 in a dynamic and isoform specific 
fashion.  I will first describe establishment of a model cellular system suitable for 
assaying PDE4 activity.  I will then discuss examination of the localisation of DISC1 
and PDE4B and D, and quantification of the expression of PDE4 isoforms in DISC1 
overexpressing and DISC1 knockdown cell lines (chapter 3).   
 
Secondly, I will describe the results of my assessment of the functional effects of the 
DISC1-PDE4 interaction in these cell lines, under basal and forskolin stimulated 
conditions Furthermore, I will discuss use of pharmacological inhibition of GSK3β to 
assess the effect it may have on PDE4 activity (chapter 4).  As before, this assay was 
performed under basal and stimulated conditions, in the presence of excess, or the 
absence of DISC1 (chapter 5).  
 
Thirdly, I describe investigation of the potential role of PDE4 downstream from two 
receptors implicated in psychiatric disease: the NMDA and DRD1 receptors.  Indirect 
evidence assessing cAMP accumulation in cortical slices has implicated PDE4 in cAMP 
inactivation downstream of NMDA receptor agonism.  I have assessed the suitability of 
using primary cortical neurons as a model to measure PDE4 activity.  I have 
characterised PDE expression in these cells using PCR, specific inhibitors of non-PDE4 
PDE enzymes, and then assayed PDE4 activity in response to treatment with NMDA 
and the DRD1 specific agonist A68930.  I will also describe investigation of PDE4 
activity in primary cortical neurons prepared from mice carrying point mutations in 
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DISC1.  Finally, I have performed immunocytochemistry on these neurons to investigate 











2  Materials and Methods 
 
2.1 Bioinformatics 
2.1.1 Phosphorylation Prediction 
Full protein sequences of human PDE4B and PDE4D were aligned using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) and submitted to a series of 
phosphorylation prediction databases with varying prediction methods.  Information 
from these databases was combined and tabulated. 
 
2.1.1.1 DISPHOS 1.3  
DISPHOS 1.3 (http://core.ist.temple.edu/pred/predhtml) uses information on the 
disorder of the protein surrounding potential phosphorylation sites to predict potential 
phosphorylation sites.  Predictions are not kinase specific.  A score of greater than 0.5 
indicates a potential phosphorylation site.  DISPHOS 1.3 accuracy is quoted as reaching 
81.3% +/- 2.2% for Serine, 74.8% +/- 2.5% for Threonine, and 79.0% +/- 2.4% for 
Tyrosine (DISPHOS). 
 
2.1.1.2 Scansite 2.0 
Scansite 2.0 (http://scansite.mit.edu/) provides kinase specific predictions of 
phosphorylation potential by comparison with 62 known phosphorylation motifs 
identified by peptide libraries.  Scanning is available at three different stringencies: high, 
medium and low.  The high stringency setting for example, will only report a site that 
falls within the top 0.2% of scores for that motif within the SwissProt vertebrate 
database.  Medium and low stringency hits will lie within the top 1 and 5% respectively.  




2.1.1.3 Phosphomotif Finder 
Phosphomotif Finder (http://www.hprd.org/PhosphoMotif_finder) searches sequences 
entered by the user for published kinase specific phosphorylation motifs, with 
information about the motif sequence and links to the literature for that motif freely 
available.  As such, there is no scoring system (Amanchy et al., 2007). 
 
2.1.1.4 KinasePhos 2.0 
KinasePhos 2.0 (http://kinasephos2.mbc.nctu.edu.tw) uses algorithms based on the 
coupling and distance between amino acids to provide a score relating to the potential 
for phosphorylation by specific kinases.  Predictive accuracy is quoted as 90, 93, 88 and 
93% for serine, threonine, tyrosine and histidine respectively (Wong et al., 2007).   
 
2.1.1.5 NetPhosK 1.0 
NetPhosK (http://www.cbs.dtu.dk/services/NetPhosK/) is trained to identify known 
kinase specific phosphomotifs, and employs these trained neural networks to identify 
further sites in sequences supplied by the user.  Studies by the developers claim higher 
predictive sensitivity than Scansite, with an even rate of false positive findings (Nikolaj 









2.2 Cell Culture 
 
2.2.1 Cell Line Maintenance 
 
Cell lines were grown at 37
o
C, 5% CO2 in a Galaxy 170S or Galaxy 170 incubator 
(Scientific Laboratory Supplies).  All reagents involved with cell culture were Gibco 
from Invitrogen.  HEK293 and SHSY5Y cells were grown in D-MEM with 10% Foetal 
Bovine Serum in Cell Star T25, T75 or T175 flasks.  Cells were split when they reached 
90-95% confluency, on average every 4-7 days.  All cell culture work was performed in 
an Envair Bio2+ Class II Safety Cabinet under containment level 1.   
 
To split cells, old media was aspirated, and cells rinsed twice with warm PBS and once 
with warm TrypLE.  Fresh TrypLE was added and incubated for 2-5 minutes, without 
removing the flask from the safety cabinet.  Cells were detached by tapping the flask, 
and at least 4 volumes of fresh media were added.  Detached cells were then pipetted 
multiple times to disperse clumps of cells, and removed to a new flask at dilutions of 
1:5-1:10 depending on future use.   
 
Where cells were to be used for lysate preparation, a T75 of SHSY5Y cells was 
generally split 1:5 into T25 flasks.  Cells were then grown for 1-3 days to 75-90% 
confluency, depending on whether transfection or functional assays were required.  
When cells were to be used for immunocytochemistry, cells were split into individual 
wells of Costar 12 Well Plates (Corning), each containing a single 16mm sterile glass 
coverslip (VWR) and 2mls DMEM, and grown until approximately 80% confluency.  If 
cells were to be nucleofected, they were grown to 80% confluency in T75 flasks, then 
treated as per Nucleofector Kit instructions.    
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2.2.2 Preparation and Maintenance of Mouse Primary Cortical 
Neurons 
If neurons were being used for immunocytochemistry, then coverslips were pre treated 
with 100% ethanol, before being heat dry sterilised.  One day prior to neuron production, 
plates were coated overnight with Poly-D-Lysine solution.  Plates were washed with 
distilled water prior to plating neurons.  If primary neurons were to be used for PDE 
assays, then 6 well plates were coated overnight with Poly-D-Lysine solution, and 
washed with distilled water prior to neuron plating.  Washed and dried cover slips and 6 
well plates can be stored at 4
o
C for up to two months. 
 
Pregnant E18 mice (CD1 or C57BL/6) were killed by schedule 1 procedure by trained 
staff at the animal facility, and then passed to me for dissection.  Embryos were 
dissected out of the mother on ice, and the brains removed to ice cold dissection buffer.  
Using a Leica MZ6 microscope with a Fiber-Lite MI-150 High Intensity Illuminator, the 
meninges were peeled from the whole brains, the cortices removed to a petri dish 
containing new dissection buffer and the hippocampi discarded.  Cortices were kept in 
fresh dissection buffer on ice until all brains were dissected.  The dissection buffer was 
then removed from the cortices, which were added to 0.1% trypsin solution in a Falcon 
tube (50mls solution per 10 pups).  Cortices were incubated in trypsin solution for 45 
minutes, before 5 passages through a wide plastic Pasteur pipette.  This resulting mixture 
was centrifuged for 5 minutes at 1500rpm, and the supernatant discarded.  The pellet 
was resuspended in 20mls DMEM with 10% FBS, then passaged 15 times through a 
wide Pasteur pipette, before a further 5 minutes centrifugation at 1500rpm.  Again the 
supernatant was discarded, the pellet resuspended in 10mls DMEM with 10% FBS, and 
the solution passaged 20 times through a wide necked, then 10 times through a fine 
necked plastic Pasteur pipette.  A third centrifugation for 5 minutes at 1500rpm was 
performed, and the pellet resuspended in 10mls DMEM without FBS.  The resulting 
solution was passed through a 40µM cell filter, and the cell number counted using a 
haemocytometer.  After a final centrifugation, the cells were resuspended in Neurobasal 




 cells per well in a 12 well plate, and 6x10
5
 per well in a 6 well plate.  
Cells were incubated at 37
o
C, 5% CO2 in a Galaxy 170 incubator. 
 
For continuing culture, half the growth medium was removed and replaced with fresh 
medium at 7 days in vitro.   
 
2.2.3 Transfection of plasmids into eukaryotic cell lines 
To exogenously express protein in cell line cultures, two methods were used: 
Lipofectamine 2000 lipofection for HEK 293 cells and stable cell line production in 
SHSY5Y cells, and Nucleofection for SHSY5Y cells in immunocytochemistry and 
functional assays.  Expression plasmids are detailed where used in the appropriate 
results chapter. 
2.2.3.1 Lipofectamine transfection (Invitrogen) 
To transfect SHSY5Y cells for stable cell line production, cells were plated in 10cm cell 
culture dishes (Iwaki) and grown to approximately 70% confluency. 
Lipofectamine2000:DNA complexes were made up in room temperature Opti-MEM 
according to the manufacturer’s instructions, containing 24µg of DNA and 60µl 
Lipofectamine 2000.  Old media was aspirated from the plates, and cells were washed 
twice with warm OptiMEM.  Cells were incubated with the lipofection complexes for 6 
hours, and the medium replaced by fresh 10% FBS DMEM.   
 
To transfect HEK cells to test DISC1 expression once subcloned into the TO vector, 
cells were grown to approximately 80% confluency in T25 flasks.  Lipofectamine 
complexes were made up as above, containing 8µg DNA and 20µl Lipofectamine 2000.  
The procedure was performed as above, and cells were lysed with 200µl REPA buffer 
the day after transfection for Western Blotting. 
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2.2.3.2 Nucleofection (Lonza) 
Nucleofection was performed according to the manufacturer’s protocol, summarised 
below.  12 well plates or T25 flasks were filled with 1ml DMEM (2 wells of a 12 well 
plate were used to plate each nucleofection transfection) and pre warmed in an 
incubator.  A T75 flask of SHSY5Y cells was grown to approximately 80% confluency.  
Cells were detached from the flask by rinsing with warm PBS then TrypLE.  Cells were 
incubated in TrypLE for less than five minutes, and resuspended in fresh DMEM with 
10% FBS.  Cell concentration was determined using a haemocytometer, and the 
appropriate number of cells spun in a centrifuge (1x10
6
 cells per transfection sample for 
ICC, 2x10
6
 for functional assays, 1000rpm for 5 minutes at 37
o
C).  Cells were 
resuspended in 100µl Nucleofector Solution (with supplement added) per transfection 
reaction.  100µl of cell suspension was combined with 2µg of the required DNA.  This 
mixture was transferred to a sterile Nucleofector cuvette, the cap closed, and placed in 
the Nucleofector machine.   Program A-023 for high cell viability was selected and 
applied.  The cuvette was removed immediately from the machine, and 1ml of warm 
10% DMEM added to the mixture.  This mixture was then split into 2 wells of a 12 well 
plate for ICC, or wholly into a T25 flask for functional assays, and could be grown for 
up to 4 days post transfection.   
 
2.2.3.3 Assessing transfection rate in SHSY5Y cells by FACS scanning 
SHSY5Y cells were transfected by both methods described previously with the pmax 
GFP plasmid supplied in the Nucleofector kit, and grown overnight in 6 well plates.  The 
next morning, cells were detached using TrypLE, then resuspended in PBS for FACS 
scanning.  Cell suspensions were fed into the machine (FACS Calibur, BD Biosciences) 
using the standard machine protocol, and the number of cells expressing GFP were 
counted, as a percentage of the total cells counted.    
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2.2.4 Drug treatment  
2.2.4.1 SHSY5Y cells 
SHSY5Y cells and stable cell lines based on SHSY5Y (TRTODISC1 DISC1 
overexpressing cells and T1 DISC1 knock down cells) were used to examine the effects 
of common drugs altering the activity of signalling pathways on PDE4 activity.  
Forskolin increases the intracellular concentration of cAMP through stimulation of 
adenylyl cyclase, and LiCl/SB216763 inhibits the activity of GSK3β.  SHSY5Y cells 
were grown in T25 cell culture flasks to approximately 90-95% confluency, and then 
serum starved overnight.  The appropriate concentration of drug was then added to the 
correct flasks the next morning, with a vehicle control of equal volume, as detailed in 
Table 2.1A  After the required treatment time had been completed, cells were rinsed 
once with ice cold PBS, and lysed with 3T3 lysis buffer for PDE assays to be performed. 
 
Drug Source Stock concentration Final concentration Vehicle Treatment time
Forskolin Sigma 50mM 10µM 1% EtOH 30 mins
Lithium Chloride Sigma 1M 3/10mM dH2O 30 mins
SB216763 Tocris 25mM 10µM DMSO 30 mins
 
Table 2.1A: Details of drug treatments performed on SHSY5Y cells. 
 
Drug Source Stock concentration Final concentration Vehicle Treatment time
NMDA & Glutamate Both Sigma 10mM NMDA 10µM dH2O 2/5 mins
100mM Glutamate 100µM dH2O
Lithium Chloride Sigma 1M 10mM dH2O 30 mins
SB216763 Tocris 25mM 10µM DMSO 30 mins
A68930 Sigma 1nM 1nM dH2O 2/5 mins
 
Table 2.1B: Details of drug treatments performed on primary cortical neurons. 
2.2.4.2 Primary neurons 
CD1 wild type, Q31L and L100P background control and mutant primary neurons were 
prepared as earlier described.  At 14 days in vitro, pre drug treatment, neurons were 
starved of B27 supplement and Glutamax (both Invitrogen) for 4 hours in 1ml of 
neurobasal medium only.  When treatment was commenced, a further 1ml of neurobasal 
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medium containing double the final concentration of drug was added to each well for the 
appropriate time.  Final concentrations and times are detailed in Table 2.1B.  Media was 
then aspirated, neurons rinsed once with ice cold PBS, and lysed with 3T3 buffer for 
PDE assays to be performed. 
 
2.2.5 Stable cell line production 
Previous attempts to produce a constitutively overexpressing DISC1 cell line had proved 
unsuccessful.  While this is interesting in itself, an alternative method of overexpression 
was needed in the face of low levels of transfection in SHSY5Y cells.  I used the 
Invitrogen T-REx system to produce a stable cell line that would inducibly overexpress 
DISC1 through the CMV promoter on application of tetracycline.  
2.2.5.1 Antibiotic sensitivity testing 
In order to select for cells successfully transfected with the pcDNA7/TRex and 
pcDNA4/TODISC1 plasmids, dual antibiotic selection was required with Zeocin and 
Blasticidin (both Invitrogen).  To this end, antibiotic sensitivity tests were performed on 
SHSY5Y cells.  6/7 plates of SHSY5Y cells per antibiotic were grown to 25% 
confluency, and a series of concentrations of Zeocin (0, 50, 125, 250, 500, 750 and 
1000µg/ml) and Blasticidin (0, 1, 3, 5, 7.5, 10µg/ml) added to the plates.  Selective 
media was replaced every 3-4 days, and the survival rate of the SHSY5Y cells 
monitored.  Final concentrations of 50µg/ml Zeocin and 2µg/ml were chosen, as these 
killed approximately 95% of cells after 2 weeks of selection. 
 
2.2.5.2 Stable cell line transfection and selection 
SHSY5Y cells were cotransfected with a ratio of 6:1 pcDNA6/TR:pcDNA4TODISC1, 
using a standard lipofectamine protocol as described in 2.2.3.1.  The cells were dual 
selected in DMEM with 10% foetal bovine serum, with antibiotic concentrations as 
described above.  After 12 days there was total cell death in the untransfected control 
plates (SHSY5Y subjected to Zeocin alone, Blasticidin alone, and both together), 
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whereas small colonies were growing in the transfected plates.  Successful colonies were 
picked using a Pasteur pipette and grown in 12 well plates for 4-6 weeks at 37
o
C in a 5% 
CO2 humidified incubator.  Selective media was replaced every 3-4 days.   
 
36 colonies were grown, of which 10 were tested for transgene expression.  Testing was 
performed by induction for 24 hours with 1µg/ml tetracycline, then Western blotting as 
described in 2.3.4.  Two successful clones were obtained, and the clone with stronger 
expression chosen for further work.   Successful clones were sequenced and the correct 
sequence confirmed.  Christoph Grünewald confirmed DISC1 mRNA overexpression in 
the stronger expressing clone by qPCR on the iCycler (BioRad) to a level of 5.07 (+/-
0.21, n=3) compared to uninduced cells (1.1 +/-0.28, n=3).  Protein overexpression was 
visualised by Western blot. 
 
2.2.6 DISC1 knockdown cell lines 
Fumiaki Ogawa kindly donated his DISC1 knock down SHSY5Y cell lines for my work 
(paper in submission).  Briefly, for reference, shRNA constructs were cloned into 
linearised pENTR
TM
/H1/TO using the Block-iT U6 system (Invitrogen).  The shRNA 
constructs used to generate these cell lines can be found in Table 2.2.  Stable cell lines 
generated from SHSY5Y as described in 2.2.5.2 using 50µg/ml Zeocin selection.  T0 
was a control line generated from a scrambled shRNA construct, shRNA for T1 was 
directed against the 3’UTR region, and for T2 against exon 2.  Knock down of the 
DISC1 L isoform mRNA was confirmed by Christoph Grunewald using qPCR on the 
iCycler (Biorad) to levels of 0.004 (+/-0.003) and 0.002 (0.002) in T1 and T2 cells 








Cell line Top strand Oligo Bottom strand Oligo Target
T0 CACCggatatcatgcaagtattaCGAAtaatacttgcatgatatccC AAAAgggatatcatgcaagtattaTTCGtaatacttgcatgatatcc Scrambled control
T1 CACCggatttgagaatagtttcaCGAAtgaaactattctcaaatccC AAAAgggatttgagaatagtttcaTTCGtgaaactattctcaaatcc 3' UTR of DISC1
T2 CACCgcgtgacatgcattctttaCGAAtaaagaatgcatgtcacgcC AAAAggcgtgacatgcattctttaTTCGtaaagaatgcatgtcacgc Exon 2 of DISC1
 
Table 2.2: shRNA constructs used by Fumiaki Ogawa to generate stable cell lines with constitutive knock down of DISC1. 
 
Name in text Specificity Species Source Conditions Notes
Anti-Flag Flag exogenous tag Rabbit Sigma x10,000
Anti-myc c-myc exogenous tag Mouse Santa Cruz Biotechnology x500
D6692 DRD1 Rabbit Sigma x200
MAB363 NR1 Mouse Chemicon x500
PDE4B (MH) Pan PDE4B Sheep Miles Houslay
1
x1000
PDE4D (MH) Pan PDE4D Sheep Miles Houslay
1
x1000
αDISC1 DISC1  Rabbit Professor Akiyama
2
x2000
Donkey anti sheep Sheep Ig Donkey Invitrogen x800 Secondary, fluorescent (594nm)
Goat anti mouse Mouse Ig Goat Invitrogen x500 Secondary, fluorescent (594nm)
Goat anti rabbit Rabbit Ig Goat Invitrogen x500 Secondary, fluorescent (488nm)
Goat anti rabbit Rabbit Ig Goat Invitrogen x800 Secondary, fluorescent (594nm)  
Table 2.3A: A list of all antibodies used for immunocytochemistry in this thesis. Incubation times were 1 hour for all antibodies, 
primary and secondary.  1Miles Houslay directs the Molecular Pharmacology Group, University of Glasgow. 2Professor Akiyama 
heads his own group in the Laboratory of Genetic and Molecular Information, University of Tokyo. 
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Name in text Specificity Species Source Conditions Notes
GAPDH 36 kDa GAPDH Mouse Chemicon x80000 O/N
PDE4B (MH) Pan PDE4B Sheep Miles Houslay
1
x5000 O/N
PDE4D (MH) Pan PDE4D Sheep Miles Houslay
1
x5000 O/N
Zymed C-term DISC1 C terminal Rabbit Zymed x200 O/N
αDISC1 DISC1  Rabbit Professor Akiyama
2
x10000 O/N
Donkey anti mouse Mouse Ig Donkey Dako x80000 30 mins HRP conjugated secondary
Donkey anti sheep Sheep Ig Donkey Dako x2000 20 mins HRP conjugated secondary
Swine anti rabbit Rabbit Ig Swine Dako x3000 20 mins HRP conjugated secondary
 
Figure 2.3B: A list of all antibodies used for Western blotting in this thesis.  O/N refers to overnight incubation with the primary 
antibody on a shaker at 4oC.  Primary antibodies were diluted in blocking buffer, secondary antibodies diluted in wash buffer.  
1Miles Houslay directs the Molecular Pharmacology Group, University of Glasgow. 2Professor Akiyama heads his own group in the 
Laboratory of Genetic and Molecular Information, University of Tokyo. 
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2.3 Protein Related Methods 
2.3.1 Antibodies 
Various antibodies were used to perform immunocytochemistry and a western blot 
during this project.  Details of the antibodies and conditions used can be found in Table 
2.4. 
2.3.2 Cell and Primary Neuron lysate preparation 
To produce cell lysates for the Western blot and PDE assays, SHSY5Y or HEK cells 
were grown to approximately 80-95% confluency in T25 cell culture flasks.  Primary 
neuron cultures were grown in 6 well plates at a density of 1.5x10
6
 neurons per well.  
Cells were treated (either drug treatment or transfection), and the media aspirated off.  
Cells were then rinsed once with ice cold PBS, and the appropriate amount of lysis 
buffer added.  200µl of RIPA buffer was used per T25 for Western blotting.  200µl of 
3T3 buffer was used for 3T3 assays.  For neurons, 60µl of 3T3 buffer was added per 
well.  Lysis buffer was well distributed across the surface by rolling, then a disposable 
cell scraper used to ensure detachment of all cells into the buffer.  The lysate was then 
pipetted into labelled eppendorf tubes, and spun at 25rpm at 4
o
C for 1 hour on a rotary 
wheel.  Lysates were then centrifuged at 13,000 rpm for 60 minutes in a desk top 
centrifuge (Biofuge Fresco, Heraeus Instruments), and the supernatant removed to a 
fresh eppendorf.  Lysates were stored at -80
o
C until use.  
2.3.3 Determining protein concentration of cell lysates 
The concentration of total protein in cell lysates was measured using the BioRad protein 
concentration assay.  Six concentrations of the BSA Protein Standard were prepared at 0, 
0.2, 0.4, 0.6, 0.8 and 1mg/ml.  Lysates were diluted ten times by adding 2.5µl of lysate 
to 22.5µl dH2O in triplicate.  To each of these preparations, 125µl of Reagent A and 1ml 
of Reagent B were added, and left to develop for up to 30 minutes at room temperature.  
The contents of each tube were removed to disposable cuvettes and read at an 
absorbance of 750nm using an Ultrospec 3000 Optical Reader (Pharmacia Biotech).  
The results for the protein standards were plotted in an excel spreadsheet to generate a 
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line graph.  The equation for this line was used to determine the concentration of the cell 
lysates.   
 
2.3.4 Western blotting 
Western blotting allows the protein present in a crude lysate to be separated on a gel by 
virtue of their difference in size, in this case enabling detection of overexpressed DISC1 
on SHSY5Y inducible cell lines.   
 
20µg of RIPA lysed protein samples were diluted in dH2O to 2µg/µl and mixed 1:1 with 
protein sample buffer, and 1:10 with DTT, to solubilise protein and reduce disulphide 
bonding respectively.  Samples were then boiled for 5 minutes to denature protein, and 
disrupt protein-protein interactions. 15µl of each boiled mixture was loaded, along with 
a standardised protein size ladder (Precision Plus Protein All Blue Standard, BioRad) 
onto 7% Invitrogen gels (to detect DISC1 at 100kDa).  Samples were electrophoresed at 
150V for 60-90 minutes, in NuPage Tris Acetate SDS Running Buffer (Invitrogen) using 
an Xcell Surelock Electrophoresis Cell connected to a Power Pac 3000 (BioRad).   
Before transferring, an Invitrolon PVDF membranes (Invitrogen) was soaked in 
methanol then NuPage Transfer Buffer.  Five sponges were also soaked in the transfer 
buffer.  The gel containing the separated protein was then cracked open, and loaded into 
an XCell II Blot Module as follows: 3 x soaked sponges, card, gel, membrane, card, 2 x 
soaked sponges.  The Blot Module was then filled with transfer buffer and connected to 
the PowerPac3000 at 30V for 60 minutes.  The module was cooled by the addition of 
cold water to the exterior box.  Ponceau staining confirmed protein transference onto the 
membrane, which was then blocked for one hour at room temperature on a rocker.   
 
2.3.4.1 Immunostaining of Western blot 
Post blocking, the primary antibody was added at the appropriate concentration to 
blocking buffer (see Table 2.3), and incubated overnight at 4
o
C.  Membranes were 
washed with wash buffer (2 quick washes, 1x15 minutes, 3x5 minutes while being 
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rocked at less than 35rpm), then stained with secondary antibody diluted in wash buffer 
for 20-30 minutes. The washing process was repeated before detection using ECL Plus 
Western blotting detection reagents (Amersham Biosciences).  After 5 minutes of 
developing, ECL Plus was blotted from the membrane, and the membranes exposed to 
photosensitive paper (Scientific Laboratory Supplies) for 2-10 minutes.  Film was 




Immunocytochemistry (ICC) can be used to visualise the localisation of endogenous 
proteins or overexpressed tagged protein within cells.  Primary antibodies directed 
against the protein of interest or the exogenous tag are incubated onto cells fixed to glass 
coverslips.  Secondary antibodies can be attached to the primaries by virtue of the 
animal it is raised in, and these secondaries are connected to a fluorescent tag that can be 
visualised using a fluorescence or confocal microscope. 
 
2.3.5.1 Fixing and immunostaining of cells for ICC 
Before ICC can be performed, cellular processes must be halted, and protein epitopes 
exposed to antibodies by virtue of a process called fixing.  Cells were grown on glass 
coverslips to around 75% confluency, to enable better visualisation of individual cells.  
Media was aspirated from the cells, which were then rinsed twice with ice cold PBS and 
fixed with chilled methanol for 10 minutes.  Fixed cells were then washed three times 
with cold PBS.   
 
Cover slips were blocked for 20 minutes at room temperature with 3% BSA in PBS. The 
wells were emptied, then primary antibodies diluted in 3% BSA/PBS were added for 1 
hour.  If two antibodies are being used, it is important to note that they must have been 
derived from different animals, in order to use two different secondary antibodies.  Cells 
were rocked gently (less than 30rpm) throughout washes and incubation with antibodies.  
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Cover slips were rinsed with PBS (2x quick washes, 3x5minutes) then secondary 
antibodies diluted in 3% BSA/PBS were applied for one hour.  As the secondary 
antibodies are fluorescent, the dish was wrapped in foil during this incubation.  The 
washing process was repeated, before inverting the cover slips to mount them onto slides 
with Mowiol plus 250ng/µl DAPI.  Slides were stored in the dark at 4
o
C before 
visualisation using either a Zeiss Axioskop 2 microscope or more often, a Zeiss Laser 
Scanning Microscope 510 with LSM510 bespoke software.   
 
2.3.5.2 Confocal Microscopy 
Confocal microscopy enables more accurate analysis of colocalisation of 
immunostaining, by using lasers of the appropriate wavelength to image the signal from 
the fluorescent dyes in a single Z plane.  Images can be taken at Z planes throughout the 
fixed sample, to give a cross sectional view of the cells being imaged.  Confocal 
microscopy was performed on a Zeiss LSM510 Confocal Microscope with LSM510 
bespoke software.  As this particular microscope had no laser suitable for imaging DAPI 
staining, a fluorescent image of nuclear staining was also obtained with each confocal 
image.  Single colour images and merged pseudo DAPI images were produced on IPLab 
software. 
 
Colocalisation of two signals was further examined by the use of the Image Correlation 
Analysis plugin for ImageJ (Li et al., 2004).  After background correction, this plugin 
generates a series of statistics relative to colocalisation.  These are dealt with in great 
detail in the aforementioned reference, but basically consist of the Pearson correlation 
coefficient, (where -1 represents exclusion, 0 random localisation, and 1 complete 
correlation), The Mander’s overlap coefficient (0 represents low colocalisation, 1 
represents high colocalisation) and the Intensity Correlation Quotient (ICQ).  The ICQ is 
the most complex of these measures, and takes into account the variation in intensities of 
each signal to produce a number between -0.5 and 0.5, where 0 equals random staining, 
negative figures show segregated staining and positive figures dependent staining.   
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2.4 Molecular Biology Methods 
 
2.4.1 PCR Primers 
 
Reference sequences of mouse cAMP PDEs and human PDE4s were identified from 
NCBI Entrez Gene and used to design exon boundary crossing primers using the NCBI 
Primer-BLAST designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi).  This relatively new tool combines the Ref Seq data on exon structure, 
Primer3 functionality for matching melting points and stipulating PCR product size, and 
the NCBI BLAST (Basic Local Alignment Search Tool) function to ensure specificity of 
primers.  A complete list of all oligonucleotide primers used for PCR in this thesis can 
be seen in Table 2.4A-B.  Primers were supplied by Sigma custom primer systems.     
2.4.2 PCR Reactions 
PCR was used as a tool to amplify untagged DISC1 for insertion into an expression 
plasmid, and to detect the expression of the various isoforms of PDE present in cDNA 
from whole mouse brain and primary neurons.  Finally, quantitative real time PCR was 
used to detect fold changes in PDE4 expression in SHSY5Y cell lines overexpressing 
DISC1 and with constitutive DISC1 knockdown.  Different versions of the basic PCR 
reaction were used for each of these functions.  Basic PCR reactions were performed on 
a PTC-225 Peltier Thermal Cycler (MJ Research).  Quantitative real time PCR was 







2.4.2.1 PfU Ultra Fusion Polymerase 
To amplify DISC1 as in insert while introducing novel restriction sites, a high fidelity 
polymerase was required.  The reaction was set up as follows: 
 
 1.0µl  5ng/µl DNA plasmid template  
 2.5µl  20pmols/µl 5’ primer 
 2.5µl  20pmols/µl 3’ primer 
 5.0µl  10x reaction buffer 
 1.25 µl  10mM dNTPs 
 Add dH2O to 49µl 
 1µl  PfU Ultra Fusion Polymerase (Stratagene) 
 
Reaction conditions were as follows: 
  1. 95
o
C 2 minutes 
  2. 95
o
C 30 seconds 
  3. 60
o
C 30 seconds 
  4. 72
o
C 45 seconds 
  5. Repeat steps 2-4 an additional 29 times 
  6. 72
o
C 10 minutes 
  7. 4
o
C Holding temperature 
2.4.2.2 Standard PCR Reaction 
To detect the presence of PDE isoforms in cDNA, a standard PCR reaction was used. 
 
 2.0µl  10x PCR buffer 
 0.6µl  5mM dNTPs 
 0.25µl  5µM 5’ primer 
 0.25µl  5µM 3’ primer 
 2µl  cDNA template 
 Up to 17.8µl with dH2O  
 0.2µl  In house produced Taq 
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Reaction conditions were as follows: 
  
  1. 95
o
C 2 minutes 
  2. 95
o
C 30 seconds 
  3. 65
o
C 30 seconds 
  4. 72
o
C 30 seconds 
  5. Repeat steps 2-4 an additional 29/34 times 
  6. 72
o
C 10 minutes 
  7. 4
o




Name Direction Sequence Purpose
WT DISC1 5' 5' GATCGAATTCGCCGCCATGCCAGGCGGGGGTCCTCAGGGC Cloning of DISC1 with a 5' EcoRI site 
WT DISC1 3' 3' GATCGCGGCCGCTCAGGCTTGTGCTTCGTGGACACC Cloning of DISC1 with a 3' NotI site 
HPan PDE4A fwd 5' CCAGAACCTCAGCAAGCGCCA Detection of PDE4 expression changes 
HPan PDE4A rev 3' TCCGGAGGACCTGGATGCGG Detection of PDE4 expression changes 
HPan PDE4B fwd 5' CCGATCGCATTCAGGTCCTTCGC Detection of PDE4 expression changes 
HPan PDE4B rev 3' TTTCCATTCCCCTCTCCCGCT Detection of PDE4 expression changes 
HPan PDE4C fwd 5' GACGCCCTTTGCCCAGGTCC Detection of PDE4 expression changes 
HPan PDE4C rev 3' CCAGCTTCTGCCCCGTGTCC Detection of PDE4 expression changes 
HPan PDE4D fwd 5' TGCTCAGGTCTTGGCCAGTCTGC Detection of PDE4 expression changes 
HPan PDE4D rev 3' TCCTCCAGGGTCTCGCTGGC Detection of PDE4 expression changes 
GAPDH fwd 5' TCAAGATCATCAGCAATGCC Detection of "Housekeeping" genes in qPCR
1
GAPDH rev 3' ATCCACAGTCTTCTGGGTGG Detection of "Housekeeping" genes in qPCR
1
RPLPO fwd 5' AATGGCAGCATCTACAACCC Detection of "Housekeeping" genes in qPCR
1
RPLPO rev 3' CCGTTGATGATAGAATGGGG Detection of "Housekeeping" genes in qPCR
1
PPIA fwd 5' AGACTGAGTGGTTGGATGGC Detection of "Housekeeping" genes in qPCR
1
PPIA rev 3' TCGAGTTGTCCACAGTCAGC Detection of "Housekeeping" genes in qPCR
1
B2M fwd 5' AAAGATGAGTATGCCTGCCG Detection of "Housekeeping" genes in qPCR
1
B2M rev 3' AGCAAGCAAGCAGAATTTGG Detection of "Housekeeping" genes in qPCR
1
 
Table 2.4A:  A table showing the human PCR primers employed during this project.  Primers based on human 
sequence information were used for cloning of DISC1 for insertion into the pcDNA4/TO vector, detection of PDE4 
isoform expresson changes in SHSY5Y based DISC1 knockdown and over expressing lines, and detection of stable 





Name Direction Sequence Purpose
Pan PDE2A fwd 5' GGGCTGGGACCTTCGGACCT Detection of PDE isoforms 
Pan PDE2A rev 3' GCAGGGCTACCAGAGCGTGC Detection of PDE isoforms 
Pan PDE3A fwd 5' CGGCTCAGCAAGCGACTCCG Detection of PDE isoforms 
Pan PDE3A rev 3' ATAGCACCGCCTGAGGGGCA Detection of PDE isoforms 
Pan PDE3B fwd 5' AGCTCTGGAGCCTCATCGTTGCT Detection of PDE isoforms 
Pan PDE3B rev 3' GCTGGGCAAAGCACCAGCTCT Detection of PDE isoforms 
Pan PDE4A fwd 5' CACGCCTGCACTGGATGCCG Detection of PDE isoforms 
Pan PDE4A rev 3' CGCTGGCGCTTGCTGAGGT Detection of PDE isoforms 
Pan PDE4B fwd 5' AGCCAAGGAGCTGGAAGACCTGA Detection of PDE isoforms 
Pan PDE4B rev 3' CTGGGCCACGTCAGCAGCAT Detection of PDE isoforms 
Pan PDE4C fwd 5' CGCATCCAGCAGGGTGACCG Detection of PDE isoforms 
Pan PDE4C rev 3' TGTGTGGAGGGCTGCAGGGA Detection of PDE isoforms 
Pan PDE4D fwd 5' TGGGGCCTCCACGTTTTCCG Detection of PDE isoforms 
Pan PDE4D rev 3' ACACAGCCTCCAAAGCGGGTG Detection of PDE isoforms 
Pan PDE7A fwd 5' ATTGCAGCCGCCACTCACGA Detection of PDE isoforms 
Pan PDE7A rev 3' TGAGCCTCCATCTCTTGCCTGCT Detection of PDE isoforms 
Pan PDE7B fwd 5' ACAAGCAAGGCACATGCTCTCCA Detection of PDE isoforms 
Pan PDE7B rev 3' GGTGACGTCGGCTGCGTGAA Detection of PDE isoforms 
Pan PDE8A fwd 5' AGCCCAGGAGAGTGAGGAACCTG Detection of PDE isoforms 
Pan PDE8A rev 3' CACGGGCATCACCACAGGCA Detection of PDE isoforms 
Pan PDE8B fwd 5' TGGCAGCTGAGAGTGAGGGCA Detection of PDE isoforms 
Pan PDE8B rev 3' GCATCACCACAGGCAGCCCC Detection of PDE isoforms 
Pan PDE10A fwd 5' GTCCCTCAAGGGCAGCTCGG Detection of PDE isoforms 
Pan PDE10A rev 3' TCAGGTGTGCTCTTGCTAGGCG Detection of PDE isoforms  
Table 2.4B: A table showing the mouse PCR primers used during this project.  Primers based on mouse sequence 
information were used for detecting cAMP PDE isoforms in cDNA prepared from whole mouse brain and cultured 
primary neurons.  
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2.4.3 Quantitative Real Time PCR 
Quantitative RT PCR was used to assess potential changes in the expression of the 
PDE4 isoforms in TRTODISC1 after 24 hours tetracycline treatment, and to compare 
the constitutive knock down line T1 with its T0 control line.  Primers were designed as 
detailed in 1.4.1, and tested on one cDNA sample and a no reverse transcriptase control.  
Primer specificity was confirmed for hPDE4A, hPDE4B and hPDE4D, using the PCR 
protocol below.  No expression was detected for hPDE4C, as was predicted from the 
literature.  Standard dilution curves were performed for the three successful primers, 
using consecutive factor of 10 dilutions of cDNA from undiluted to 1:1000.  Successful 
standard curves were obtained, and final experiments performed using 3 sets of cDNA 
kindly supplied by Christoph Grünewald.  2 technical replicates of these samples were 
performed.   
 
2.4.3.1 Basic Quantitative PCR Reaction 
Where large scale experiments were performed, two master mixes were prepared.  The 
first of these contained SybrGreen, cDNA and dH2O.  The second contained primer pairs 
diluted in dH2O.   
 
 10µl  SybrGreen (BioRad) 
 1µl  cDNA diluted 1:10 
 1µl  10µM forward primer 
 1µl  10µM reverse primer 
 7µl  dH2O 
 
Reaction conditions were as follows 
 
  1. 95
o
C 2 minutes 
  2. 95
o
C 30 seconds 
  3. 60
o
C 30 seconds 
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  4. 80
o
C 30 seconds 
  5. Repeat steps 2-4 an additional 35 times 
  6. 72
o
C 10 minutes 
  7. 4
o
C Holding temperature 
 
Analysis of fold changes was performed in Excel using values obtained from MyIQ 
bespoke software (BioRad). 
 
2.4.4 Sequencing 
Sequencing was used to confirm the correct sequence of the DISC1 insert post cloning.  
DISC1 sequencing primers were kindly designed and provided by Shaun Mackie, who 
ordered them from Invitrogen custom primer service.  All sequencing was performed in 
96 well plates. 
 
2.4.4.1 Big Dye pre-sequencing PCR 
The Big Dye Terminator Ready Reaction Mix v3.1 system was used.  Sequencing 
reactions were set up as follows: 
 
 1.5µl  5 x Sequencing Buffer (Applied Biosystems) 
 1.0µl  Big Dye 3.1 (Applied Biosystems) 
 ~1µl  Template (at least 0.5µg DNA) 
 0.5µl  60ng/µl primer 
 
Reactions were then processed using the Big Dye 3.1 program as follows: 
 
  1. 96
o
C 1 minutes 
  2. 96
o
C 10 seconds 
  3. 50
o
C 5 seconds 
  4. 60
o
C 4 minutes 
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  5. Repeat steps 2-4 an additional 24 times 
  6. 4
o
C Holding temperature 
 
2.4.5 Sequencing plasmids 
Sequencing was performed on the DISC1 insert post cloning into pcDNA4/TO, to 
ensure no mutations had been introduced in the process.  Firstly, plasmid DNA was used 
in pre sequencing reactions described in 2.4.5.1, using a series of primers corresponding 
to adjacent and overlapping regions of DISC1.  These primers are detailed in Table 2.5.  
This enables sequencing of the whole open reading frame.   
 
The product was then precipitated via a series of steps.   All reagents used were sterile.  
5µl of 125mM EDTA (Sigma), then 60µl of 95% ethanol (Fisher) was added to each 
reaction product.  Plates were briefly inverted and left to stand for 15 minutes, before 
spinning for 30 minutes at 3000rpm on a Jouan CR422 centrifuge.  Post centrifugation, 
ethanol was removed via tapping and pulse spinning the plate upside down.  60µl of 
70% ethanol was added to each well, and the plate spun at 3000rpm for 15 minutes.  
Again, ethanol was removed via tapping and pulse spinning.  Plates were then air dried 
for 30 minutes in the dark, taken to the sequencing facility for processing,  and held at -
20
o
C prior to analysis. 
 
The nucleic acid sequence of the precipitated product was determined by Agnes 
Gallacher at the Medical Research Council Human Genetics Unit.  Results were viewed 









Name Direction Sequence Purpose
M150S 5' ATGGATAGTTCTGAGACCCT Sequencing of DISC1 from pcDNA4/TO1
S301S 5' TCCTCCAGTTCTCTGGATCC Sequencing of DISC1 from pcDNA4/TO1
S451S 5' TCCATCACGAGACGAGACTG Sequencing of DISC1 from pcDNA4/TO1
K551S 5' AAATCCCTCAACTTGTCACT Sequencing of DISC1 from pcDNA4/TO1
A180AS 3' TGCTGATGGCAGAGAGCCTG Sequencing of DISC1 from pcDNA4/TO1
I560AS 3' GATTTCTTTAAGTGACAAGT Sequencing of DISC1 from pcDNA4/TO1
CMV Fwd 5' CGCAAATGGGCGGTAGGCGTG Sequencing of DISC1 from pcDNA4/TO2
BGH Reverse 3' TAGAAGGCACAGTCGAGG Sequencing of DISC1 from pcDNA4/TO
2
 
Table 2.5: a list of primers used to sequence DISC1 post cloning.  1Primers 
designed and supplied by Shaun Mackie.  2Primers supplied as part of 
Invitrogen TRex cloning kit. 
2.4.6 Purification of PCR products 
Prior to ligation into the expression plasmid, the PCR amplified DISC1 insert was 
purified to remove elements of the PCR reaction mix which may contaminate further 
reactions.  This was performed using a QIAquick PCR purification kit (Qiagen).  The 
spin protocol was followed, as per the manufacturer’s instructions. 
 
2.4.7 Making and Running Agarose DNA gels 
Agarose gels were used to assess the size of DNA products obtained by PCR, and the 
efficiency of restriction enzyme digestion.  Gels were prepared by adding the 
appropriate concentration (usually between 1-2%) of agarose (Invitrogen) to 0.5x TBE 
buffer, then gently heated.  Sybr Safe DNA Gel Stain (BioRad) was added at a 
concentration of 5µl per 100ml agarose solution, and the gel poured into a tray with the 
appropriate number of combs.  Once the gel had set, combs were removed, and the gel 
placed in an electrophoresis tank filled with 0.5x TBE buffer (Bioscience Service). 
 
The DNA samples were then loaded into the wells of the gel, alongside an appropriately 
sized DNA ladder.  Gels were run at a voltage of less than 100mV for up to two hours, 
then viewed with UV light in a Uvidoc light box (Uvitec).   
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2.4.8 RNA extraction 
RNA was extracted from whole mouse brain and cultured primary neurons using the 
Qiagen RNeasy Mini Kit.  Cultured primary neurons were lysed as previously described 
with RLT buffer (Qiagen kit component).  Whole mouse brain was dissected from an 
adult CD1 mouse, placed immediately in RNA later (Applied Biosystems) and stored at 
4
o
C. Before RNA extraction, the brain was homogenised by chopping into small 
sections and placing into Precellys 1.4mm Ceramic homogeniser tubes (Peqlab) with 
RLT buffer.  Samples were then homogenised in the Precellys 24 homogeniser (Stretton 
scientific), and applied to the RNeasy protocol as per the Manufacturer’s instructions.  In 
all cases the additional step of on column DNase digestion was performed.  
 
2.4.9 cDNA Synthesis 
Before cDNA synthesis was performed, an extra DNA clean up was performed using 
Turbo DNAfree (Ambion) according to the manufacturer’s instructions.  Depending on 
the yield of RNA from extraction, two different methods of cDNA synthesis from RNA 
were employed. 
 
2.4.9.1 First Strand (AMV) cDNA Synthesis Kit (Roche) 
This kit was used when a high yield of RNA had been obtained, as it requires a smaller 
volume of RNA.  RNA samples were diluted in dH2O to a concentration of 2µg RNA 
per 16.4µl (half this for the no RT control).  Samples were denatured for 15 minutes at 
65
o
C, then placed on ice for 5 minutes.  During this process, two mixes were prepared.  
All reagents come from the First Strand cDNA synthesis kit. 
 
Mix 1 
  4µl 10x buffer 
  8µl 25mM MgCl2 
  4µl dNTPs 
  4µl random primers 
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  2µl RNase inhibitor 
  1.6µl AMV Reverse Transcriptase 
 
Mix 2 (no RT control) 
  2µl 10x buffer 
  4µl 25mM MgCl2 
  2µl dNTPs 
  2µl random primers 
  1µl RNase inhibitor 
 
After denaturing, 23.6µl of Mix 1 was added to each 2µg RNA sample, and 11µl of mix 
2 added to each 1µg no RT control.  A no RNA control was also employed.  All samples 
were then incubated at 42
o
C for 1 hour, then 95
o
C for 10 minutes to denature the 
enzymes.  Samples were cooled to 4
o




2.4.9.2 Transcriptor First Strand cDNA Synthesis (Roche) 
This method allows for a larger volume of RNA if RNA yield was low.  Again, all 
reagents used are from the Roche kit of the same name.  2µg of each RNA sample was 
diluted into 22µl dH2O, and 1µg into 11.5µl for the no RT controls.  4µl random primers 
were added to each sample (2µl for the no RT controls) and the mix denatured for 10 
minutes at 65
o




Once again, two mixes were prepared: 
Mix 1 
  8µl 5x buffer 
  1µl RNase inhibitor 
  4µl dNTPs 




  4µl 5x buffer 
  0.5µl RNase inhibitor 
  2µl dNTPs 
 
After denaturing, 14µl of Mix 1 was added to each 2µg RNA sample, and 6.5µl of mix 2 
added to each 1µg no RT control.  A no RNA control was also employed.  All samples 
were then incubated at 25
o
C for 10 minutes, 55
o
C for 30 minutes, then 85
o
C for 5 




2.4.10 Transformation of E coli with plasmid constructs 
Transformation of E coli allows propagation of DNA plasmids for further use.  For this 
purpose a heat shock protocol was used, with JM109 Competent E Coli (Promega).  
First, 100µl of JM109 cells per reaction were thawed slowly on ice.  Once thawed, the 
cells were mixed gently by flicking, and 50ng of a DNA plasmid diluted into 1µl of 
dH2O was added to the mixture.  The whole mixture was incubated on ice for 30 
minutes, before being heat shocked by removal to a water bath at 42
o
C for 45 seconds.  
After the shock, cells are removed back to ice for 2 minutes.  900µl of room temperature 
L Broth was added to the cells, which were then shaken at 200rpm at 37
o
C for 45 
minutes in an Innova incubator shaker (New Brunswick Scientific).  After 45 minutes, 
100-200µl of the bacterial culture was spread evenly onto pre poured Agar plates 
containing the appropriate antibiotic using a sterile disposable spreader.  Plates were 
incubated upside down at 37
o
C with 5% CO2 overnight (Plus II incubator, Gallencamp), 
or until colonies were visible.   
 
2.4.11 Purification of plasmid constructs from E coli 
In order to purify DNA from transformed cultures, single clones must be selected from 
the agar plate and amplified further.  To do this, single colonies are picked from the 
plate using a disposable sterile loop.  This loop was placed in 5ml L-Broth containing 
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the appropriate antibiotic and shaken at 200rpm at 37
o
C with 5% CO2 for 6-8 hours to 
assure growth.  These mini cultures can be pelleted by centrifugation at 13,000rpm for 1 
minute, and the plasmids harvested by using a Spin Miniprep kit (Qiagen).  This method 
of purification is quick, easy, and is ideal for analysing plasmids post cloning. 
 
If larger amounts of plasmid were required, for transfection for example, these mini 
cultures were then transferred to 400ml of L-Broth with the appropriate antibiotic, and 
subjected to the same incubation conditions overnight.  The next morning the bacterial 
pellet was harvested by centrifuging at 5000rpm, 4
o
C for 10 minutes in an Avanti J-201 
centrifuge (Beckman Coulter), and subjected to purification using the Qiagen Plasmid 
Maxiprep Kit as per the manufacturer’s instructions.  Purified DNA from both methods 
was suspended in dH2O and stored at 4
o
C for short term storage, or -20
o
C for longer 
term. 
 
2.4.12 Measuring DNA/RNA concentration  
In order to determine the concentration of a purified plasmid or extracted DNA, the 
Nanodrop 2000 spectrophotometer (ThermoScientific) was used.  1µl of nucleic samples 
were loaded onto the pedestal, the correct option selected in the bespoke software, and 
an absorbance reading is taken automatically at the correct wavelength.  The software 
produces a graph and two ratios which give information about the quality of the nucleic 
acid tested.  260/280nm ratios of approximately 1.8 and 2.0 are generally considered 
pure for DNA and RNA respectively.  The 260/230 ratio should be between 2-2.2, and a 
lower reading may indicate the presence of carbohydrate or phenol in the preparation.  
 
2.4.13 Cloning techniques 
2.4.13.1 Restriction Digests 
Restriction enzyme digestion was used to cleave plasmid DNA at the desired cloning 
sites.  Restriction enzymes are supplied with their appropriate buffer, in this case they 
were EcoRI and NotI (Both buffer H, Roche). 3µg of plasmid DNA, and 40µl of post 
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clean up insert DNA was diluted in 1x buffer H and dH2O, and 3 or 4µl of restriction 
enzyme added to the mix respectively.  The reaction was incubated for 1 hour at 37
o
C.  
The digested product plasmid was run on a gel to confirm that full digestion had 
occurred. 
 
2.4.13.2 Phenol-chloroform extraction and DNA precipitation 
In order to use the digested DNA in a ligation reaction, contaminating proteins 
remaining from the digest must first be extracted.  100µl of phenol/choloroform/isoamyl 
alcohol mix was added to each DNA digest.  The mixture was vortexed then spun at 
13,000rpm for two minutes to separate the phases.  40µl of the aqueous phase was 
removed to a fresh eppendorf tube.   
 
The remaining mixture underwent back extraction by addition of 40µl of TE buffer 
(Qiagen), then repeating the vortex and centrifuge procedure.  A further 80µl of the 
aqueous phase was removed, and added to the fresh eppendorf containing the 40µl 
fraction.  1.2µl 3M sodium acetate (Fisher), 240µl absolute ethanol and 2µl of glycogen 
(Promega) was added to the eppendorf, and this solution frozen at -20
o
C for at least 30 
minutes.  After this time, the solution was thawed and spun at 13,000rpm on a desktop 
centrifuge for 30 minutes to produce a DNA pellet.  The supernatant was discarded, the 
pellet resuspended in 70% ethanol, and re-centrifuged for 5 minutes at 13,000rpm.  
Again, the supernatant was discarded, and the pellet air dried for up to 15 minutes.  Once 
dry, it was finally resuspended in 30µl dH2O. 
 
2.4.13.3 SAP Phosphatase Treatment 
Following restriction digestion, extraction and DNA precipitation, the DNA vector was 
treated with shrimp alkaline phosphatase (USB Corporation), to remove phosphate 
groups and hence decrease the likelihood of self ligation of the vector.  10µl of the 
vector DNA was made up to 20µl with SAP buffer, and 1.5µl of the SAP enzyme added.  
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The reaction was incubated at 37
o
C for 30 minutes, and terminated by incubation at 
70
o
C for 10 minutes to denature the SAP enzyme. 
 
2.4.13.4 Ligation reaction 
The final point in the subcloning procedure was ligation of the insert into the DNA 
vector, following restriction digestion, extraction, DNA precipitation and SAP 
phosphatase treatment of the vector.  Ligation reactions were set up to 10µl, containing 
1µl T4 ligase (Roche), 2µl vector and 5µl insert (with a 1:3 ratio of vector to insert) in 
T4 ligase buffer.  Reactions were incubated at room temperature for at least four hours, 
and the resulting DNA transformed into JM109 competent E coli for amplification and 
testing. 
 
2.5 Functional Assays 
 
2.5.1   Phosphodiesterase activity assay 
PDE Assays were performed to a protocol adapted from Marchmont and Houslay 
(Marchmont and Houslay, 1980).  Cell and tissue lysates were prepared using 3T3 buffer 
plus Complete Protease Inhibitor cocktail tablets (Roche) and Phosphatase Inhibitor II 
(Calbiochem).  Volumes used were 200µl per confluent T25 flask and 60µl per well of a 
6 well plate.  Lysates were prepared as described in section 2.3.2. 
 
A standard amount of lysate protein (determined by concentration curve) was diluted in 
pH7.5 Tris solution (Fisher) to a total of 50µl.  Generally 20µg protein was used per 
reaction for SHSY5Y lysate, and 15µg per reaction for primary cortical neuron lysate.  6 
replicates of each sample were set up, half with the PDE4 inhibitor Rolipram (1µl of a 
1mM stock solution, Sigma) to enable the PDE4 component of activity to be measured.   
 
In the first stage of the two step assay, 50µl of the PDE assay substrate solution was 
added to the 50µl lysate solutions.  Final reaction concentrations of PDE Assay buffer 
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components were therefore 5mM MgCl2, 1µM cAMP, and 200,000 decays per minute 
arising from [
3
H] cAMP.  The reaction was vortexed, spun down on a desk top 
centrifuge, and incubated at 37
o
C for 10 minutes.  The reaction was then terminated by 
removal to a boiling water bath for two minutes.  Tubes were then placed on ice for 15 
minutes, before the addition of 25µl of Western Diamondback Snake Venom (Sigma).  
This mixture was incubated for a further 10 minutes, in which the [
3
H] labelled cAMP 
hydrolysis product, 5’AMP is dephosphorylated to adenosine by the snake venom.  The 
negatively charged non hydrolysed cAMP is then separated out of the reaction mixture 
by additional of 400µl of Dowex ion exchange resin (Sigma, made up to slurry 1:1:1 
Dowex:water:absolute alcohol), left to stand for 15 minutes with inversion of the tubes 
every five minutes, followed by centrifugation at 14,000rpm for 3 minutes.  150µl of the 
supernatant was carefully removed and added to 1ml of Ecoscintillant fluid (AGTC 
BioProducts), the tubes inverted, and read on a LS6500 Multi Purpose scintillation 
counter (Beckman Coulter, Human Genetics Unit, Medical Research Council).  
Background counts were accounted for by use of a Tris buffer only control. 
 
2.5.1.1 Protein concentration curves 
To determine the appropriate amount of protein to utilise when PDE assaying different 
cell types, protein concentration curves were determined.  A range of protein quantities 
were assayed as described earlier, and plotted on a graph.  An amount of protein in the 
linear phase of the graph was chosen for maximising detection of changes.  PDE activity 
values were calculated using the equation below: 
 






2.5.2 cAMP AlphaScreen (Perkin Elmer) 
The basis of the Perkin Elmer AlphaScreen is a competition assay, where streptavidin 
coated donor beads bind to exogenous biotinylated cAMP, under low endogenous cAMP 
conditions.  When acceptor beads conjugated to a cAMP antibody are added to a 
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solution containing these molecules, the antibody also binds the biotinylated cAMP, 
bringing the acceptor and donor beads into close proximity.  On excitation by the 
EnVision microplateplatereader (Perkin Elmer) at 680nm, this proximity allows for the 
transfer of singlet oxygen between the donor and acceptor bead.  This transfer results in 
fluorescence of the acceptor bead at 520-620nm, which can then be measured on the 
plate reader.  When endogenous cAMP is increased, by Forskolin addition, for example, 
the endogenous cAMP displaces the exogenously biotinylated cAMP from the donor 
beads, increasing the distance between the donor and acceptor beads, and preventing the 
transfer of singlet oxygen.  Fluorescence intensity at 520-620nm is decreased.  To 
summarise, the higher the endogenous cAMP, the lower the fluorescence intensity.  This 
is an important point to remember for interpretation of graphs. 
 
2.5.2.1 cAMP Standard Curve Procedure 
All initial AlphaScreen work was performed as described in the AlphaScreen manual.  
To briefly summarise, a standard cAMP solution was serially diluted in Control Buffer 




M cAMP with 11 assay 
points.  A positive control with no cAMP (highest signal) was also prepared.  The 
“detection mix” combining streptavidin coated donor beads and biotinylated cAMP was 
prepared fresh, and incubated in the dark for 30 minutes.   
 
While this solution was incubating, the anti-cAMP acceptor bead solution was prepared.  
In triplicate, 5µl of the anti-cAMP acceptor bead mix was added to 12 rows of an 
OptiPlate-384 well plate (Perkin Elmer).  This was followed by the addition of 5µl of 
each of the cAMP dilutions, sequentially to the plate.  The plate was incubated in the 
dark at room temperature for 30 minutes.  After 30 minutes 15µl of the detection mix 
were added to each of the wells in use, and the plate incubated in the dark at room 
temperature for 1 hour.  The plate was then read on the EnVision Microplate Reader, 
and data plotted as a signal curve corresponding to the log concentration of cAMP. 
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2.5.2.2 Forskolin Dose-Response / Determination of the Optimal Cell 
Concentration 
This protocol is slightly adapted from the one in the manual, as I chose to perform the 
assay on adherent cells.  Two days prior to the assay a T25 flask of 95% confluent 
SHSY5Y cells was harvested.  Cells were resuspended, counted on a haemocytometer, 
and spun at 1000rpm for 5 minutes on a centrifuge.  Post centrifugation, the supernatant 
was removed, and the cells resuspended to a concentration of 10,000 cells/µl.  Three 
further dilutions were then produced, according to the Perkin Elmer booklet, as 
reproduced in Table 2.6. 
 
Cells/well (final) 10,000cells/µl solution (µl) DMEM (µl)
10,000 50 200
3,000 15 240
1,000 5 245  
Table 2.6: Table showing the dilution of cells performed to prepare SHSY5Y 
cells for the cell number optimisation assay. 
 
5µl of the cell concentration solution was added in triplicate to 12 rows each of a Perkin 
Elmer OptiPlate-384 well plate.  50µL of warm DMEM with 10% FBS was then added 
to each well containing cells, and the plate incubated for two days at 37
o
C with 5% CO2. 
 
To perform the cell number optimisation assay 40ml of Stimulation buffer containing 
IBMX was prepared to pH 7.4.  Lysis buffer was also prepared to pH 7.4.  A forskolin 
serial dilution series was prepared in stimulation buffer, amounting to 11 concentrations 




M in ½ log intervals, and a no forskolin 
control.  Detection mix was then prepared and incubated in the dark at room temperature 
for a minimum of 30 minutes.  Finally, Acceptor bead mix was made. 
 
The 384 well plate containing the cells was then rinsed twice carefully with stimulation 
buffer, and dried by tapping.  The reagents were added to the wells.  First added was 5µl 
of the Acceptor bead mix, followed by 5µl of the Forskolin dilutions (1 dilution per row 
of the assay), and included a cAMP standard control (5µM) and a no cells, no cAMP 
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positive control.  This mixture was then incubated in the dark for 30 minutes at room 
temperature.  After 30 minutes, 15µl of the Detection Mix was added to each well, and 
the plate incubated in the dark at room temperature for 4 hours.  The plate was rocked 
for the first ten minutes to encourage full lysis of cells.  After 4 hours the plate was read 
on the EnVision microplate reader. 
 
2.5.2.3 Lithium Chloride cAMP Screen 
To screen SHSY5Y cells for an effect of LiCl on cAMP concentration, an adapted 
version of the cell number optimisation assay with no IBMX in the stimulation buffer 
was performed.  This enables detection of cAMP changes resulting from changes in 
PDE activity.  For this experiment, a dilution series of LiCl (Sigma) in stimulation 
buffer from 0-20mM in 2mM intervals was prepared, along with a 20µm forskolin 
solution in stimulation buffer.  5µl of each LiCl dilution was added to 6 wells of the 384 
well plate, containing 10,000 initial adherent cells per well.  To half of these dilutions 
5µl of stimulation buffer was added, and to the other half, 5µl of 20µM forskolin 
solution.  After incubation for 30 minutes in the dark at room temperature, 15µl of 








3 Assay work up and SHSY5Y as a model system 
3.1 Introduction 
 
In order to investigate the potential for DISC1 and chemical compounds to alter PDE4 
activity, two factors must be considered.  The first is the use of assays that are 
sufficiently sensitive and appropriate to measure cellular changes resulting from 
alterations in PDE4 activity, which are likely to be subtle.  The second is the use of a 
suitable cellular system for PDE4 measurement which should be easy to manipulate, 
both genetically and chemically, while producing highly consistent and reproducible 
measurements.  This chapter deals with the choice of assays, the work up of these 
assays, and the use of SHSY5Y human neuroblastoma cells as an appropriate model 
cellular system for measuring PDE4 activity. 
 
3.2 Choosing an assay for PDE activity 
 
There are two major routes available to an investigator wanting to assess the activity of a 
PDE enzyme.  The first of these routes is to perform an investigation of protein activity.  
PDE activity can be assayed directly, through loading of cells with radiolabelled cAMP, 
but the majority of methods employed rely on use of in vitro purified enzyme 
(Skoumbourdis et al., 2008), or overexpression of the enzyme or related cellular 
components in a stable cell line system.  The drawbacks of assaying purified enzyme 
separated from its cellular context are clear: only compounds directly affecting the 
enzyme itself will show as “hits,” and no information is obtained about the membrane 
permeability of the compound.  Overexpression of PDE or related reporter proteins in 
cell lines avoids these particular drawbacks, but can lead to aberrant long term 
regulation of the pathways being investigated.  This leads to the second route of 
investigation, which infers PDE activity indirectly by measuring cellular cAMP 
fluctuations, often without the need for expression of exogenous protein.    Each of these 
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routes offers a number of choices of assay with a variety of advantages and 
disadvantages, which I will briefly review in this section. 
 
3.2.1 cAMP concentration/accumulation assays 
Early methods to measure cAMP in cells relied on rather labour intensive processes of 
extraction, or labelling the ATP pool with tritium to measure radiolabelled cAMP.  
These methods provide highly accurate measures of whole cell cAMP levels, and 
formed the base for cAMP assays for many years, but have been surpassed by recent 
technology due to their lack of spatial and temporal resolution (reviewed by Willoughby 
and Cooper, 2008). 
 
These early methods have since been adapted to increase assay throughput (reviewed 
Williams, 2004).  To summarise briefly, there are a large number of commercially 
available cAMP accumulation assays on the market, which are generally based on the 
principle of competition between endogenous cAMP and exogenous cAMP labelled 
either fluorescently, radioactively, with bioluminescence or with enzyme donors.  
Usually these commercial assays require specific microtitre well plates and plate 
readers, thus making this a primary consideration in assay choice.  The Perkin Elmer 
AlphaScreen is just one example of this technology, which uses luminescence proximity 
to produce a signal detectable by the plate reader (see Williams, 2004 for more 
commercially available options).  These assays are generally more suitable for 
measurement of cAMP accumulation after GPCR activity, as sensitivity is increased if 
PDEs are blocked with a substance such as IBMX.  These assays can usually be 
performed on live cells or pre prepared protein lysates, but generally rely on a cell lysis 
step before the final reading.   
 
As Williams (2004) also details, the other main procedure for assaying cAMP relies on 
reporter gene constructs such as luciferase and β-galactosidase which contain cAMP 
responsive elements (CRE).  Binding of cAMP to these elements results in a highly 
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sensitive measure of cAMP concentration within the cell.  In fact, at very low levels of 
cAMP this approach may actually amplify the signal generated in a non linear fashion, 
falsely inflating the effect of a compound.  As with any assay dependant on a genetic 
sensor, the main limitation is the creation and initial testing of a stable cell line, which 
can be time consuming. 
 
In recent years there has been a vast explosion in the number of genetically encoded 
intracellular cAMP sensors available.  These are reviewed in great detail in Willoughby 
and Cooper (2008), but are mostly founded on changes in activity of downstream 
proteins, such as FRET or BRET based cAMP dependant PKAs and “exchange protein 
directly activated by cAMP” (Epac) assays.  An alternative to these are measurements 
made from cyclic nucleotide gated channels using calcium sensing dyes or single 
channel electrophysiology, but a major limitation of these sensors is that they can only 
sense changes occurring close to the plasma membrane (Willoughby and Cooper, 2008).  
These probes provide excellent information on the location and timing of cAMP fluxes, 
and some combinations of sensors which use ratiometric read outs from two 
wavelengths directly correlate to calcium or cAMP concentration, thus are suitable for 
miniaturisation.  These systems have been used reliably in high throughput screens 
(Reinscheid et al., 2003, Jiang et al., 2007), but are complex and time consuming to set 
up and calibrate.   
 
3.2.2 Lysate based PDE4 activity assay 
Marchmont and Houslay (1980) took the approach of radiolabelled cAMP (discussed 
above) a step further by loading cell lysates with a known amount of tritiated cAMP, 
which was then broken down by endogenous PDE activity.  The break down product, 
5’AMP, is then dephosphorylated using snake venom, leaving an uncharged product 
which can be separated from negatively charged, uncleaved cAMP.  This tritiated 
breakdown product can then be measured on a scintillation counter (Marchmont and 
Houslay, 1980, Figure 3.1).  The advantage of this method is that it negates the need for 
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overexpression of cAMP pathway components, and so genetic and chemical 
manipulations can be performed without the confounding factor of pathway changes.  
The major disadvantage to this method is that it is not directly PDE isoform specific.  
Specific activity can be inferred from the use of replicates treated with isoform specific 
inhibitors, or is achieved via antibody mediated immunoprecipitation of specific 
isoforms (Millar et al., 2005b).  The assay also has multiple steps, is labour intensive, 
and the need for multiple centrifugation steps limits throughput. 
 
 
Figure 3.1 depicts the procedure adapted from Marchmont and Houslay for 
measuring PDE activity in cell lysates.  Diagrams to show the alterations to the 
chemical structure and charge of cAMP from each step can be found above the 
experimental scheme.  To make the assay PDE4 specific, six replicates are 
used in total, 3 treated with 10µM rolipram and 3 without.  PDE4 activity can 
then be resolved by a simple subtraction of the activity remaining post rolipram 
treatment: the non-PDE4 component. 
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3.2.3 Live cell based assays for PDE4 activity  
As exemplified by Bora et al, a common means of designing cell based assays for PDE 
activity relies on stable overexpression of a PDE isoform.  For their assay, they 
transiently transfected stable HEK293 cell lines overexpressing PDE4 isoforms with a 
CRE based luciferase reporter (Bora et al., 2007).  While this technique has the 
advantage of being able to assess PDE4 subtype specific effects of compounds, it relies 
on the constitutive overexpression of a protein that may significantly alter intracellular 
signalling pathways.  Allen et al took a similar approach, transiently overexpressing 
PDE4A-D with a β-adrenergic receptor that can be stimulated with isoprenaline to 
elevate cAMP. PDE activity is obtained indirectly by measuring the amount of 5’AMP 
generated.  This assay system was successfully used to assess potential new PDE4 
inhibitors (Allen et al., 1999).  It is clear that to avoid variability being introduced by 
variations in transient transfection rate, a very rigorous system of cell counting, timing, 
and reagent measurement must be employed.  This adds an extra level of complexity to a 
screening procedure. 
 
Titus et al, 2008 extended the approach of Rich et al, 2001, to use a HEK293 based 
stable cell line with a constitutively active adenylate cyclase coupled GPCR, co 
expressed with a cyclic nucleotide gated (CNG) cation channel.   This method enables 
measurement of PDE activity in a 1536 well plate as a function of changes in calcium 
levels (Rich et al., 2001) or membrane potential using a membrane potential sensitive 
dye (Titus et al., 2008).  PDE4 specificity was confirmed by Titus et al in a cell free 
PDE4 A1A assay, and 7 potential novel PDE4 inhibitors discovered.  While this assay is 
rather exquisitely designed to avoid perturbations to the specific signalling system being 
studied, by foregoing the need to stimulate cells with an agent such as forskolin, its 
specificity relies on PDE4 being the predominant PDE active in HEK293 cells.  It is 
however, extremely effective when miniaturised, and very simple to employ once the 
cell lines have been created. 
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3.2.4 PDE Assaying Strategy  
It is clear from the brief review of the available technology that the set up of an assay for 
PDE4 activity can be complex and time consuming.  There is no perfect method, so the 
advantages and drawbacks of each approach must be contrasted, especially with respect 
to the time and funds available.  It was decided that within the time restraints of a PhD 
project, previously well defined PDE assay systems that were easy to set up should to be 
used.  This ruled out the creation, calibration and testing of a PDE activity sensing stable 
cell line, particularly as further genetic manipulations would be required to alter DISC1 
expression status.  This left two major options – to detect cAMP using a competition 
based commercial assay, and the lower throughput radiolabelled assay adapted from 
Marchmont and Houslay.   
 
To perform a higher throughput screen to measure the effect of varying concentrations 
of a compound of interest on intracellular cAMP, the Perkin Elmer AlphaScreen was 
chosen, as there was an EnVision Multilabel plate reader available within the home 
Institute (Hupp group, Edinburgh Cancer Research Centre, CRUK).  To provide a more 
accurate measure of factors specifically affecting PDE4 activity, the assay developed by 
Marchmont and Houslay in combination with 10µM rolipram was used, as this assay 
allows for assessment of PDE4 activity within an unaltered cellular context, and is 
relatively easy and quick to set up.  The major drawback of this choice was that 
equipment in the radiation controlled area restricts the throughput of the experiment, 
allowing a maximum of 5 treated samples (in triplicate, plus and minus rolipram) and a 
negative control per experiment. 








3.3.1 The majority of PDE activity in SHSY5Y cells is PDE4 specific 
Being initially derived from human neuroblastoma cells, it is presumed that SHSY5Y 
cells are a better model of neural environment than other cell lines available within the 
lab, for example HEK293 cells derived from human embryonic kidney.  To ensure that 
SHSY5Y possess adequate endogenous PDE4 activity to assay, and discern the 
appropriate amount of protein to use in these assays, a simple standard curve of PDE 
activity was produced at increasing protein concentrations for SHSY5Y cells, using the 
PDE assay method described in 2.5.1 and 2.5.1.1.  A comparative curve of endogenous 
PDE4 in HEK293 cells was also performed.  The PDE4 specific component at each 
lysate concentration was discerned through the use of replicates containing 10µM 
rolipram as described previously. 
 
In SHSY5Y cells the majority of the measurable activity was PDE4 specific.  At 50µg of 
protein the assay was not yet saturated (Figure 3.2A).  In HEK293 cell lysate, there was 
marginally less total PDE activity that in SHSY5Y (Figure 3.2B).  Although there is 
marginally more PDE4 specific activity than non-PDE4 in HEK293, both amounts are 
sufficiently small that the error involved in measurements is much larger than in 
SHSY5Y cells.  Furthermore, the assay did not saturate even at 75µg of protein.   
 
An amount of 20µg of protein per sample was chosen for further work with SHSY5Y 
cells, as this is an easily obtainable amount of protein from small cell culture flasks and 
sits in the middle of the steepest section of the standard concentration curve.  This 
maximises the potential for detecting changes in PDE4 activity in response to genetic or 
chemical manipulation of the cell line. 
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Figure 3.2A:  A graph depicting the standard curve of PDE activity for increasing 
amounts of SHSY5Y lysate.  PDE4 specific activity is inferred by the use of 
10µM rolipram.  SHSY5Y have a large range of measurable PDE4 activity, 
making them appropriate for detecting changes in PDE4 activity in response to 
genetic or chemical manipulations. 
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Figure 3.2B: A graph depicting the standard curve of PDE activity for increasing 
amounts of HEK293 lysate.  PDE4 specific activity is inferred by the use of 
10µM rolipram.  HEK293 cells have slightly lower and more variable PDE 
activity than SHSY5Y cells, making them less useful to exploit with regards to 
PDE4 activity. 
3.3.2 AlphaScreen Standard Curve 
To assess that the EnVision Multi Label plate reader is correctly set up for AlphaScreen 
protocols, and assess the accuracy of the pipetting system being employed, a standard 
curve must be performed, as detailed in 2.5.2.1.  This is a simple cell free experiment 
involving the preparation of a dilution series of cAMP, added to the donor and acceptor 
beads.  A successful cAMP curve was obtained, using a manual CappAero 16 channel 
multi pipette, with very little error between triplicates (Figure 3.3). 
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Figure 3.3: A standard cell free cAMP curve obtained from the AlphaScreen 
procedure on the EnVision MultiLabel Plate Reader.  Error bars are shown, but 
are barely visible due to variation between triplicates being very small.  
 
3.3.3 SHSY5Y density affects AlphaScreen efficacy 
To define the number of cells to be used per well in the AlphaScreen assay, SHSY5Y 
cells were seeded at three different densities as described in 2.5.2.2.  The standard 
AlphaScreen procedure using IBMX was performed as described in that section, where 
cells were stimulated with Forskolin to activate adenylate cyclase and increase cAMP 
production.  After 30 minutes of treatment cells were lysed, and plates were read 4 hours 
later. 
 
At a density of 10,000 cells per well, SHSY5Y cells produced a dose response to 
forskolin with a range of 10,000 AlphaScreen counts per second (Figure 3.4).  A dose 
response was observed at lower densities with high concentrations of forskolin, but the  
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Figure 3.4: Graph showing the response of different density SHSY5Y cells to a 
dilution series of Forskolin.  At 10,000 cells/well a good dose response with a 
large range of measurement is obtained.  At lower densities, a response is only 
detectable at the highest concentrations of forskolin.  
 
range was much smaller (~3000-5000 counts per second).  This is most likely because 
the total cAMP in the low density wells was below the detection limit for the assay.  For 
this reason, a cell density of 10,000 cells per well was chosen for further investigative 
assays. 
 
3.3.4 Short term transfection of DISC1 variants 
Increasingly in the research of genetics of psychiatric disease, attention has focussed on 
the presence of structural variants in DNA sequence, both common and rare, that may 
increase an individual’s susceptibility to illness (Song et al., 2008). As these variants 
came to light relatively late in my project, it would have been useful to be able to 
transiently transfect variants of interest to assess their effect on PDE activity without the 
need for creation of a stable cell line.  Transfection efficiency of SHSY5Y cells was 
investigated using the Nucleofector method described in 2.2.3.2, and a transfection rate 
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of 72% (+/-3.5) obtained over 4 experiments using the pmax optimised plasmid.  
Transfection rates with DISC1 GFP were significantly lower.  Unfortunately, when 
PDE4 activity was measured, there was a large effect of transfection on PDE4 activity 
(37% decrease -/+3).  As the assaying system used has a restricted throughput, it was not 
possible to perform a properly controlled experiment, and so this approach was 
discontinued.  Only experiments using stable cell lines are featured in this thesis. 
3.3.5 Creation of an inducible cell line overexpressing DISC1 
Previous attempts in house to produce a stable cell line constitutively overexpressing 
DISC1 had proved unsuccessful.  I was also unable to find evidence of other labs who 
had made successful attempts.  For this reason the decision I produced an inducible 
stable cell line under the control of a tetracycline repressor, so that it was possible to 
“switch on” DISC1 expression 24 hours prior to experiments.  The Invitrogen TRex 
system was used, which uses Tetracycline repressors to repress gene expression in the 
absence of tetracycline.  Tetracycline binds to the tetracycline repressor homodimer and 
causes a conformational change that prevents the repressor from binding to the Tet 
operator controlling the expression of your gene of interest (http://tools.invitrogen.com/ 
content/sfs/manuals/trexsystem_man.pdf).   
 
Stable cell lines were created as described in 2.2.5, and overexpression of DISC1 tested 
initially by western blot with Zymed C-terminal antibody.  Of the 10 clones tested, 2 
showed strong expression of DISC1 after 24 hours treatment with Tetracycline (Figure 
3.5) and had no leakage from the expression construct when tetracycline was absent.  
One of these clones was taken forward for further experiments (TRTODISC1).  
Overexpression of DISC1 mRNA was confirmed by Christoph Grünewald using qPCR 
on the iCycler (BioRad) to a level of 5.07 (+/-0.21, n=3) compared to uninduced cells 




Figure 3.5: Western blot showing overexpression of the 100kDa form of DISC1 
using the Zymed C-terminal antibody in TRTODISC1.  The positive control 
shows transient transfection of the expression plasmid only into SHSY5Y cells.  
This clone has no leakage from the expression plasmid when tetracycline is not 
present.   
3.3.6 DISC1, PDE4B and PDE4D localisation in stable cell lines 
Immunostaining of endogenous PDE4B and DISC1 overlaps significantly in the 
cytoplasmic compartment of wild type SHSY5Y cells.  To ascertain whether changes in 
DISC1 expression levels altered PDE4 localisation, immunocytochemistry was 
performed to label endogenous DISC1, PDE4B and PDE4D. 
 
The αDISC1 antibody (kindly supplied by Professor Akiyama, University of Tokyo) was 
used to immunostain for DISC1, and displayed a heavily saturated signal when DISC1 
was overexpressed, if the amplification gain of the laser used to image the uninduced 
cells was used.  Overlap but not dependant colocalisation of DISC1 and PDE4B 
immunostaining was evident throughout the SHSY5Y cells regardless of DISC1 
overexpression status (Figures 3.6A-F), and doesn’t appear to be related to a single 
specific organelle.  The signal from both proteins was increased in perinuclear regions.  
However, when the amplification gain was turned down to image the overexpressing 
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cells, it became evident that there was a large increase of nuclear signal from both 
DISC1 and PDE4B, when compared to the uninduced control cells (Figures 3.6G-I).   
 
A very similar pattern of staining is observed with co staining of DISC1 with PDE4D.  
Again, there is an overlapping signal from both proteins throughout the cell, though low 
levels of staining within the nucleus (Figures 3.7A-F).  The signal from both proteins is 
stronger in perinuclear regions, but PDE4D also shows strong staining in the cellular 
processes which contain neurofilaments and resemble primitive neurites (Glass et al., 
2002).  Overexpression of DISC1 again leads to an accumulation of both proteins in the 
nucleus, in contrast to the uninduced control (Figures 3.7G-I). 
 
In the DISC1 knockdown line (created and provided by Fumiaki Ogawa, see section 
2.2.6 for details), a very weak background signal is obtained from using the αDISC1 
antibody.  Again, overlap of DISC1 immunostaining can be seen throughout the control 
cells with both PDE4B and PDE4D, but is strongest in the perinuclear regions (Figures 
3.8A-C, 3.9A-C).  As would be expected, there is no observable colocalisation of signals 
when DISC1 is knocked down.  Furthermore, the absence of DISC1 does not appear to 






Figure 3.6 A-I:  Immunocytochemistry of DISC1 and PDE4B in SHSY5Y cells.  
A-C shows the interaction in uninduced control TRTODISC cells.  D-F shows the 
interaction in cells with 24 hours of DISC1 induction, with the amplification gain 
of the laser maintained at the same level as for the uninduced cells.  In G-I, this 
gain is turned down to reveal an accumulation of DISC1 and PDE4B in the cell 




Figure 3.7 A-I:  Immunocytochemistry of DISC1 and PDE4D in SHSY5Y cells.  
A-C shows the interaction in uninduced control TRTODISC cells.  D-F shows the 
interaction in cells with 24 hours of DISC1 induction, with the amplification gain 
of the laser maintained at the same level as for the uninduced cells.  As with 
Figure 3.6, in G-I, this gain is turned down to reveal an accumulation of DISC1 
and PDE4D in the cell nucleus.   
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Figure 3.8 A-F:  Immunocytochemistry of DISC1 and PDE4B in T0 (A-C), the 
control scramble stable cell line, and T1, the DISC1 knock down cell line (D-F).   
 
Figure 3.9 A-F:  Immunocytochemistry of DISC1 and PDE4D in T0 (A-C), the 
control scramble stable cell line, and T1, the DISC1 knock down cell line (D-F).   
 117 
3.3.7 The expression of PDE4 mRNA in stable cell lines 
The major issue with the use of stable cell lines is that long term adaptive changes may 
take place in these cells that could effect the expression of related genes.  It was 
important to eliminate changes in PDE4 isoform expression as being causal in any 
measured change in PDE4 activity.  This was likely to be more of an issue in the DISC1 
knockdown cell line supplied by Fumiaki Ogawa, as this was a constitutive knockdown 
of DISC1.  However, gene expression changes would also be possible after 24 hours of 
DISC1 induction in the overexpressing cell line, so it was prudent to check in both cell 
lines.  3 sets of matched cDNA (T0 scramble vs T1 knock down, and TRTODISC1 with 
and without tetracycline) were kindly provided by Christoph Grünewald.   
 
3.3.8 Primer design for quantitative RT PCR by the iCycler 
Primers were designed using the NCBI Primer Blast Tool as described in section 2.4.1.  
Human PDE4A-D subfamily sequences were aligned using ClustalW, and a pan primer 
(Pan PDE4A, Pan PDE4B etc) for each gene identified by defining a point downstream 
of the isoform specific N termini.  NCBI Primer Blast tested and suggested suitable 
primer pairs where at least one primer crosses an exon exon junction, and generates a 
PCR product in cDNA of 150-200 base pairs.  Primers were ordered and tested on the 
iCycler using the method described in section 2.4.3.  Melt curves were obtained from 
PDE4A, 4B and 4D, no melt curve was obtained from PDE4C.  The PCR products were 
run on a gel to ensure a product of the correct size had been formed, and it was 
confirmed that there was no PCR product in the PDE4C reaction (Figure 3.10).  Basic 
PCR was performed on human heart and brain cDNA (kindly provided by Christoph 
Grünewald) with the PDE4C primers pairs, under the same cycle conditions as qPCR.  A 
PCR product of the correct size was obtained from heart and brain cDNA, but not 
SHSY5Y (Figure 3.11).  This suggests that the PDE4C isoform is not present at levels 
detectable by qPCR in SHSY5Y cells.   
 
Once this initial test had been performed, standard curves were obtained for each of the 
successful primer pairs as described in 2.4.4.  Successful standard curves were obtained 
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for each of the primer pairs, although PDE4A and PDE4B had efficiencies at the top of 
the acceptable range (Figure 3.12). 
   
Figure 3.10: Diagram showing the gel on which the pan PDE4A, B, C and D 
primer products were run, to confirm correct product size.  PDE4A should have 
a product size of 188bp, PDE4B 150bp, PDE4C 161bp and PDE4D 171bp.  All 
primer pairs produced products of the correct size, except for PDE4C where no 
product was detected on the iCycler or gel. 
 
Figure 3.11: A PCR product of the expected size of 161bp is obtained when 
basic PCR is performed on human heart and brain cDNA using PDE4C primers.  








Figure 3.12 A-F:  Standard cDNA dilution curves for PDE4A (A and B), PDE4B 
(C and D) and PDE4D (E and F) primer pairs.  In all three cases, the upper 
graph depicts the amplification of product per PCR cycle.  The lower graph is the 
standard curve graph, depicting logged cDNA dilution against CT values (the 
cycle number where product was detected above the threshold marked on the 
upper graph), and thus the efficiency of the primer pair. 
3.3.9 qPCR Data Analysis 
The relative expression of PDE4A, 4B and 4D in TROTODISC1 with and without 24 
hours of induced DISC1, and in T0 and T1, the DISC1 knockdown line, was assessed in 
3 separate paired cDNA samples.  The entire experiment was performed twice, resulting 
in two technical replicates of each sample.  Raw CT values were obtained for each of the 
three primer pairs, alongside values from each cDNA sample for 4 reference genes: 
GAPDH, RPLPO, PPIA and B2M.  Primer pairs for these genes were previously tested 
and supplied by Christoph Grünewald. Raw CT values for the reference genes were 
input into NormFinder (Andersen et al., 2004), to assess the stability of reference genes 
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throughout the experiment.  In both replicate experiments, B2M proved highly unstable, 
and so was excluded from further analysis (Figure 3.13).   
 
 B 




B2M 0.95  
Figure 3.13A: Graph depicting the raw CT values for each reference gene 
across both RTPCR experiments.  The greater variability in B2M can be clearly 
seen by the increased size of the error bars.  Table 3.13B depicts the stability 
values of each reference gene as found using NormFinder.  A stability value of 0 
indicates no variation between samples, and increasing values correspond to 
increasing variation.  B2M has a much higher value than the other three primer 
pairs, and was removed from further analysis. 
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After excluding B2M, the lowest raw CT value for each primer pair was identified and 








where WR is the quantity for relative expression for one sample, E is the previously 
determined primer pair efficiency, CT
min
 the previously determined lowest raw CT 
value, and CT
x
 the raw CT value of the well of interest.  If the primer pair was 100% 
efficient, (E=1) then the PCR product would double with every qPCR cycle.  This 
formula allows for a correction to be performed when the efficiency is not 100%.   
 
The next step in the analysis involves normalising these relative expression values to the 
geometric mean of the three remaining housekeeping genes (GAPDH, RPLPO, PPIA) in 
each sample.  Finally, a fold change was obtained for each matched sample pair by 
division (T1/T0 and TOTRDISC1 plus Tetracycline / TRTODISC1 no Tetracycline).  
The arithmetic mean of the 3 fold changes was obtained for each experimental run.  To 
combine the two technical replicates, the arithmetic mean of the two experiments was 






Where SEM equals the total standard error of the mean for the experiment, SEM1 the 
SEM from the first run and SEM2 the standard error for run 2. 
 
3.3.10 The expression of PDE4 isoforms in SHSY5Y based 
stable cell lines 
There was no difference in expression of PDE4A, PDE4B or PDE4D with regards to the 
DISC1 status of the SHSY5Y based cell lines (Figure 3.14).  There is considered to be 
no biologically meaningful difference in expression when the fold change value lies 
between 0.8 and 1.2, and all means fell within this range.  There was, however, more 
variation between samples in the constitutive knock down line than in the inducible cell 




Figure 3.14 A-D: A shows the fold changes of PDE4 isoforms in TRTODISC1 
with induction of DISC1 in comparison to uninduced cells.  B shows the same 
data as a scatter plot of individual matched samples.  C shows the fold changes 
of PDE4 isoforms in the T1 knockdown line compared to the T0 scramble control 
line.  Again, D shows the same data as a scatter plot of fold changes from 
individual matched samples.  All mean values lie within the range of fold 






As yet, there is no ideal means for detecting changes to PDE activity in the endogenous 
context of a cell.  Whilst means to measure compounds and cellular processes that have 
effects on PDE4 activity have improved quite significantly over recent years, there 
remains no direct way of measuring activity in situ.  Recent advances in genetic reporter 
systems and high throughput cAMP accumulation assays allow for measurement of 
PDE4 activity in situ, but with perturbed expression of important pathway components, 
or indirect measurement through cAMP accumulation respectively.  For this reason a 
dual approach was chosen, using resources already available in house, of medium 
throughput AlphaScreen cAMP accumulation assays combined with low throughput 
PDE activity assays as described earlier.   
 
SHSY5Y cells were validated as an appropriate model system for investigating changes 
in PDE4 activity.  They are a well established, well characterised cell line derived from a 
human neuroblastoma and used regularly in cell culture experiments as a model for 
signalling in neurons (some examples include Smith et al., 2006, Olivieri et al., 2003, 
Smart et al., 1995) as they are easier to prepare and less time consuming to grow than 
primary neuron cultures.  SHSY5Y are also less differentiated than primary neurons, 
which makes them a somewhat simpler system to use in early exploratory experiments, 
reducing the complexity resulting from having neurons with specific functional regions 
(axons, dendrites, spines, cell bodies).   SHSY5Y are known to endogenously express 
PDE4 isoforms (Jang IS, 2001), and addition of the PDE4 specific inhibitor Rolipram to 
cultures results in a large scale increase in intracellular cAMP (Morgan et al., 1993), 
suggesting PDE4 is constitutively active.  Endogenous 71kDa DISC1 interacts 
dynamically with PDE4B1 in SHSY5Y cells (Millar et al., 2005b).  Similar interactions 
were later observed with exogenous DISC1 and PDE4D3 (Murdoch et al., 2007).  I have 
demonstrated that the majority of measurable PDE activity in these cells is PDE4 
specific, and that they are very responsive to forskolin challenge, providing an excellent 
workable range with which to study changes in PDE4 activity.  The increases due to 
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forskolin are at the lower range of published fold changes, and thus tentative 
assumptions can be made as to the composition of the active PDE4s in these cells.  It 
appears that there may be a combination of short form PDEs, which are unresponsive to 
PKA phoshorylation as they lack the appropriate consensus site, and the responsive long 
form PDE4s. 
 
The main drawback of this cell type is that they are relatively difficult to transfect by 
standard chemical methods, but this can be surmounted to some extent by the use of 
nucleofection.  However, exploratory experiments using this type of transient 
transfection procedure showed a significant effect of transfection on PDE4 activity, thus 
this approach was deemed inappropriate for further investigation.  The remainder of the 
results throughout the thesis are performed on stable lines with inducible DISC1 or 
constitutive DISC1 knockdown.   
 
The localisation of PDE4B, PDE4D and DISC1 was assessed to investigate whether a 
change in the DISC1 expression status of the stable cell lines would lead to a change in 
localisation of these proteins.  In all cells expressing DISC1 substantial overlap of 
DISC1 and PDE4B immunostaining was seen throughout the cell, with the strongest 
signal arising from perinuclear regions, as seen previously (Millar et al., 2005b).  While 
knockdown of DISC1 resulted in no gross changes to PDE4B and PDE4D localisation, 
overexpression of DISC1 resulted in an accumulation of DISC1 and both PDE4s in the 
nucleus, where little signal was seen previously.  It is unclear from previous work what 
the cause of this movement may be: full length DISC1 possesses a clear nuclear 
localisation signal, and a nuclear enriched 75-85kDa form of DISC1 has been reported 
(Sawamura et al., 2005), but there is no reason to suspect that expression of this form of 
DISC1 would be favoured in these cells.  Indeed, western blots of over expressing cells 
show a dominant signal at the predicted 100kDa (see Figure 5.2 for an example).  
 
Characterisation of the expression of PDE4 mRNA was performed by qPCR on the 
iCycler using pan isoform probes.  As expected from studies on brain tissue (Engels et 
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al., 1995, Iona et al., 1998), the pan PDE4C probe failed to produce a PCR product even 
at high cycle numbers, suggesting there is little or no PDE4C expressed in SHSY5Y 
cells.  Expression of PDE4A, PDE4B and PDE4D was clearly detectable.  qPCR showed 
that, consistent with previous in house microarray work on the DISC1 translocation 
family lymphoblastoid cell lines and DISC1 mutant Q31L and L100P mice (Camargo et 
al, paper in preparation, Brown et al, paper in preparation), changes in the DISC1 status 
of SHSY5Y cells (24 hours of DISC1 overexpression and constitutive knockdown) had 
no effect on the expression of PDE4 mRNA.  Any differences observed in these cell 
lines are thus likely to be directly due to changes of activity in PDE4s, and not an 
indirect measure of a change in PDE4 expression.  This makes these cell lines as 
excellent model for studying changes to PDE4 activity with regards to DISC1, and 
common neuroactive chemical compounds. 
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4 The effect of Short Term Forskolin and Lithium 




It is well accepted that the treatment of cells with forskolin activates adenylate cyclase, 
increasing production of cAMP and activating PKA signalling (Seamon et al., 1981, 
Scott, 1991).   Exogenously transfected long PDE4 isoforms are activated by PKA 
phosphorylation following treatment with forskolin in COS7 cells.  PDE activity 
increases 1.4-1.6 fold from baseline on forskolin treatment, using the same approach as 
used in this thesis (MacKenzie et al., 2002).  The first part of this chapter describes an 
experiment to establish the range of endogenous PDE4 response to a 10µM forskolin 
challenge in SHSY5Y cells.  This concentration of forskolin produced a robust increase 
in cAMP concentration in this same cell line using the AlphaScreen protocol (Figure 
3.4).    
 
The main body of this chapter follows on from recent work which demonstrated the 
binding and inhibitory activity of DISC1 on GSK3β (Mao et al., 2009). Using an anti 
DISC1 antibody, GSK3β was immunoprecipated from E14 foetal mouse brain lysate. 
GST pulldown assays reported two regions of DISC1, amino acids 1-220 and 356-595, 
that bound to GSK3β. Of these two fragments, 1-220 demonstrated the ability to inhibit 
autophosphorylation of GSK3β in vitro in a dose-dependent fashion. Surface Plasmon 
resonance was used to further define this binding site to within residues 211-225 (Mao et 
al., 2009).  This area overlaps the first common binding site of PDE4B and D on DISC1, 
identified by peptide array, which lies between amino acids 192-239 (Murdoch et al., 
2007). The interesting possibility is therefore raised of competitive binding or co 
regulation of these two enzymes, through their interaction with DISC1. 
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GSK3β is an enzyme intricately involved with AKT signalling, via inhibitory 
phosphorylation by AKT of Ser9 on GSK3β (Cross et al., 1995).  This association has 
been independently implicated in the pathogenesis of schizophrenia by observations that  
AKT1 protein levels and inhibitory phosphorylation of GSK3β are both decreased in the 
frontal cortex and hippocampus in schizophrenic cases (Emamian et al., 2004a).   
GSK3β is also strongly implicated in psychiatric illness by virtue of its inhibition by 
LiCl, a common mood stabiliser (Beaulieu and Caron, 2008) and primary treatment for 
Bipolar Disorder.  It is still unclear whether there are single or multiple molecular 
mechanisms by which lithium exerts its effects.  At present there are two major 
pathways implicated: disruption of inositol homeostasis and the aforementioned 
inhibition of GSK3β.  
 
As discussed in the introduction, GSK3β was originally proposed as a target of lithium 
after observations that the teratogenic effects of lithium on Xenopus embryos were 
markedly similar to the effects resulting from disruption or inhibition of GSK3β and 
wingless (Wnt) signalling.  Lithium has an IC50 of 2mM for inhibition of bacterially 
purified GSK3β in vitro. In in vitro enzyme reaction studies however, LiCl became more 
potent at inhibiting GSK3β as the Mg
2+
 concentration decreased, implying that the IC50 
of the enzyme may vary depending on the magnesium content of the tissue (Ryves and 
Harwood, 2001).   
 
Since these initial experiments, pharmacological and genetic manipulation of GSK3β 
related pathways has shown behavioural effects relevant to lithium treatment.  GSK3β 
heterozygous knock out mice recapitulate the behavioural effects of lithium treated wild 
types, demonstrating both decreased immobile time in the forced swim test and 
decreased “hole pokes,” in an exploratory behaviour paradigm (O'Brien et al., 2004).  
Brain specific expression of a constitutively active form of GSK3β results in abnormal 
behaviour of transgenic mice, including decreased food intake, increased locomotor 
activity, hyper-responsiveness to acoustic startle and decreased immobility in the forced 
swim test.  Overexpression of GSK3β disrupts regulation of various components of the 
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AKT signalling pathway (Prickaerts et al., 2006).  DISC1 also binds and alters the 
function of KIAA1212 (Kim et al., 2009b, Enomoto et al., 2009), which directly binds 




of AKT (Anai et al., 
2005).  AKT in turn is an upstream regulator of GSK3β (Cross et al., 1995), suggesting 
the possibility for multiple regulatory cell signalling circuits of GSK3β and a role for 
DISC1.  
 
Finally, there is also evidence that cAMP signalling acts upstream of GSK3β.  Studies in 
zebrafish highlight the importance of prostaglandin E2 activity for increasing β-catenin 
stability, leading to the formation of larger pools of haematopoetic precursor cells.  
Treatment of zebrafish with indomethacin, a non selective cycloxygenase inhibitor, 
results in a decrease in numbers of haematopoetic stem cells, which is rescued by 
treatment with forskolin.  This rescue effect is removed by adding H89, a PKA inhibitor, 
suggesting a role for cAMP/PKA signalling upstream of prostaglandin mediated Wnt 
signalling.  In lethally irradiated mice (a process which ablates bone marrow), GSK3β 
inhibition increases the rate of bone marrow repopulation, whereas indomethacin 
treatment has the opposite effect.  In ex vivo whole bone marrow, PGE2 activation and 
forskolin treatment results in both raised cAMP and increased stability of β-catenin.  A 
concomitant change (the direction of this changed is not stated, but an increase is 
assumed) is observed in phosphorylation of Ser9 of GSK3β in these cells, but this 
experiment was unable to establish whether this is a direct effect of cAMP fluctuations 
(Goessling et al., 2009).  Forskolin increases phosphorylation of Ser9 of GSK3β, 
decreasing GSK3β activity by 50% and preventing apoptotic death due to KCl 
withdrawal in primary cerebellar granule cells.  These effects are blocked by 
administration of H89 to cultures, but are independent of ERK and AKT signalling.  
Indeed, purified PKA directly phosphorylates purified GSK3β in vitro, although 
immunoprecipation experiments in vivo have not proved a direct interaction (Li et al., 
2000). 
 
There are multiple reasons therefore, to hypothesise that PDE4 activity may alter as part 
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of a series of regulatory loop responding changes in the activity of cAMP/PKA, AKT 
and GSK3β.  The finding that DISC1 interacts and inhibits the activity of GSK3β (Mao 
et al., 2009), a protein linked to multiple processes involved with psychiatric disease 
including synaptic plasticity, cell survival, CREB and Wnt signalling (reviewed 
Beaulieu and Caron, 2008), is tantalising.  To investigate the hypothesis that GSK3β 
activity may affect PDE4 activity, I performed a series of assays measuring cAMP 
accumulation and enzyme activity in the presence of LiCl and SB216763 (a GSK3β 
specific inhibitor).  
 
4.2 Results 
4.2.1 The effect of forskolin on endogenous PDE4 activity in 
SHSY5Y cells 
Wild type SHSY5Y cells were treated for 30 minutes with 10µM forskolin or vehicle, 
lysed and assayed for PDE4 activity as described in 2.3.2 and 2.5.1.  This treatment led 
to a highly significant 1.4 fold increase in PDE4 activity (Figure 4.1, +/-0.05, p=0.02, 
n=3).  This magnitude of effect is comparable to the previously reported activity level of 
endogenous PDE4B1 transfected into COS7 cells, despite use of a lower concentration 
of forskolin (MacKenzie et al., 2002).  This suggests that at 10µM forskolin, maximal 
PKA mediated PDE4 activation is occurring. 
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Figure 4.1: The effect of treatment with 10µM forskolin on endogenous PDE4 
activity in SHSY5Y cells.  A highly significant increase is observed.  *p=0.002, 
n=3.  Mean PDE4 activity in the vehicle treated control is 108.4 pmoles/mg/min. 
4.2.2 The effect of Lithium on cAMP accumulation in SHSY5Y cells 
SHSY5Y cells were AlphaScreened for cAMP accumulation in response to 30 minutes 
treatment with varying concentrations of LiCl (from 0-10mM), without or without the 
presence of Forskolin as described in 2.5.2.3.  LiCl treatment at concentrations above 
5mM resulted in an increase in cAMP levels (Figure 4.2A), which was highly significant 
at 10mM (p=0.00002, n=4, summarised in Figure 4.2B).  There is a non significant trend 
in the inhibition observed at 3mM in this experiment.  In this experiment the inhibitory 
effect of lithium was masked by treatment with 10µM forskolin, which stimulates 
adenylyl cyclase to increase production of cAMP at the cell membrane, activating PKA 
signalling.  Results are displayed as relative to control as there was not sufficient cAMP 
standard available to produce a full standard curve with each assay. 
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Figure 4.2A. Graph showing the effect of LiCl treatment on cAMP accumulation 
in SHSY5Y cells.  cAMP concentration is plotted as relative to the signal 
obtained by vehicle treated SHSY5Y cells.  
 
Figure 4.2B: Graph to summarise the effect illustrated in figure 4.2A of short 
term LiCl treatment on cAMP levels in SHSY5Y cells, as measured by 
AlphaScreen.   *n=4, p=0.00002 
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This finding is open to several interpretations.  The two most obvious to consider are 
that LiCl treatment acts on a pathway that affects the rate at which adenylyl cyclase 
produces cAMP.  The second is that it acts to inhibit the activity of phosphodiesterase 
enzymes, which break down cAMP.  Early work on the effect of lithium treatment on 
adenylyl cyclase on treated membranes and brain slices suggested that lithium actually 
inhibits the production of cAMP through inhibition of adenylyl cyclase (Ebstein et al., 
1980, Newman and Belmaker, 1987).  It later became apparent that only three of the ten 
isoforms of adenylyl cyclase were actually susceptible to this inhibition.  Isoforms II, V 
and VII are all susceptible to inhibition by low concentrations of LiCl (1-2mM), but the 
magnitude of this effect varies depending on the presence of Forskolin or concomitantly 
overexpressed dopamine type 1 receptors (Mann et al., 2008).  While little work appears 
to have been done on assessing the isoforms of adenylyl cyclase present in SHSY5Y 
cells, pharmacological characterisation of M3 muscarinic receptor stimulation of the 
aforementioned cells suggests the presence of isoform I, and perhaps VIII (Hirst and 
Lambert, 1995), which would mean they were not susceptible to this effect on adenylyl 
cyclase.  There is no evidence in the literature that LiCl would lead to an increase in AC 
activity, as is potentially being seen here. 
 
The other possibility is that LiCl treatment at this concentration is, either directly or 
indirectly, altering the activity of the phosphodiesterase enzymes which break down 
cAMP.  Inhibition of these enzymes would lead to an increase in cAMP levels.  For this 
reason I performed a simple experiment to assess this possibility. 
 
4.2.3 The effect of Short Term Lithium Chloride treatment on 
Phosphodiesterase 4 activity 
 
Low throughput PDE assays were used (Marchmont and Houslay, 1980) to directly 
assess the effect of LiCl treatment on PDE activity.  Serum starved wild type SHSY5Y 
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cells were treated for 30 minutes with either vehicle or LiCl at 3mM and 10mM 
concentrations, and assayed as described in 2.5.1.   
 
Short term treatment of SHSY5Y cells with 3 and 10mM concentrations of LiCl results 
in a decrease in PDE4 specific activity in a range of magnitude very similar to the 
changes seen in cAMP levels (Figures 4.2B and 4.3A).  This decrease in activity is 
highly significant at the 10mM concentration (p=.005, n=3).  There is no trend observed 
in the non-PDE4 activity in the same lysates (Figure 4.3B), which comprises a small 
fraction of the measurable PDE activity (Figure 3.2A).  It is therefore likely that 





Figure 4.3A The effect of short term LiCl treatment on PDE4 activity in SHSY5Y 
cells.  Treatment with 3mM LiCl leads to a non significant decrease in PDE4 
activity, while treatment with 10mM LiCl results in a highly significant decrease 
in activity.  * N=3, p=0.005  Mean PDE4 activity of the vehicle treated control is 
104.9pmoles/mg/min. 
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Figure 4.3B - The effect of short term LiCl treatment on non-PDE4 activity in 
SHSY5Y cells.  There are no significant effects of LiCl treatment.  Mean non-
PDE4 activity in the vehicle treated control is 26.3 pmoles/mg/min. 
 
As mentioned previously, LiCl is a drug with many known targets (Beaulieu and Caron, 
2008), and potentially some others which are unknown.  There is no evidence in the 
literature that Lithium directly inhibits PDE4, but PDE4 does have a magnesium co-
factor (Saldou et al., 1998), and hence there is hypothetical potential for this to occur 
(Hallcher and Sherman, 1980, Ryves and Harwood, 2001).  Alternatively, and perhaps 
more likely, it may be that PDE4s are controlled through the actions of GSK3β, one of 
the major known targets of LiCl.  GSK3β has multiple downstream effectors, and thus it 
is highly possible that through one of these pathways, an unknown pathway, or the 
interaction with DISC1, that GSK3β also regulates PDE4 activity. 
 
4.2.4 The effect of GSK3β specific inhibitors on PDE4 activity 
Low throughput phosphodiesterase assays were performed to compare the inhibition of 
PDE4 by 10mM LiCl with 3µM SB216763, a compound that inhibits GSK3β with a Ki 
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of 9nM by competing with ATP (Coghlan et al., 2000) with minimal effects at other 
similarly structured cyclin dependent kinases (CDKs).   
 
Serum starved SHSY5Y cells were treated with either vehicle (DMSO at a final 
concentration of less than 0.1%), 3µM SB216763, 10mM LiCl or a combination of LiCl 
and SB216763.  Cells were incubated for 30 minutes, before assaying as described 
earlier.  Cells treated with 3µM SB216763 showed a significant decrease (p=0.003, n=3) 
in PDE4 activity, equal in magnitude to treatment with 10mM LiCl (Figure 4.4A).  
There was a small, but non-significant additive effect of combining both compounds, 
suggesting that GSK3β was responsible for most, if not all of the inhibition observed.  
Conversely, as with LiCl treatment, SB216763 had no effect on non-PDE4 activity 
(Figure 4.4B).  Combining both compounds produced a non significant decrease in non-
PDE4 activity, similar to the decrease due to LiCl observed earlier in Figure 4.3B.     
 
Figure 4.4A: The effect of the GSK3β specific inhibitor SB216763 and 10mM 
LiCl on PDE4 activity. *n=3, p<0.01 in all cases.  Mean PDE4 activity in the 
vehicle treated control is 130.2 pmoles/mg/min. 
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Figure 4.4B: The effect of 3µM SB216763 and 10mM LiCl on non-PDE4 activity, 
as dissected out by addition of 10uM Rolipram.  None of the changes depicted 
are approaching statistical significance after 3 experiments.  Mean non-PDE4 
activity in the vehicle treated control is 27.5pmoles/mg/min. 
4.2.5 Colocalisation of exogenous tagged GSK3β and PDE4B in 
nucleofected SHSY5Y cells 
Due to problems finding an anti GSK3β antibody suitable for endogenous 
immunocytochemistry, the experiment was performed using cotransfected myc tagged 
GSK3β and flag tagged PDE4B1.  pcDNA3.1-myc-GSK3β and pcDNA3.1-Flag-
PDE4B1 were generated and kindly supplied by Fumiaki Ogawa.  SHSY5Y cells were  
cotransfected with the expression constructs by nucleofection as described in 2.2.3.2 and 
seeded onto baked glass coverslips at a density of 5x10
5
 cells per well.  These coverslips 
were incubated overnight, then fixed and immunostained as described in 2.3.5.   As a 
control, untransfected cells were also labeled with the primary antibodies and secondary 
antibodies alone.  Neither of these controls showed significant non-specific staining 
(data not shown).  
 





Figure 4.5: Immunocytochemistry showing the localisation of myc tagged 
GSK3β (A and D) and flag tagged PDE4B1 (B and E) contransfected into wild 
type SHSY5Y cells.   
Colocalisation was clearly evident between these two exogenously expressed proteins 
(Figure 4.5).  As observed previously with endogenous PDE4B, PDE4D and DISC1, 
both signals were strongest in perinuclear regions, with minimal signal from nuclear 
regions.  The mitochondria, endoplasmic reticulum and microtubules all cluster in a 
similar distribution within this region, but staining in this experiment is unlikely to relate 
to a single one of these organelles as they all have very specific pattern of distribution 
not evident here (http://www.cellsignal.com/catalog/organelle.html).  Endogenous 
DISC1 and PDE4B have been shown previously in this region to colocalise with 
mitochondrial staining in a small subset of SHSY5Y cells (Millar et al., 2005b).  
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Cellular fractionation in SHSY5Y cells and neurons has demonstrated the presence of 
GSK3β in purified mitochondria as well as in cytoplasmic fractions (Bijur and Jope, 
2003, Hoshi et al., 1996), thus it is clearly possible that colocalisation of PDE4B and 
GSK3β is occurring, amongst other organelles, in the mitochondria. 
 
4.2.6 Do PDE4B and PDE4D contain canonical GSK3β 
phosphorylation sites? 
Sequences of human PDE4B and PDE4D isoforms were aligned using ClustalW, and 
run through a series of phosphorylation prediction databases as detailed in Materials and 
Methods.  No highly scoring potential canonical GSK3β phosphorylation sites were 
discovered in these databases (Figures 4.6A-D).  However, it is becoming increasingly 
apparent with GSK3β that the presence of other proteins in a complex may significantly 
alter the phosphorylation capacity of the enzyme (Ikeda et al., 1998).  While this means 
it is unwise to rule out PDE4B as a direct target for GSK3β, it also means that further 
studies to investigate this possibility are made more complex.  Complicating matters yet 
further, GSK3β often requires phosphorylation of a priming proximal serine or threonine 
4 residues away from the residue of interest, making direct studies mixing recombinant 
forms of the protein difficult (Fiol et al., 1987, Jope and Roh, 2006, Thomas G, 1999).  
Whether the effect observed of GSK3β phosphorylation is direct or via the involvement 
of other proteins is therefore still unclear, and outside the scope of this investigation.   
 
In the PDE4B isoforms Scansite, the only database searched that distinguishes between 
GSK3α and GSK3β phosphorylation sites, detected potential GSK3β sites in PDE4B3, 
but these were only detected by the lowest stringency scan.  These sites clustered at 
residues 42, 46, 50 and 54, with an outlier at residue 87, in an arrangement providing the 
potential for priming that can favour phosphorylation by GSK3β.  Scansite noted 
GSK3β specific sites, again only on a low stringency search, at residues 55 and 59 of 
PDE4D5 and PDE4D3.  These residues are found on the same background sequence in 
both of these isoforms, but ClustalW has aligned them differently.  Again, these residues 
are the correct distance to allow for priming.   
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A series of other potential sites were detected by the other phosphorylation databases, all 
of which were GSK3 specific, except for Disphos 1.3.  Disphos 1.3 was used because 
this takes the disorder of a protein into an account to assess the accessibility of a putative 
phosphorylation site.  In PDE4B1, a three site cluster was detected at residues 145, 150 
and 154, and these sites are fully conserved in PDE4B3, with partial conservation near 
the N terminal of B2.  The other sites detected in more than one database have no 
potential priming site, and all have low likelihood scores (Figure 4.6C).   
 
In the PDE4Ds there is a cluster of potential sites found between the PKA 
phosphorylation site and the common DISC1 binding site, at conserved residues 
corresponding to 202, 207 and 211 in PDE4D4, which would allow for priming 
phosphorylation.  As one can see from Figure 4.6B, there are two other 2 residue 
clusters, but again these have noncanonical spacing for a priming site.  Once more, all 
sites have low likelihood scores (Figure 4.6D). 
 
I compared these results to those observed in a substrate of GSK3β with well defined 
phosphorylation sites: β-catenin.  In this protein, priming phosphorylation is required by 
a different kinase at Ser45, before GSK3β phosphorylates residues Thr41, Ser37 and 
Ser33 (Hagen and Vidal-Puig, 2002).  This is a similar clustering to that described above 
in PDE4B1, PDE4B3 and PDE4D4.  The human β-catenin protein sequence was 
obtained from NCBI protein database (Ref Seq NP_001895.1) and run through the 5 
phosphoprediction tools used for the PDE4 isoforms.  It is likely that this sequence was 
used to train DisPhos1.3 and KinasePhos2.0, as Ser33 and Ser37 received scores of 1 in 
both databases, while Ser41 received scores of 1 and 0.88 respectively.  Scansite 
however, only detected all three sites on a low stringency scan, Phosphomotif finder 
detected only Ser33 as a putative site, and NetPhosK failed to detect any of the three 
sites.  It seems therefore, that prediction of phosphorylation by GSK3β is not a simple 
procedure, and that the low scores obtained in this exercise should not be taken as 
definitive evidence that the PDE4s are not a direct target for GSK3β phosphorylation.  
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Therefore, further experimentation is required.  This lies beyond the scope of this thesis, 






Figures 4.6A and B overleaf show aligned sequences of human PDE4B (A) and 
PDE4D (B) isoforms.  As with all alignments performed by Clustal, a “*” depicts 
full conservation of an amino acid residue throughout isoforms, “:” depicts a 
conserved substitution, and “.” A semi conserved substitution.  Highlighted in 
green are the DISC1 PDE4 binding sites as defined in Murdoch et al, 2007.  
Highlighted in blue are known PKA and ERK phosphorylation sites, as defined 
by Mackenzie et al 2002, and Baillie et al 2000 respectively. 
The key to highlighting throughout the figure is as follows:                                                     
S = identified as having phosphorylation potential in 2 databases                                                                 
S = identified in 3 databases                                                                          
S = identified in 2 databases, Scansite suggests GSK3α and β potential         
S = identified in 2 databases, Scansite suggests GSK3α only 
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Figure 4.6A 
CLUSTAL 2.0.10 multiple sequence alignment 
 
PDE4B3|NP_001032417.1      ---------MTAKDSSKELTASEPEVCIKTFKEQMHLELELPRLPGN--- 38 
PDE4B5|ABQ85407.1|         -------------------------------------------------- 
PDE4B2|NP_001032416.1      -------------------------------------------------- 
PDE4B1|NP_002591.2|        MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL 50 
                                                                                       
 
PDE4B3|NP_001032417.1      --RPTSPKISPRSSPRNSPCFFR-KLLVNKSIRQRRRFTVAHTCFDVENG 85 
PDE4B5|ABQ85407.1|         -------------------------------------------------- 
PDE4B2|NP_001032416.1      -------------------------------------------------- 
PDE4B1|NP_002591.2|        QLPPLSQRQSERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENG 100 
                                                                                       
           PKA 
PDE4B3|NP_001032417.1      PSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLSPKAMS 135 
PDE4B5|ABQ85407.1|         -------------------------------------------------- 
PDE4B2|NP_001032416.1      ------------------------------------MKEHGGTFSSTGIS 14 
PDE4B1|NP_002591.2|        PSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLSPKAMS 150 
                                                                                       
 
PDE4B3|NP_001032417.1      RNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNKRSPAA 185 
PDE4B5|ABQ85407.1|         ----------------------------------------------MPEA 4 
PDE4B2|NP_001032416.1      GGS-------GD--------SAMDSLQPLQPNYMPVCLFAEESYQKLAME 49 
PDE4B1|NP_002591.2|        RNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNKRSPAA 200 
                                                                                   .   
        DISC1 Common 
PDE4B3|NP_001032417.1      SQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEMASNKF 235 
PDE4B5|ABQ85407.1|         N-------------------------------------YLLSVSWGYIKF 17 
PDE4B2|NP_001032416.1      T---------------------LEELDWCLDQLETIQTYRSVSEMASNKF 78 
PDE4B1|NP_002591.2|        SQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEMASNKF 250 
                           .                                     *    . .  ** 
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PDE4B3|NP_001032417.1      KRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK 285 
PDE4B5|ABQ85407.1|         KRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK 67 
PDE4B2|NP_001032416.1      KRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK 128 
PDE4B1|NP_002591.2|        KRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK 300 
                           ************************************************** 
 
PDE4B3|NP_001032417.1      KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGL 335 
PDE4B5|ABQ85407.1|         KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGL 117 
PDE4B2|NP_001032416.1      KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGL 178 
PDE4B1|NP_002591.2|        KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGL 350 
                           ************************************************** 
     DISC1 PDE4B specific 
PDE4B3|NP_001032417.1      NIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYH 385 
PDE4B5|ABQ85407.1|         NIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYH 167 
PDE4B2|NP_001032416.1      NIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYH 228 
PDE4B1|NP_002591.2|        NIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYH 400 
                           ************************************************** 
 
PDE4B3|NP_001032417.1      SDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDH 435 
PDE4B5|ABQ85407.1|         SDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDH 217 
PDE4B2|NP_001032416.1      SDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDH 278 
PDE4B1|NP_002591.2|        SDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDH 450 
                           ************************************************** 
           DISC1 common 
PDE4B3|NP_001032417.1      PGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTK 485 
PDE4B5|ABQ85407.1|         PGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTK 267 
PDE4B2|NP_001032416.1      PGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTK 328 
PDE4B1|NP_002591.2|        PGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTK 500 
                           ************************************************** 
 
PDE4B3|NP_001032417.1      KQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYT 535 
PDE4B5|ABQ85407.1|         KQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYT 317 
PDE4B2|NP_001032416.1      KQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYT 378 
PDE4B1|NP_002591.2|        KQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYT 550 
                           ************************************************** 
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PDE4B3|NP_001032417.1      DRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI 585 
PDE4B5|ABQ85407.1|         DRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI 367 
PDE4B2|NP_001032416.1      DRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI 428 
PDE4B1|NP_002591.2|        DRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI 600 
                           ************************************************** 
 
PDE4B3|NP_001032417.1      SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRN 635 
PDE4B5|ABQ85407.1|         SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRN 417 
PDE4B2|NP_001032416.1      SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRN 478 
PDE4B1|NP_002591.2|        SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRN 650 
                           ************************************************** 
       ERK 
PDE4B3|NP_001032417.1      WYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHS 685 
PDE4B5|ABQ85407.1|         WYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHS 467 
PDE4B2|NP_001032416.1      WYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHS 528 
PDE4B1|NP_002591.2|        WYQSMIPQSPSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHS 700 
                           ************************************************** 
 
PDE4B3|NP_001032417.1      YFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT 721 
PDE4B5|ABQ85407.1|         YFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT 503 
PDE4B2|NP_001032416.1      YFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT 564 
PDE4B1|NP_002591.2|        YFSSTKTLCVIDPENRDSLGETDIDIATEDKSPVDT 736 
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Figure 4.6B 
 
Q08499-4   PDE4D1     ------------------------------------------------------------ 
Q08499-5   PDE4D5     ------------------------------------------------------------ 
Q08499-8   PDE4D6     ------------------------------------------------------------ 
Q08499-11  PDE4D7     ------------------------------------------------------------ 
Q08499-9   PDE4D8     ------------------------------------------------------------ 
Q08499-2   PDE4D3     ------------------------------------------------------------ 
Q08499-1   PDE4D4     MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPP 60 
Q08499-10  PDE4D9     ------------------------------------------------------------ 
Q08499-6   PDE4D5     ------------------------------------------------------------ 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
 
Q08499-4   PDE4D1     ------------------------------------------------------------ 
Q08499-5   PDE4D5     ------------------------------------------------------------ 
Q08499-8   PDE4D6     ------------------------------------------------------------ 
Q08499-11  PDE4D7     -MKRNTCDLLSRSKSASEETLHSSNEEEDPFRGMEPYLVRRLSCRNIQLPPLAFRQLEQA 59 
Q08499-9   PDE4D8     ------------------------------------------------------------ 
Q08499-2   PDE4D3     ------------------------------------------------------------ 
Q08499-1   PDE4D4     PPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRA 120 
Q08499-10  PDE4D9     ------------------------------------------------------------ 
Q08499-6   PDE4D5     ---------MAQQTSPDTLTVPEVDNPHCPNPWLNEDLVKSLRENLLQHEKSKTARKSVS 51 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
 
Q08499-4   PDE4D1     --------------------------------------MKEQPSCAGTG--HPMAGYGR- 19 
Q08499-5   PDE4D5     ------------------------------------------------------------ 
Q08499-8   PDE4D6     ------------------------------------------------------------ 
Q08499-11  PDE4D7     DLKSESENIQRPTSLPLKILPLIAIT-----SAESSGFDVDNGTSAGRSPLDPMTSPGSG 114 
Q08499-9   PDE4D8     --MAFVWDPLGATVPGPSTRAKSRLR-----FSKSYSFDVDNGTSAGRSPLDPMTSPGSG 53 
Q08499-2   PDE4D3     -----------------MMHVNNFFR-----RHSWICFDVDNGTSAGRSPLDPMTSPGSG 38 
Q08499-1   PDE4D4     MDRTSYAVETGHRPGLKKSRMSWPSS-----FQGLRRFDVDNGTSAGRSPLDPMTSPGSG 175 
Q08499-10  PDE4D9     ----------MSIIMKPRSRSTSSLR-----TAEAVCFDVDNGTSAGRSPLDPMTSPGSG 45 
Q08499-6   PDE4D5     PKLSPVISPRNSPRLLRRMLLSSNIPKQRRFTVAHTCFDVDNGTSAGRSPLDPMTSPGSG 111 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
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              PKA 
Q08499-4   PDE4D1     -----------------------------------------------MAPFELASGPVKR 32 
Q08499-5   PDE4D5     ------------------------------------------------------------ 
Q08499-8   PDE4D6     ------------------------------------------------------------ 
Q08499-11  PDE4D7     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 174 
Q08499-9   PDE4D8     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 113 
Q08499-2   PDE4D3     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 98 
Q08499-1   PDE4D4     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 235 
Q08499-10  PDE4D9     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 105 
Q08499-6   PDE4D5     LILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRT 171 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
     
               DISC1 Common Site 
Q08499-4   PDE4D1     LR----------------------TESPFPCLFAEEAYQKLASETLEELDWCLDQLETLQ 70 
Q08499-5   PDE4D5     ------------------------------------------------------------ 
Q08499-8   PDE4D6     ---------------------------------------------MPEANYLLS------ 9 
Q08499-11  PDE4D7     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 234 
Q08499-9   PDE4D8     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 173 
Q08499-2   PDE4D3     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 158 
Q08499-1   PDE4D4     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 295 
Q08499-10  PDE4D9     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 165 
Q08499-6   PDE4D5     VRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQ 231 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
                                                                             
 
Q08499-4   PDE4D1     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 130 
Q08499-5   PDE4D5     -------MASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 53 
Q08499-8   PDE4D6     -----VSWGYIKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 64 
Q08499-11  PDE4D7     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 294 
Q08499-9   PDE4D8     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 233 
Q08499-2   PDE4D3     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 218 
Q08499-1   PDE4D4     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 355 
Q08499-10  PDE4D9     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 225 
Q08499-6   PDE4D5     TRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKE 291 
Q08499-7   PDE4DN3    ------------------------------------------------------------ 
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Q08499-4    PDE4D1    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 190 
Q08499-5    PDE4D5    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 113 
Q08499-8    PDE4D6    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 124 
Q08499-11   PDE4D7    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 354 
Q08499-9    PDE4D8    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 293 
Q08499-2    PDE4D3    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 278 
Q08499-1    PDE4D4    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 415 
Q08499-10   PDE4D9    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 285 
Q08499-6    PDE4D5    KKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELS 351 
Q08499-7    PDE4DN3   -----MAQQTSPDTLTVP-EVDNPHCP-------------------NPW----------- 24 
                           *:* :. ..*  . .: *.  *                   * *            
 
Q08499-4    PDE4D1    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 250 
Q08499-5    PDE4D5    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 173 
Q08499-8    PDE4D6    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 184 
Q08499-11   PDE4D7    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 414 
Q08499-9    PDE4D8    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 353 
Q08499-2    PDE4D3    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 338 
Q08499-1    PDE4D4    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 475 
Q08499-10   PDE4D9    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 345 
Q08499-6    PDE4D5    GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTH 411 
Q08499-7    PDE4DN3   -------------LNEDLVKSLR----------ENLLQHEKSKTARKS------------ 49 
                                    :.**:*:::           .* :* ::..* :.             
 
 
Q08499-4    PDE4D1    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 310 
Q08499-5    PDE4D5    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 233 
Q08499-8    PDE4D6    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 244 
Q08499-11   PDE4D7    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 474 
Q08499-9    PDE4D8    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 413 
Q08499-2    PDE4D3    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 398 
Q08499-1    PDE4D4    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 535 
Q08499-10   PDE4D9    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 405 
Q08499-6    PDE4D5    VLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHH 471 
Q08499-7    PDE4DN3   -----------------VSPKLSPVISPRNSPRLLRRMLLSSN----------------- 75 
                                       ::. ::..*   : * : .::*:.:*                  
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             DISC1 Common Site 
Q08499-4    PDE4D1    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 370 
Q08499-5    PDE4D5    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 293 
Q08499-8    PDE4D6    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 304 
Q08499-11   PDE4D7    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 534 
Q08499-9    PDE4D8    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 473 
Q08499-2    PDE4D3    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 458 
Q08499-1    PDE4D4    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 595 
Q08499-10   PDE4D9    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 465 
Q08499-6    PDE4D5    LAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVT 531 
Q08499-7    PDE4DN3   ------------------IPKQRRFTVAHTCFDVDNGTSAGR-----SPLDPMTS----P 108 
                                        :.*::* :: :  :*:  .*. .:     : *..*..    . 
 
 
Q08499-4    PDE4D1    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 430 
Q08499-5    PDE4D5    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 353 
Q08499-8    PDE4D6    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 364 
Q08499-11   PDE4D7    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 594 
Q08499-9    PDE4D8    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 533 
Q08499-2    PDE4D3    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 518 
Q08499-1    PDE4D4    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 655 
Q08499-10   PDE4D9    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 525 
Q08499-6    PDE4D5    SSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGME 591 
Q08499-7    PDE4DN3   GSGLILQAN----------FVHSQRR------------------ESFLYRSDSD----YD 136 
                      .**::*  *          :**.                     *.*: :.* :     : 
                DISC1 PDE4D Specific       ERK 
Q08499-4    PDE4D1    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 490 
Q08499-5    PDE4D5    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 413 
Q08499-8    PDE4D6    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 424 
Q08499-11   PDE4D7    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 654 
Q08499-9    PDE4D8    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 593 
Q08499-2    PDE4D3    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 578 
Q08499-1    PDE4D4    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 715 
Q08499-10   PDE4D9    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 585 
Q08499-6    PDE4D5    ISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 651 
Q08499-7    PDE4DN3   LSPKSMSRNSSIA-SDIHGDDLIVTPFAQVLASLR---------TVRNN--FAALTNLQD 184 
                      :** . .:*:*:  *::   * ** *: :. *.*          *:.:*  :   *  *. 
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Q08499-4    PDE4D1    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 550 
Q08499-5    PDE4D5    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 473 
Q08499-8    PDE4D6    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 484 
Q08499-11   PDE4D7    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 714 
Q08499-9    PDE4D8    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 653 
Q08499-2    PDE4D3    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 638 
Q08499-1    PDE4D4    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 775 
Q08499-10   PDE4D9    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 645 
Q08499-6    PDE4D5    PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSES 711 
Q08499-7    PDE4DN3   RAPSKRSP--------------------------------------------MCNQPS-- 198 
                       :*:  .*                                            :*.* *   
 
Q08499-4    PDE4D1    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 584 
Q08499-5    PDE4D5    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 507 
Q08499-8    PDE4D6    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 518 
Q08499-11   PDE4D7    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 748 
Q08499-9    PDE4D8    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 687 
Q08499-2    PDE4D3    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 672 
Q08499-1    PDE4D4    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 809 
Q08499-10   PDE4D9    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 679 
Q08499-6    PDE4D5    TEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT 745 
Q08499-7    PDE4DN3   --------INKATITGLYNGIIAFL--------- 215 
                               ::: ::                     
  150 
 
Figure 4.6C 
Position Residue DP 1.3 Scansite KP 2.0 PM Finder NPK
6 S 0.50 0.52
56 S 3A Yes
65 T 0.50 Yes
76 T 3A 0.56
102 S 0.54 3A Yes 0.54
106 S 0.60 3A Yes 0.54
145 S 0.64 Yes
150 S 0.58 0.78 Yes
154 S 0.55 0.65
197 S Yes 0.52
290 S 0.59 0.56 Yes 0.51
424 T 0.62 Yes
601 S Yes 0.5
610 S 0.65 Yes
718 S 0.51 0.62  
Figure 4.6D 
Position Residue DP 1.3 Scansite KP 2.0 PM finder NPK
14 S 0.935 3A Yes 0.51
18 S 0.68 0.767
64 S 0.827 3A Yes 0.53
97 S 0.75 0.7555
142 S 0.643 Yes
164 S Yes 0.51
171 S 3A Yes 0.51
202 S 0.655 Yes
207 S 0.56 0.5608 Yes
211 S 0.509 0.547
252 S 0.512 0.792
348 S 0.612 3A 0.555 Yes 0.5
480 T 0.6288 Yes
657 S Yes 0.5
666 S 0.7137 Yes
715 S 0.621 3A Yes 0.51
717 S 0.606 3A 0.6192
754 S 0.89 0.5308
761 S 0.747 Yes
806 S 0.754 Yes 0.5  
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Figure 4.6C-D (previous page): Tables showing the potential phosphorylation 
sites depicted on the sequence alignments of PDE4B (C) and PDE4D (D), and 
the scores obtained from each phosphorylation database.  In Disphos 1.3 (DP 
1.3), KinasePhos 2.0 (KP2.0) and NetPhosK (NPK), the score roughly 
approximates to the probability of phosphorylation, and so a score of 0 implies 
there in no probability of phosphorylation, and a score of 1 implies 
phosphorylation will definitely occur.  0.5 is the threshold value for reporting a 
site.  In the Scansite column, if the site is recognised by a high stringency scan, 
it is depicted in bold, if medium stringency in normal type, and by low stringency 
in italics.  Phosphomotif finder (PM Finder) gives a binary response for a 




In this chapter I have confirmed the validity of the SHSY5Y system as a model for 
assessing PDE4 activity.  SHSY5Y cells produced a PDE4 specific 1.4 fold increase in 
activity in response to forskolin, almost identical to that observed in the previous 
literature by over expressed PDE4B1 in COS7 cells (MacKenzie et al., 2002).  This 
response has been shown to be wholly due to phosphorylation of PDE4 long forms by 
PKA, as the response was obliterated by the use of the specific PKA inhibitor H89, and 
by site directed mutagenesis of the PKA phosphorylation site corresponding to residue 
133 in PDE4B1.  Thus, forskolin activates PKA signalling by switching on adenylate 
cyclase, PKA phosphorylates long forms of PDE4, and a measurable increase in PDE4 
activity is observed (MacKenzie et al., 2002).  qPCR with pan probes for PDE4 isoforms 
in Chapter 3 detected the presence of PDE4A, B and D in SHSY5Y cells, but not 
PDE4C.      
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GSK3β is an enzyme that has been strongly implicated in psychiatric disease both by 
virtue of its inhibition by the mood stabilising drug lithium, and genetic and 
pharmacological experiments reviewed in the Introduction.  Over 40 putative 
downstream targets for GSK3β phosphorylation have been described, and the enzyme 
itself has an exquisitely complex and multi tiered regulatory system (Jope and Johnson, 
2004).  GSK3β itself is phosphorylated by kinases from a variety of different signalling 
pathways, including the structurally similar AKT and PKA, both of which phosphorylate 
Ser9 to inhibit GSK3β activity (Cross et al., 1995, Fang et al., 2000).  The RII subunit of 
PKA is in turn phosphorylated by GSK3β (Brian et al., 1982).  This enables integration 
of multiple signalling pathways within the cell to produce very fine control of output.  
Further to this level of regulation, the presence or absence of proteins in a binding 
complex (Ikeda et al., 1998), and the presence of pre phosphorylated “primed” residues 
can effect the affinity of GSK3β for a substrate (Fiol et al., 1987, Thomas G, 1999), 
allowing even finer contextual control of enzyme activity. 
 
It has recently been shown that DISC1 binds to GSK3β in foetal mouse brain lysate 
(Mao et al., 2009), which has raised the interesting idea of the formation of a complex 
between GSK3β, DISC1, and PDE4B/D.  The formation of such a complex could have 
implications for the activity of both GSK3β and the PDE4s, with DISC1 acting as a 
scaffold bringing other interacting proteins together and altering substrate specificity of 
GSK3β.  To this end, I performed simple pharmacological manipulations to try and 
ascertain whether GSK3β has an effect on PDE4 activity.    
 
I used the AlphaScreen assay system to assess cAMP accumulation in SHSY5Y cells in 
response to LiCl treatment. cAMP accumulation increased significantly at high 10mM 
concentrations of LiCl treatment, corresponding to five times the IC50 of LiCl for 
GSK3β.  The IC50 is the concentration required to inhibit 50% of a biological process, 
thus it is likely that at 10mM the system is approaching complete inhibition of GSK3β.  
The AlphaScreen signal decreased by 15% (+/-1.17), corresponding to an equivalent 
increase in cAMP concentration.  A corresponding decrease in PDE4 specific activity of 
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24% (=/-2.4) was observed in low throughput PDE assays.  No significant changes were 
observed in non-PDE4 activity, although this component of the response forms a small 
minority of the activity measured.   To assess whether the observed changes were due to 
inhibition of GSK3β by LiCl, the same assay was performed using 3µM SB216763, a 
GSK3β specific inhibitor with an IC50 of 34nM (Coghlan et al., 2000).  In this series of 
experiments, 10mM LiCl treatment caused an 18% (+/-2.6) decrease in PDE4 activity, 
while 3µM SB216763 resulted in a 13% (+/-1.1) decrease that was not statistically 
different by t-test to the effect produced by LiCl.  There was a small trend towards an 
additive effect of using both compounds, but again this was not statistically significant.  
Thus it is apparent that the changes in PDE4 activity due to LiCl treatment are due to the 
effect of LiCl in inhibiting GSK3β.  SB216763 has minimal effects at other cyclin 
dependant kinases, but LiCl does not inhibit these same kinases, and thus they are ruled 
out as a responsible pathway (Cohen and Goedert, 2004).   
 
10mM treatment of cell culture with LiCl is above the generally accepted “therapeutic 
threshold,” of lithium treatment, which is a blood plasma concentration of between 0.6-
1.2mM (Jope and Song, 1997).  It is difficult to find reports in the literature of whether 
there is potential for accumulation of lithium in particular compartments of the body.  
Mechanisms for amplifying the effects of lower concentrations of lithium however, have 
been described.  Firstly, GSK3β is very highly expressed in brain tissue (Woodgett, 
1990).  Competition with magnesium ions is the mechanism by which lithium exerts its 
effect (Ryves and Harwood, 2001), and magnesium concentration within the brain is 
very tightly regulated: infusing high concentrations of magnesium into the plasma does 
not alter brain magnesium levels in swine (Gee et al., 2001).  The mechanism of action 
infers that lithium treatment will have a greater effect where free tissue magnesium is 
low. In the rat brain, total tissue magnesium concentration is 6.2µmoles/g, lower than the 
concentration in liver and kidney.  Free magnesium however, does not vary between 
these three tissues, lying between 0.6-1.3µM/g (Veloso et al., 1973).  At these 
concentrations of magnesium, the IC50 of lithium may be decreased to 0.8mM, clearly 
allowing for significant inhibition within the therapeutic index (Ryves and Harwood, 
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2001). Finally, increased inhibitory phosphorylation of Ser9
 
of GSK3β has been shown 
in SHSY5Y cells in response to medium term lithium treatment.  Phosphorylation of the 
residue increased over the course of the 24 hour experiment.  There was no concomitant 
change in AKT activation by phosphorylation, and so this adaptive change is thought to 
be independent of AKT signalling.  Increased Ser9
 
phosphorylation was also 
demonstrated in vivo, with an increase observed in mouse cortex and hippocampus after 
4 weeks of treatment resulting in serum concentrations of 0.7mM lithium (De Sarno et 
al., 2002).  These factors could all lead to the potentiation of the effects of lithium in 
brain tissue after medium to long term treatment in vivo. 
  
The potential for PDE4s to be directly phosphorylated by GSK3β was briefly 
investigated through the use of phosphorylation databases.  The most stringent of these, 
Scansite, was only able to detect putative GSK3β sites in PDE4B3, D5 and DN3, and 
these sites were only suggested on a low stringency scan, ranking just under halfway 
down the list of total possible GSK3β sites in the vertebrate section of the SwissProt 
database.  Further clusters of low scoring putative sites were highlighted by the other 
non GSK3β specific databases, but none of these stood out as obvious candidates for 
further study such as site directed mutagenesis.  GSK3β however, is not a typical kinase 
enzyme.  To phosphorylate a majority of substrates it prefers the substrate to be primed 
by phosphorylation four residues away from the GSK3β site.  The affinity for a substrate 
can also be altered by the presence or absence of other proteins from the complex 
binding to it (Frame and Cohen, 2001, Jope and Johnson, 2004).  When the sequence of 
β-catenin, a protein with a cluster of well characterised GSK3β phosphorylation sites 
was run through the same prediction tools, three of them either failed to detect these 
established sites, or only detected them in low stringency scans.  This tendency towards 
non canonical behaviour suggests that the presence of no clear canonical GSK3β site in 
the phosphorylation databases should not totally rule out the potential for direct 
phosphorylation of PDE4s by GSK3β.   
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Further investigation however, is complicated by the tendency of GSK3β to require 
priming phosphorylation.  Without priming, the efficiency of phosphorylation is 
seriously reduced.  There are no putative GSK3β sites four residues distant from 
established PKA and ERK phosphorylation sites (Figures 4.6A and B).  This makes in 
vitro phosphorylation assays involving direct mixing of recombinant protein and kinase 
difficult.  Should another kinase be added to the mix?  If so, which one?  It may also be 
possible to drive a phosphorylation by using a very high concentration of purified 
GSK3β.  From the phosphorylation prediction tools, there is no clear or even leading 
candidate for functional studies involving mutagenesis.  It is likely that a higher 
throughput approach to phosphorylation detection is required, such as mass spectrometry 
(Mann et al., 2002) or the use of microarray technology.  Recent advances in technology 
allow immobilisation of small peptide sequences onto assay chips, which can then be 
probed with the kinase of interest.  “Hits” can be detected by incubation with 
radioactively labeled ATP, phosphospecific antibodies or phosphopeptide chelators 
attached to a label such as a fluorescent dye or horse radish peroxidase (Henderson and 
Bradley, 2007, Schutkowski M et al., 2005).  Again, this fails to get round the need for 
substrate priming, and there are also arguments about whether such small peptide 
fragments can mimic kinase behaviour in vivo, due to their lack of complex tertiary 
structure.  Further investigation of the potential for direct phosphorylation was thus 
outside the capabilities of this project, but not ruled out by initial work.   
 
The possibility that basal activity of PDE4s is maintained by GSK3β is tantalising.  The 
further means for integration of PKA and cAMP signalling with GSK3β and AKT 
pathways would allow for even finer contextual control of exquisitely sensitive 
signalling systems, allowing the tuning of the response of an enzyme with a large 
number of substrates to very specific cellular situations.  The dynamic binding of DISC1 
to PDE4s and GSK3β also suggests a role for DISC1 in this integration of signals, and 
this will be investigated in Chapter 5. 
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5 The effect of DISC1 on PDE4 activity – does it alter 




The dynamic and isoform specific interaction between DISC1 and the PDE4s is one of 
the most well characterised and established interactions of DISC1.  As a brief summary, 
in transfected HEK cells, PKA dependent phosphorylation of PDE4D3 and PDE4C2 
results in dissociation of 100kDa DISC1.  Forskolin stimulation has no effect on the 
binding of PDE4A5 or PDE4B1 to 100kDa DISC1 (Murdoch et al., 2007).  This is in 
contrast to the interaction observed with the 71kDa isoform of endogenous DISC1, 
which is released from PDE4B upon activation by PKA in SHSY5Y cells (Millar et al., 
2005b).    The interaction between DISC1 and GSK3β is less well established (Mao et 
al., 2009), indeed, unpublished work by Fumiaki Ogawa has shown that DISC1 and 
GSK3β interact only weakly when both are exogenously expressed in COS7 cells.  This 
weak interaction appears to stabilise if a putative GSK3β phosphorylation site on 
DISC1, S396A, is mutated to an alanine residue (Ogawa et al, paper in preparation).  
DISC1 interaction with both PDE4 and GSK3β therefore raises the possibility of a 
highly dynamic intracellular signalling complex being formed, with the scaffolding 
protein DISC1 having the potential to alter the outcome of a signalling event by direct 
binding to PDE4s or GSK3β, or by bringing other interactors into close proximity with 
these and/or other signalling molecules. 
 
PDE4B, C and D isoforms are phosphorylated at their C terminus by ERK2.  This event 
inhibits the activity of long forms of the PDE4s, and activates the short form PDE4B2 
(Baillie et al., 2000).  DISC1 is already believed to play a role in ERK and AKT 
signalling (Hashimoto et al., 2006, Kim et al., 2009b, Enomoto et al., 2009, Shinoda et 
al., 2007).  A 70% reduction in DISC1 expression in 7 D.I.V primary cortical neuron 
cultures leads to decreased activating phosphorylation of ERK1/2 and AKT.  
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Conversely, overexpression of DISC1 leads to increased levels of pERK1/2.  When 
DISC1 containing either the serine and cysteine form of the SNP at residue 704 is 
overexpressed, only the serine variant caused a significant increase in pAKT levels.  
Rescue experiments with the cysteine form of DISC1 returned phosphorylation levels of 
pAKT and pERK1/2 to those of control cells, while neurons rescued with the serine 
form “overshot” the baseline control measurement (Hashimoto et al., 2006).  An 
alternate study however found that DISC1 knockdown did not alter ERK 
phosphorylation when PC12 cells were stimulated by NGF treatment (Shinoda et al., 
2007).  They did observe reduction of pERK1/2 at growth cones in hippocampal neurons 
with DISC1 knockdown, but not in the cell bodies.  ERK1/2 phosphorylation was 
restored by DISC1 overexpression in a successful rescue experiment (Shinoda et al., 
2007).   
 
As previously alluded to in Chapter 4, changes in DISC1 expression can also have 
effects on AKT signalling.  Two groups have shown direct binding of KIAA1212 to 
DISC1, though there is controversy as to the regions involved in the interaction (Kim et 
al., 2009b, Enomoto et al., 2009).  This interaction appears to modulate KIAA1212 (also 
known as Girdin and AKT phosphorylation enhanced, APE), a protein highly expressed 
during neuronal differentiation which directly binds and activates AKT.  DISC1 
knockdown in primary hippocampal neurons leads to increased levels of phosphor AKT 
(Kim et al., 2009b) and aberrant localisation of KIAA1212 (Enomoto et al., 2009).  As 
alluded to previously, AKT signalling feeds into GSK3β signalling via inhibitory 
phosphorylation of Ser9 of GSK3β (Cross et al., 1995).  Despite this, no effect was 
reported of DISC1 knockdown on Ser9 phosphorylation  in adult hippocampal 
progenitor cells (Mao et al., 2009). 
 
If one brings together this knowledge about the binding partners of DISC1, the multi-
tiered levels of control over the activity of GSK3β, and the finding in the previous 
chapter that GSK3β affects the activity of PDE4s, it is reasonable to hypothesise that a 
multi-component signalling complex exists.  The components of this complex may be 
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dynamically recruited and released in response to specific stimuli, and in different 
subcellular locations.  Thus, this complex may act as a point of integration for external 
stimuli and internal signalling pathways.  The context in which the complex finds itself, 
the proteins present within it and the phosphorylation states of these proteins are key to 
the output, be this the activation of further signalling pathways, the switching off or on 
of cellular processes, or changes in the activity of the enzymes involved, such as PDE4.  
It is certainly possible, given its function as a scaffold with the potential for binding 
multiple proteins, that the presence or absence of DISC1 may significantly alter the 
output of these complexes.  I have attempted to address this possibility with a series of 
simple pharmacological manipulations and phosphodiesterase activity assays of the 




5.2.1 Short term overexpression of DISC1 inhibits the increase in 
PDE4 activity in response to forskolin treatment 
DISC1 overexpression was induced in the DISC1 inducible stable cell line using 1µg/ml 
tetracycline for 24 hours.  This SHSY5Y based cell line overexpresses 100kDa DISC1 
in response to application of tetracycline.  For the final 4 hours of this treatment, cells 
were also serum starved.  Cells were then treated for 30 minutes with vehicle or 10µM 
forskolin, and PDE activity assayed as described previously.  There was no significant 
change in baseline PDE4 activity with respect to the induction status of DISC1.  In 
uninduced cells, a 22% (+/-7) increase in activity occurred on treatment with forskolin.  
When DISC1 was induced, this increase was not observed: PDE4 activity remained at 
baseline levels (Figure 5.1A).     
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Figure 5.1A: Graph showing the effect of 10µM forskolin treatment on PDE4 
activity in DISC1 inducible SHSY5Y cells.  The effect of forskolin treatment in 
uninduced cells is clearly significant (*1, n=4, p=0.02).  When DISC1 is induced, 
PDE4 activity remains at baseline: *2, n=4, p=0.02.  Mean PDE4 activity in the 
vehicle treated control is 111.8 pmoles/mg/min.   
 
Figure 5.1B:  Graph showing the effect of 10µM forskolin treatment on non-
PDE4 activity in DISC1 inducible SHSY5Y cells.  Non-PDE4 activity is a small 
component of the measurable activity (20%), and the only change that reaches 
significance is the increase in baseline non-PDE4 activity.  *n=4, p=0.01.  Mean 
non-PDE4 activity in the vehicle treated control is 23.9 pmoles/mg/min. 
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In these same treated cells, there is a trend to a similar response in non-PDE4 activity, 
but none of these changes are significant.   There is however, a significant increase in 
the baseline of non-PDE4 activity when DISC1 is induced, perhaps suggesting that a 
mechanism operates to compensate for effects of DISC1 on PDE4 (Figure 5.1B). 
 
Western blotting was performed with the α-DISC1 antibody to ensure that 
overexpression of 100kDa DISC1 occurred in response to tetracycline treatment as 
expected.  At a short exposure time of 30 seconds overexpression of DISC1 was clearly 
visible.  Two sample Western blots from this experiment are shown in Figure 5.2A.  As 
a comparison, a blot from the same cells is shown at 2.5 minutes exposure, to show 
endogenous DISC1 staining beginning to appear (Figure 5.2B) 
 
 
Figure 5.2A:  Sample western blot of two experiments from 5.2.1.  At a short 
exposure time of 30 seconds, overexpression of DISC1 is clearly visible in 
induced cells.  An exposure time of over 2 minutes is required to visualise 
endogenous protein.  
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Figure 5.2B: A blot from the same samples as 5.2A after 2.5 minutes of 
exposure to film.  The signal from endogenous DISC1 is beginning to appear, 
with strong bands at 100kDa and 75kDa. 
5.2.2 Constitutive knockdown of DISC1 inhibits the forskolin 
stimulated increase in PDE4 activity  
The stable SHSY5Y lines constitutively expressing T0 (control scramble shRNA) and 
T1 (DISC1 knockdown) were serum starved overnight and subjected to 30 minutes of 
treatment with 10µM forskolin, then PDE activity assayed as previously described.  No 
significant difference in basal unstimulated PDE4 activity was observed on DISC1 
knockdown (Figure 5.3A).  A significant increase in PDE4 activity was observed in both 
control and knock down cell lines in response to forskolin treatment (n=7, p=0.000003, 
p=0.04 respectively, Figure 5.3A).  The PDE4 activity increase observed in control 
scramble shRNA expressing cells fell within the range of activity previously defined in 
wild type SHSY5Y cells (Figure 4.1), demonstrating that there was no effect of shRNA 
expression on PDE4 activity in response to forskolin.  In the DISC1 knockdown cell 
line, the magnitude of the increase in PDE4 activity following forskolin treatment was 
significantly smaller (n=7, p=0.02), from an average of 34% (+/-4) in the control line to 
17% (+/-5) in the knockdown line (Figure 5.3B).  Once again, none of the changes 
observed in the non-PDE4 component of the response were significant (Figure 5.3C). 
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Western blot analysis was performed to ensure that DISC1 was being knocked down in 
the T1 cells as expected.  After 10 minutes exposure, a clear signal was obtained from 
the control scramble line T0 in all experiments, but no signal was visible in the knock 
down T1 line.   Two sample western blots are shown in Figure 5.4. 
 
Figure 5.3A: Graph to show the effect of 10µM forskolin treatment on PDE4 
activity in control and DISC1 knockdown SHSY5Y cells.  A significant increase 
in PDE4 activity occurs in both cell lines on treatment with forskolin: *1, n=7, 
p=0.000003 (scramble), *2, p=0.04 (knockdown).  The mean PDE4 activity of 
the vehicle treated control is 91.8pmoles/mg/min. 
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Figure 5.3B: Graph showing the percentage increase in PDE4 activity in 
response to treatment with 10µM forskolin.  PDE4 activity increases significantly 
from unstimulated levels in both cell lines, but the increase in the knockdown cell 
line is significantly lower than that observed in control shRNA expressing cells 
(n=7, p=0.02).   
 
 
Figure 5.3C: Graph to show the effect of 10µM forskolin treatment on non-PDE4 
activity in control and DISC1 knockdown SHSY5Y cells.  There are no significant 
changes observed, suggesting the non-PDE4 response remains at baseline.  
The mean non-PDE4 activity of the vehicle treated control is 
21.8pmoles/mg/min. 




Figure 5.4: Sample Western blot from experiment 5.2.2.  At 10 mins exposure a 
clear signal is seen at 100kDa using the αDISC1 antibody in the control 
scramble line (T0).  No signal is visible from the knockdown cell line (T1). 
 
 
5.2.3 DISC1 overexpression amplifies the response of PDE4 activity 
to short term lithium treatment 
DISC1 overexpression was induced in TRTODISC1 by treatment for 24 hours with 
1µg/ml tetracycline, with cells being serum starved for the final four hours of treatment.  
Cells were then treated for 30 mins with vehicle or LiCl at a final concentration of 
10mM.  Both uninduced and induced cells showed a significant decrease in PDE4 
activity in response to treatment with lithium chloride (Figure 5.5A).  In the cells 
overexpressing DISC1, the decrease in PDE4 activity in response to lithium was 
significantly greater than in uninduced cells (Figure 5.5B).  In the uninduced cells, the 
non-PDE4 response to lithium was also statistically significant, but did not alter with 
regard to DISC1 expression status (Figure 5.5C).  
 
Again, western blots were performed to ensure DISC1 was induced where expected.  
Sample blots from 2 of the 3 experiments are shown in Figure 5.6. 
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Figure 5.5A:  Graph showing the effect of 10mM lithium treatment on PDE4 
activity in DISC1 inducible SHSY5Y cells.  The effect of lithium treatment is 
significant in cells regardless of the DISC1 status:  *1, n=3, p=0.0008 
(uninduced), *2, p=0.007 (DISC1 induced).  Mean PDE4 activity of the vehicle 
treated control is 110.1pmoles/mg/min. 
 
Figure 5.5B: Graph showing the percentage decrease in PDE4 activity in 
response to treatment with 10mM lithium.  The decrease in cells overexpressing 
DISC1 is significantly larger than that observed in uninduced cells: n=3, p=0.05.   
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Figure 5.5B: Graph showing the effect of 10mM lithium treatment on non-PDE4 
activity in DISC1 inducible SHSY5Y cells.  The effect of lithium treatment is 
significant in uninduced cells:  n=3, p=0.01.  The mean non-PDE4 activity of the 




Figure 5.6:  Sample western blot of two experiments from 5.2.3.  At a short 
exposure time of 30 seconds, over expression of 100kDa DISC1 is clearly 
visible in induced cells.   
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5.2.4 Short term DISC1 overexpression has the same effect as LiCl 
on the PDE4 activity increase induced by forskolin 
Thus far I have shown that both DISC1 overexpression and knock down has significant 
effects in modulating the increase in PDE4 activity in response to a forskolin challenge, 
which is presumed from the literature to be a result of PKA activation (MacKenzie et al., 
2002).  I have also shown that LiCl decreases basal PDE4 activity, and that 
overexpression of DISC1 augments this effect.  Thus, as the final experiment in this 
investigation, DISC1 was overexpressed in combination with forskolin alone, and 
forskolin treatment plus lithium, to try and discern whether DISC1 and PDE4 were 
acting in the same signalling pathways. 
 
As before, DISC1 overexpression was induced by 24 hours of treatment with 1µg/ml 
tetracycline, and for the final 4 hours cells were serum starved.  Cells were treated with 
vehicle, 10µM forskolin alone, or 10µM forskolin plus 10mM LiCl, lysed and PDE 
assayed as previously described.  
 
As expected, after 9 experiments, treatment of the uninduced cells with forskolin alone 
produced a highly significant increase (p=0.0001) in PDE4 activity.  Cells with induced 
DISC1 this time showed a small increase in activity in response to forskolin, but this 
increase was still significantly lower than the increase due to forskolin alone (p=0.02).  
LiCl treatment had a similar effect to overexpression of DISC1, in this case completely 
preventing the forskolin stimulated increase in PDE4 activity.  There was no additive 
effect of both overexpressing DISC1 and treating with LiCl.  Thus, it appears that 
DISC1 overexpression and lithium treatment have the same effect on forskolin 
stimulated increases in PDE4 activity.  Both treatments lead to PDE4 activity remaining 
at baseline when cells undergo a forskolin challenge (Figure 5.7A).   
 
As for the non-PDE4 component of the measurable activity, there was a significant 
effect of treatment with both lithium and forskolin, regardless of the DISC1 induction 
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status (Figure 5.7B).   This may be because the stimulation of the cells alters the 
accessibility of other PDEs, for example to GSK3β. 
 
As with the other experiments, western blots were performed to ensure DISC1 
overexpression was as expected.  Sample blots are shown in Figure 5.8. 
 
Figures 5.7A: A graph showing the effect of 10µM forskolin treatment in 
combination with 10mM lithium treatment on PDE4 activity in DISC1 inducible 
SHSY5Y cells.  There is no measurement taken from vehicle treated induced 
cells as the throughput of each experiment is limited to 5 samples.  In previous 
experiments there was no significant DISC1 dependent difference in basal 
PDE4 activity (Figures 5.1A and S.2.2).  Forskolin treatment results in an 
increase in PDE4 activity in uninduced and DISC1 induced cells: *1 p=0.0001, *2 
p=0.01.  Despite this, the increase in DISC1 induced cells is significantly less 
than in uninduced cells: *3 p=0.02.  Addition of LiCl prevents the PDE4 activity 
increase in response to forskolin: *4 p=0.006, *5 p=0.0004.  Finally, PDE4 activity 
in cells with DISC1 induction and lithium treatment is significantly lower than 
cells with DISC1 induction alone: *6 p=0.01.  There is no difference in PDE4 
activity in lithium treated cells, regardless of DISC1 induction status, suggesting 
there is no additive effect of both treatment.  The mean PDE4 activity in the 
vehicle treated control is 101.3pmoles/mg/min. 
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Figure 5.7B: Graph showing the effect of 10µM forskolin treatment in 
combination with 10mM lithium treatment on non-PDE4 activity in DISC1 
inducible SHSY5Y cells.  The combination of forskolin and lithium treatment is 
significant regardless of DISC1 induction status:* n=9, p=0.0003 (uninduced), 
p=0.008 (DISC1 induced).   The mean non-PDE4 activity of the vehicle treated 






Figure 5.8: Western blot confirming overexpression of DISC1 in induced cells.  A 
clear signal is evident at 100kDa after only 30 seconds exposure using the 
αDISC1 antibody. 
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5.2.5 DISC1 knockdown does not affect the response to short term 
lithium treatment 
DISC1 knock down (T1) cells and control scramble shRNA cells (T0) were serum 
starved overnight before being treated with vehicle or 10mM LiCl.  Cells were lysed and 
PDE activity assayed as previously described.  Treatment of both cell lines with LiCl 
resulted in a significant decrease of PDE4 activity from basal activity levels, which was 
within the ranges observed in previous experiments (Figure 5.9A, Figures 4.3A, 4.4A).  
There was no DISC1 dependant difference in the magnitude of the decrease.  There were 
no significant changes observed in the non-PDE4 component of the measurable activity 
(Figure 5.9C).  As previously, western blots were performed to ensure DISC1 was 
knocked down as expected.  This was the case, and two sample blots from this 
experiment are shown in Figure 5.11.   
 
During this experiment it was also observed that as the knock down cells reached a 
higher passage number, the basal PDE4 activity in these cells decreased (Figure 5.10).  
This decrease in PDE4 activity increased as cell passage number increased over P15, 
and was not observed in experiments performed with cells at a lower passage number 
(Figure 5.3A).  This meant that in this experiment, basal PDE4 activity was significantly 
lower in DISC1 knock down cells than in cells expressing a control scramble shRNA at 
the same passage number (n=6, p=0.01).   
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Figure 5.9A:  Graph showing the decrease in PDE4 activity in response to 
treatment with 10mM lithium in control scramble and DISC1 knockdown cells.  
Both cell lines produce a decrease in activity which is significantly different to 
basal activity levels for that line (n=6, p=0.02 for both cell lines), but there is no 
difference between them in magnitude of the response.  
 
Figure 5.9B: Graph to show the effect of 10mM lithium treatment on non-PDE4 
activity in control and DISC1 knockdown SHSY5Y cells.  No significant changes 
in activity are observed. n=6.  Mean non-PDE4 activity of the vehicle treated 
control was 25.5pmoles/mg/min. 
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Figure 5.10A: Basal PDE4 activity decreases in DISC1 knockdown cells as 
higher passage numbers are reached.  B: This results in DISC1 knockdown cells 
possessing significantly lower basal PDE4 activity than the control scramble cell 
population (n=6, p=0.01).  Mean PDE4 activity of the control scramble line was 
114.3pmoles/mg/min. 
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Figure 5.11: Sample Western blot from two replicates during experiment 5.2.4.  
At 10 mins exposure a clear signal is seen at 100kDa using the αDISC1 
antibody in the control scramble line (T0).  No signal is visible from the 
knockdown cell line (T1). 
5.2.6 Changes in PDE4 activity are not due to changes in PDE4B or 
PDE4D protein expression 
 
As has already been demonstrated in 3.3.7.3, there is no change in PDE4A, C or D 
mRNA expression in either of the stable cell lines.  To analyse the expression of protein 
in these cell lines, 4 western blots from each of the cell lines were probed with the pan 
PDE4B and pan PDE4D antibodies, along with a GAPDH loading control.  The αDISC1 
antibody was kindly supplied by Professor Akiyama, University of Tokyo, while 
panPDE4B and panPDE4D were kind gifts from Miles Houslay at the University of 
Glasgow.  The strength of signal from each antibody was analysed using densitometry 
on ImageJ software, then normalised to GAPDH signal for that lane and compared. 
 
Staining of these blots with the pan PDE4B antibody produced a doublet of PDE4B1 
and PDE4B3 at approximately 82kDa (Millar et al., 2005b).  Densitometry was 
performed on this doublet.  Staining with the pan PDE4D antibody produced a series of 
bands (there are at least 12 recorded human isoforms of PDE4D 
(http://www.ebi.ac.uk/uniprot)), and the bands that densitometry were performed on 
were those that migrated to approximately 98kDa, 86kDa and 80kDa.  It is difficult to 
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predict precisely which isoforms these are, as there are so many similarly sized PDE4D 
isoforms, but PDE4D3, 4, 5, 7, 8 and 9 all migrate to this area of a gel (Richter et al., 
2005).  There were no gross differences in PDE4B or PDE4D protein expression, 
regardless of the DISC1 status of the stable cell lines (Figure 5.12A-D).  This is 













Figure 5.12A: Western blots probed with αDISC1, pan PDE4B, pan PDE4D and GAPDH antibodies to compare the 
expression of protein with regards to the DISC1 induction status of TRTODISC1.  Clear induction of DISC1 can be 
seen after 30 seconds of exposure.  At this exposure time, the signal from endogenous DISC1 is not visible.  No 
gross differences can be observed in the expression of PDE4B or PDE4D protein with respect to DISC1 
overexpression, once the signal is normalised to the GAPDH loading control.   






Figure 5.12B: Western blots probed with αDISC1, pan PDE4B, pan PDE4D and GAPDH antibodies to compare the 
expression of protein in DISC1 knockdown (T1) cells versus cells expressing the scramble control shRNA (T0).  A 
clear DISC1 signal can be seen in the control cells after 5 minutes of exposure time.  No gross difference can be 
observed in the expression of PDE4B or PDE4D protein with respect to DISC1 presence, once the signal is 
normalised to the GAPDH loading control. 




Figure 5.12: Graphs showing densitometry results from DISC1 overexpressing 
and knockdown cells.  The only significant differences observed are from 
DISC1.  C: In the overexpressing line, a 100kDa DISC1 signal is clear after 30 
seconds exposure, while no endogenous signal is apparent.  D: After 5 minutes 
exposure, DISC1 in control cells is clearly visible, with no signal from the 
knockdown cells.  n=8, p<0.0001.  There is no differential expression of PDE4s 
in either cell line. 
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5.2.7 DISC1 overexpression and knock down has no effect on the 
localisation of exogenous PDE4B and GSK3β 
As was seen in 4.4.5, transiently transfected PDE4B-Flag and GSK3β-myc colocalise 
throughout the cytoplasm of SHSY5Y cells.  After noting effects of DISC1 on the 
activity of PDE4s, I performed the same immunocytochemistry on the DISC1 
overexpressing cell line, and on the DISC1 knockdown cell lines.  Colocalisation of 
PDE4B-flag and GSK3β-myc was analysed using the Intensity Correlation Analysis 
(ICA) plugin for ImageJ (Li et al., 2004, section 2.3.5.2), and the Pearson Correlation 
co-efficient, Mander’s overlap coefficient and Intensity Correlation Quotient (ICQ) 
obtained for comparison.   
 
All images showed clear colocalisation of PDE4B-flag and GSK3β-myc, with Pearson 
correlation coefficients ranging between 0.429 and 0.752 (where -1 represents exclusion, 
0 random localisation, and 1 complete correlation), Mander’s coefficients ranging 
between 0.745 to 0.905 (where 0 represents low and 1 represents high colocalisation) 
and ICQs ranging between 0.14 and 0.282 (where 0 equals random staining, 0>x>-0.5 
shows segregated staining, and 0.5>x>0 dependent staining).  In addition, intensity 
correlation plots for both PDE4B-flag and GSK3β-myc were positively skewed, 
indicating dependant staining (Figure 5.13A-C) (Grünewald et al., 2009).   
 
3 images of each cell type (TRTODISC1 with and without DISC1 induction, T0 
scramble control and T1 DISC1 knockdown) were analysed using the ICA plugin.  The 
above coefficients were compared, and no difference in colocalisation was observed 
when DISC1 status changed (Figure 5.14A-F, 5.15A-F).  Correlation coefficients 
remained stable regardless of the levels of DISC1 present (Figure 5.16A-C).  
Overexpressing or knocking down DISC1 therefore has no effect on the localisation of 
PDE4B-flag and GSK3β-myc.  It would be interesting to look at the effect of DISC1 on 
endogenous protein if a suitable GSK3β specific antibody could be obtained.   
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Figure 5.13: A is a correlation scatter plot depicting red versus green intensity in 
image 5.14C.  In this plot yellow pixels denotes colocalisation.  B and C show 
intensity correlation plots of GSK3β and PDE4B staining respectively.  These 
graphs plot the differences from the mean intensity of each channel for each 
pixel, and a positive skew of both graphs indicates dependent staining.  This 
same formula is used to form the ICQ values.   
 
  180 
Figure 5.14 (previous page): Immunocytochemistry showing staining of 
transiently transfected exogenous GSK3β-myc and PDE4B-flag in control cells 
(A-C) and cells with DISC1 overexpression induced for 24 hours (D-F).  
Induction of DISC1 does not result in any gross differences in localisation of 
these exogenous proteins. 
 
Figure 5.15: Immunocytochemistry showing staining of transiently transfected 
endogenous GSK3β-myc and PDE4B-flag in control scramble shRNA cells (A-
C) and DISC1 knockdown cells (D-F).  Knockdown of DISC1 does not result in 
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Figure 5.16: A shows the Pearson correlation co-efficient of GSK3β-myc and PDE4B-flag remains stable despite 
changes in DISC1 expression, where 0 equals random localisation and 1 absolute colocalisation.  B shows the 
Mander’s overlap coefficient also remains stable regardless of changes to DISC1 expression.  Here 0 is low 
colocalisation and 1 high colocalisation.  Finally, C shows that the intensity correlation quotient also remains stable, 
where a negative value equals segregated staining, and a positive value between 0 and 0.5 demonstrates dependent 
staining. 
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5.3 Discussion 
 
In this chapter I have shown that DISC1 may be responsible for some of the fine control 
of PDE4 activity by GSK3β, and potentially also by PKA.  DISC1 is not, however, a 
necessary and essential modulator of PDE4 activity, as both forskolin and lithium 
treatment affect PDE4 activity when DISC1 is knocked down.  Changes in DISC1 do 
alter the magnitude of the response to these drugs, suggesting that the presence of 
DISC1, most likely as part of a multi-component and dynamic signalling complex, can 
help to fine tune the responses to these different modulators.   
 
5.3.1 DISC1, GSK3β and Lithium 
We saw in the previous chapter that inhibition of GSK3β by lithium and the specific 
inhibitor SB216763 results in cAMP accumulation, and a highly significant and 
replicable decrease in basal PDE4 activity (p<0.01).  This suggests that GSK3β, be it 
directly or indirectly, has a tonic activating effect on basal PDE4 activity.  Mao et al 
(2009) demonstrated that DISC1 has the capacity to inhibit GSK3β, but this was not 
initially apparent with regards to GSK3β-mediated effects on PDE4 activity in this 
experiment, where overexpression of DISC1 did not result in decreased basal PDE4 
activity. 
 
However, DISC1 overexpression does potentiate the decrease in basal PDE4 activity 
that occurs in response to LiCl treatment.  PDE4 activity of control uninduced cells 
decreased by 16% (+/-1.7) on lithium treatment, in DISC1 induced cells the decrease 
was 26% (+/-3.5).  This finding challenges the current literature.  If there is inhibition of 
GSK3β by DISC1 under basal conditions, this effect is somehow compensated for, with 
respect to PDE4 activity.  Other proteins in the DISC1 signalling complex may maintain 
GSK3β-mediated modulation of PDE4 activity, despite overexpression of DISC1, 
perhaps by blocking the inhibitory effect of DISC1 upon GSK3β activity.  When the 
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activity of GSK3β is altered, by lithium treatment, the cellular context may change so 
that DISC1 inhibition of GSK3β takes effect, decreasing PDE4 activity yet further.   
 
An alternative hypothesis, contrary to the inhibitory interaction reported by experiments 
using fragments of DISC1 to bind GSK3β by Mao et al, 2009, can be formed on the 
basis that DISC1 does not inhibit GSK3β under basal conditions.  There are then two 
ways that overexpressed DISC1 may act to augment the effect of lithium on PDE4 
activity.  Firstly, the presence of excess DISC1 may sensitise the cells to lithium, by 
altering the binding partners present in a multi-component complex.  For example, 
DISC1 has shown activating effects on AKT in some cell types (Hashimoto et al., 2006), 
and AKT is known to phosphorylate and inactivate GSK3β (Cross et al., 1995).  
Secondly, overexpression of DISC1 may force an inhibitory interaction, such as that 
reported by Mao et al, between full length DISC1 and GSK3β that does not occur at 
normal levels of DISC1 expression.  Figure 5.17 is an attempt to illustrate these 
concepts.   
 
In contrast, DISC1 knockdown had no effect of the magnitude of the PDE4 response to 
lithium, which could be predicted if DISC1 was only acting as a GSK3β inhibitor under 
certain cellular contexts, such as increased cAMP, or overexpressed DISC1. 
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Figure 5.17: Schema depicting the effect of changes in DISC1 status on the 
response of PDE4 activity to lithium.  Solid green arrows indicate activation 
events reported in the literature, dashed green arrows represent possible 
interpretations of my experimental results.  Red dotted lines represent the 
different hypotheses detailed in the main text as to why presence of DISC1 is 
affecting the magnitude of changes in PDE4 activity.  Under basal conditions, 
GSK3β tonically activates PDE4, leading to a decrease in local cAMP.  Thus, 
when lithium is added, PDE4 activity decreases and cAMP concentration 
increases.  Overexpression of DISC1 plus lithium treatment results in a larger 
decrease in PDE4 activity, potentially due to increased GSK3β inhibition by 
DISC1, while DISC1 knockdown has no effect on the lithium related decrease in 
PDE4 activity.  In this paradigm, DISC1 may be inhibiting GSK3β directly, or 
indirectly, through increased AKT activation for example. 
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5.3.2 DISC1, GSK3β and the induction of PDE4 activity in response 
to forskolin 
The data presented here demonstrate that both short term induction of DISC1 and 
treatment with lithium suppressed the increase in PDE4 activity in response to a 
forskolin challenge.  In the first of these experiments, DISC1 overexpression prevented 
PDE4 activity increasing from baseline.  Lithium treatment had the same effect.  In the 
second DISC1 overexpression experiment, PDE4 activity did not remain at baseline, but 
increased by a significantly smaller amount then in uninduced cells: a 23% (+/-8) 
increase compared to a 51% increase (+/-12).  There was no additive effect on PDE 
activity changes when DISC1 overexpression and lithium treatment were combined.  
 
These results suggest that in addition to PKA activity, GSK3β activity is also required 
for the forskolin stimulated increase in PDE4 activity to occur.  Treatment of SHSY5Y 
cells with forskolin leads to activation of adenylyl cyclase, increased production of 
cAMP, and activation of PDE4.  This activity increase is attributed to PKA 
phosphorylation, due to it being blocked by either PKA inhibitors or site directed 
mutation of the PKA phosphorylation site on PDE4 (depicted in Figures 4.6A & B 
MacKenzie et al., 2002).  These results do not necessarily conflict with the evidence I 
have provided here.  Lithium may simply be blocking PDE4 activity, so that no response 
to forskolin is possible.  Alternatively, GSK3β may be acting downstream of, or 
synergistically with PKA, to produce the forskolin mediated increase in PDE4 activity.   
All activity assays performed by Mackenzie et al (2002) were performed in cell lysates, 
where GSK3β would have been active.  PDE4B and PDE4D isoforms both have clusters 
of potential GSK3β phosphorylation sites (Ser145, Ser 150, Ser154 in PDE4B1 and Ser 
138, Ser143, Ser 147 in PDE4D5) close to the PKA phosphorylation site (Ser133 in 
PDE4B1, Ser126 in PDE4D5).  Although the spacing between these residues is non-
canonical for GSK3β phosphorylation, this arrangement is conserved between long 
isoforms of PDE4B and PDE4D (Figures 4.6AandB).      
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If this model is correct, then there are in fact two possible mechanisms through which 
DISC1 may act to inhibit a forskolin mediated increase in PDE4 activity.  Firstly, DISC1 
may directly inhibit GSK3β, as suggested by Mao et al, but only under conditions of 
increased cAMP.  Secondly, DISC1 may prevent phosphorylation of PDE4 by PKA.  
Both these mechanisms would result in suppression of the forskolin stimulated increase 
in PDE4 activity.  I have attempted to illustrate this model in Figure 5.18. 
 
Figure 5.18: A schema to illustrate the alternate model proposed in the main text 
by which overexpressed DISC1 and lithium act to inhibit the forskolin stimulated 
increase in PDE4 activity.  Activating events reported in the literature are 
depicted as solid green arrows.  In the original model, forskolin challenge results 
in activation of adenylyl cyclase, increased cAMP and activation of PKA.  PKA 
then phosphorylates PDE4s to increase their rate of activity and causing 
dissociation of some PDE4 isoforms from DISC1.  All these components have 
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been shown to interact with AKAP9, a scaffolding protein involved in assembly 
of signalling complexes (Conti et al., 2003a, Camargo, 2006, Millar et al., 2003, 
Wong and Scott, 2004).  In the alternate model, GSK3β activity is required for 
PDE4 activation to occur.  Thus, inhibition of GSK3β activity by lithium results in 
no change of PDE4 activity in response to forskolin.  There are multiple 
mechanisms by which DISC1 can have the same effect, these are detailed in 
the main text and illustrated by dashed red lines.  Depicted in blue are 
interactions reported in the literature that may conflict with this model.  A 
discussion of these points follows in the main text.    
 
There are numerous potential mechanisms for how overexpressed DISC1 may interrupt 
phosphorylation of PDE4 by PKA.  Firstly, excess DISC1 may bind to PDE4 and 
prevent access to the phosphorylation site by PKA.  In both PDE4B and PDE4D, the 
PKA phosphorylation site is relatively close to the common DISC1 binding site, 78 
amino acids away in PDE4B and 75 amino acids in PDE4D (see Figures 4.6A and B).  
Recent work solving the crystal structure of PDE4D when bound to inhibitors suggests 
that many of these compounds function by binding to the UCR2 domain of PDE4D, 
effectively “closing” the active site by enhancing interactions between UCR2 and the 
active site.  DISC1 interacts with both the UCR2 and catalytic domains of PDE4D, 
implying that it may function in the same mechanism (Burgin et al., 2010).  This work 
does not offer an explanation as to how some PDE4 isoforms are released from DISC1 
in response to forskolin stimulation.  In conditions where 100kDa DISC1 is 
overexpressed, some PDE4 isoforms, including PDE4A5 and PDE4B1 would not be 
released on forskolin treatment (Murdoch et al., 2007), potentially preventing an 
increase in PDE4 activity.   
 
A further potential explanation is that the excess DISC1 simply sequesters PDE4 away 
from its sites of activation. Immunocytochemistry revealed an increased presence of 
DISC1, PDE4B and PDE4D in the nucleus when DISC1 was overexpressed (Figures 3.7 
and 3.8), which may add some weight to this hypothesis.  Finally, work by Hashimoto et 
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al (2006) raises the possibility that DISC1 may also be acting more indirectly, for 
example through ERK signalling.  Overexpression of DISC1 in cortical neuron cultures 
results in increased levels of activated pERK1/2, with knockdown of DISC1 having the 
opposite effect (Hashimoto et al., 2006).  Activated ERK2 phosphorylates PDE4s at 
their C-termini, within the catalytic domain.  In long isoforms, this phosphorylation is 
inhibitory (Baillie et al., 2000), potentially because this phosphorylation stabilises the 
“closed” state of the PDE4 active site (Burgin et al.).  DISC1 induction could therefore 
result in increased ERK activation, causing increased inhibitory phosphorylation of the 
long forms of PDE4.  This pathway would have to be active only when cells are 
forskolin challenged, and not at basal levels of activity. 
 
5.3.3 Evidence that may counter the alternate model 
Long forms of PDE4s are already known to be activated by PKA.  In this conclusion I 
have proposed an alternative model where GSK3β is also able to modulate PDE4 
activity.  I have presented a series of potential means by which this may be achieved.  
There is some evidence however, that may counter this model.  DISC1 knockdown also 
had an effect on the forskolin stimulated increase in PDE4 activity.  Knockdown of 
DISC1, perhaps contrary to expectations from the overexpression experiment, also 
resulted in a decreased magnitude of response to forskolin: a 17% (+/-5) increase 
compared to a 34% (+/-4) increase in control cells.  If DISC1 were acting solely as an 
inhibitor of GSK3β, then knockdown would result in change to the magnitude of the 
PDE4 increase.  This experiment emphasises the likely importance of all these changes 
occurring as part of a complex.  While DISC1 might not be critical for the PKA 
mediated PDE4 increase to occur, it may bind another protein in the complex that is 
required for the elevation to occur to the expected magnitude.  For example, it may bring 
GSK3β into close proximity with PKA and PDE4.  As compartmentalisation is key to 
the activity of many of these proteins, it may simply be that certain PDE4 isoforms are 
not present in their usual locations if DISC1 is absent.  This would have to occur on a 
very local scale, as no gross changes in PDE4B and PDE4D localisation were observed 
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by immunocytochemistry of DISC1 knockdown cell lines (Figures 3.9and3.10 A-F).  
Finally, there may be involvement of a third (or multiple) protein which interacts with 
DISC1 to mediate the response of PDE4 to PKA.  Candidates for this third protein 
include AKAP9, one member of the AKAP family of proteins, which acts as a scaffold 
for assembly of a large array of components involved in signalling pathways, including 
PKA, PDE4, adenylyl cyclases and phosphatase enzymes (Wong and Scott, 2004, Conti 
et al., 2003b).  AKAP9 was identified as a putative DISC1 interactor by yeast-2-hybrid 
screening (Camargo, 2006, Millar et al., 2003).  
 
It is highly likely that even this more complex “alternate model” is still a simplified view 
of the actual events occurring in this experiment, and, by implication, in neurons.  
Indeed, there is evidence in the literature that conflicts with this hypothesis.  PKA is 
known to inhibit GSK3β by phosphorylation at Ser9, in response to a forskolin challenge 
and G protein coupled adenylyl cyclase activity.  The reduction in GSK3β activity was 
not complete however, reducing levels to 50% of control activity (Li et al., 2000).  PKA 
reciprocally forms one of the targets of GSK3β, which phosphorylates the RII regulatory 
region of PKA (Brian et al., 1982).  It is unclear from the literature what the purpose of 
this phosphorylation may be, but the leading theory is that phosphorylation of the RII 
region at this site can change localisation of catalytic subunits, as is seen with 
phosphorylation by cyclin B-p34cdc2 during the onset of mitosis.  Phosphorylation 
decreases the affinity of PKA for AKAP9, and increases the affinity for AKAP95, 
resulting in a dynamic change in PKA localisation (reviewed Griffioen and Thevelein, 
2002).  Reciprocal phosphorylation of each of these proteins by the other could 
potentially switch activity on or off, or alter the localisation of critical pathway players, 
depending on the cellular context and presence of other proteins such as AKT and ERK.  
Thus the contradictory evidence from the literature that both GSK3β and PKA inhibit 
each other, yet from my work appear to be critical for response of PDE4 to forskolin, 
may simply suggest the presence of an autoregulatory cAMP responsive loop, that is not 
yet fully understood. 
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5.3.4 Adaptive changes observed in stable cell lines 
The data presented here may also have shown the potential for the loss of DISC1 
function to reset the normal activity levels of some of the involved signalling pathways.  
At high passage numbers the basal PDE4 activity of DISC1 knockdown cells began to 
decrease quite significantly (Figure 5.10), whereas activity levels in the scramble control 
cell line remained stable at the same passage numbers.  Both cell lines were maintained 
on the same antibiotic, Zeocin, thus this was not a response to antibiotic treatment alone.  
This observation could imply a resetting of some of the cellular circuits involved with 
DISC1 function to a lower basal level of activity, to compensate for the loss of the 
modulating influence of DISC1.   
 
In the majority of these experiments, there were no significant changes to the non-PDE4 
component of measurable activity.  In Figure 5.1B there is a small but significant 
increase in basal non-PDE4 activity after 24 hours of DISC1 induction, which may 
indicate the beginning of an adaptive response to DISC1 overexpression, but this was 
not seen in other experiments.  In Figure 5.5C, treatment of uninduced cells with lithium 
causes a significant decrease in non-PDE4 activity: a trend towards this behaviour has 
been observed in other experiments.  Finally, in Figure 5.7B, there is a significant effect 
of treating both induced and uninduced cells with forskolin and lithium combined, as the 
PDE4 activity drops significantly below basal activity.  It is thus possible that while this 
system serves to maximise the ability to record changes in PDE4, the effect of lithium, 
and thus GSK3β, is not specific to PDE4s, but can also affect other PDEs.      All these 
significant changes occur in the TRTODISC1 inducible cell line, where PDE4 activity 
occupies a slightly lower percentage of the measurable PDE activity (29% +/-5, n=10) as 
opposed to 12.5-20% observed in wild type SHSY5Y and T0/T1.  This decrease appears 
to be due to a lower PDE4 activity, as total activity in vehicle treated controls recorded 
from the inducible cell line is decreased (10 random experiments, 29957dps +/-1137 in 
wild type SHSY5Y, 26400dps +/- 1291 in the inducible cell line, p=0.04).  This is the 
only cell line that was maintained long term on Blasticidin (though antibiotics were 
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withdrawn for a week before treatment), thus an interaction with this drug may result in 
decreased PDE4 activity.  I can find no evidence of this in the literature.  Alternatively, 
as this cell line is clonal, it may be that a cell with lower endogenous PDE4 activity was 
selected for in the production of the inducible line. 
 
5.3.5 PDE4 expression in stable cell lines 
All of these observed changes in PDE4 activity occur on a background of stable PDE4 
gene and (Figure 3.13A-D) protein expression (Figures 5.12A and B).  This is consistent 
with observations from in house microarray studies on lymphoblastoid cell lines from 
the translocation family and DISC1 mutant mice that DISC1 mutations do not alter the 
expression of PDE4 isoforms (Brown et al, paper in preparation, Camargo et al, paper in 
preparation).  Importantly this infers that the decrease in PDE4 activity observed at 
higher passage numbers in the knockdown line is not due to a change in protein 
expression, only enzyme activity.   
 
Thus, as described earlier, it is difficult to reconcile all of my experimental results with 
the existing literature.   The multi tiered regulation of enzymes such as PKA and GSK3β 
is so complex, that there may be existing feedback loops that we are as yet unaware of.  
What is clear is that while DISC1 is not essential for changes in PDE4 activity to occur, 
its presence can alter the magnitude of these changes, allowing for fine tuning of the 
PDE4 response.  I have proposed a model for how DISC1 may be imposing effects on 
the SHSY5Y system employed here.  In this model, activity of both GSK3β and PKA 
are required for PDE4 activity to increase in response to forskolin.  The ability DISC1 
possesses to bind a large number of other proteins may add to the contextual control of 
these enzymes, and the outcome of this control can be seen in PDE4 activity changes. 
PDE4 acts to break down cAMP, which will then feed back into these same signalling 
pathways.  The exquisitely balanced control of such signalling makes it is easy to 
imagine how the loss or malfunction of a mediating protein such as DISC1, GSK3β or 
PDE4 may lead to dysregulation with time. 
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6  Using Primary Cortical Neurons as a model for 
measuring PDE4 activity downstream of NMDA and 
Dopamine Type I receptors 
 
6.1 Introduction 
In chapters 4 and 5, I described how SHSY5Y cells can be used successfully as a model 
for assessing PDE4 activity.  SHSY5Y are ideal for such a purpose, as endogenous PDE 
activity is relatively high, and the majority of measurable activity is PDE4 specific 
(Figure 3.2A).  SHSY5Y cells are derived from a human neuroblastoma, and as such 
have been used frequently in functional assays as models for a neural cellular 
environment (Millar et al., 2005b, Shinoda, 2007 #184), being easy to culture with a 
shorter lag time than using primary cultured neurons.  They are not however, perfect 
models of the neural environment.  SHSY5Y are a relatively stable cell line when 
undifferentiated, whereas neurons are highly differentiated large cells with multiple 
functionally specific compartments.  SHSY5Y can be induced to develop certain 
neuronal features by retinoic acid induced differentiation (Encinas M et al., 2000).  It is 
relatively common that a clear effect observed in cultured cell whole lysate, such as the 
effect of DISC1 knockdown on ERK1/2 phosphorylation in PC12 cells, stems from a 
localised sub cellular change in activity – the growth cone in this example (Shinoda et 
al., 2007). 
 
Perhaps the largest difference between primary neuronal cultures and standard 
transformed cultured cells, is the large range of receptors expressed by primary neurons.  
The question of whether SHSY5Y cells express receptors that have been associated with 
schizophrenia pathophysiology such as dopamine type I (Iizuka et al., 2007, Machida et 
al., 2005, Nair V, 1996) and NMDA receptors (Jantas and Lason, 2009, Nair V, 1996, 
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Kulikov et al., 2007) is contentious.  Furthermore, undifferentiated SHSY5Y cells do not 
form the dendritic structures where receptors are located in primary neurons.  Primary 
cortical neurons clearly express dopamine type I receptors by 7 D.I.V, and expression 
continues until at least 14 D.I.V (Noh and Gwag, 1997, Nagai et al., 2007, Outeiro et al., 
2009).  There is also a consensus that functional NMDA receptors are expressed in 
primary neuron cultures within a similar timescale (Chen et al., 2005, Javier et al., 
2007).     
 
Agonism of these two receptors in particular was of interest both because of their 
potential role in schizophrenia (see the introduction for a basic review of the 
dopaminergic and glutamatergic theories), and because of their downstream signalling 
pathways.  DRD1 is directly coupled to adenylyl cyclase to produce cAMP on receptor 
agonism, (Missale et al., 1998), and thus invokes PKA activation as seen by direct 
stimulation of adenylyl cyclase with forskolin.  NMDA receptors are of interest for two 
reasons.  Firstly, DISC1 interacts with AKAP9 (Mackie et al, manuscript in 
preparation,), the Yotiao fragment of which associates with the NR1 subunit of the 
NMDA receptor, and is found in complexes with NMDA receptors.  Secondly, the 
calcium fluxes caused by agonism of NMDA receptors are closely coupled to cAMP 
fluxes: five of the isoforms of adenylyl cyclase are directly regulated by calcium (I, III, 
and VIII are stimulated, V and VI are inhibited).  Indeed, adenylyl cyclase 
immunoreactivity is concentrated at hippocampal post synaptic densities in the striatum 
radium, thus positioned to respond to calcium fluxes initiated by NMDA receptor 
agonism and play a potent role in LTP (reviewed Cooper et al., 1995).  Exposure of 
hippocampal brain slices to LTP inducing high frequency stimulation or a ten min 
NMDA bath results in an increase of cAMP concentration, which is blocked by NMDA 
antagonists (Chetkovich and Sweatt, 1993).  cAMP concentration in hippocampal slices 
is increased at 1 and 5 minutes by an increase calmodulin dependant adenylyl cyclase 
activity in response to NMDA treatment (NMDA has an EC50 of 55µM for this effect), 
but returns to baseline by 20 minutes (Chetkovich and Sweatt, 1993).    
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It is clear that in SHSY5Y cells, where the effect of manipulations on PDE4 activity is 
easily detectable, that DISC1 and lithium are having comparable effects.  To examine 
the wider significance of this model, and whether similar changes might be occurring 
downstream of schizophrenia associated receptors I prepared primary neuron cultures 
from CD1 and C57BL/6 background mice, and investigated their potential use as a 
model for assessing PDE4 activity. This assessment involved reverse transcription PCR 
to investigate which PDEs were expressed in these cultures, treatment of whole neuron 
lysates with PDE inhibitors to assess which PDEs were active, immunocytochemistry to 
look at localisation of receptors with respect to PDE4B and PDE4D, and treatment of 
cultures with A68930, a DRD1 specific agonist (DeNinno et al., 1991) and a 
combination of NMDA and Glutamate known to invoke significant calcium transients 
(Sanchez-Martin et al., 2006).  I also wanted to test whether I could replicate the effect 
of the DISC1 point mutations described by Clapcote (Clapcote et al., 2007) on PDE4 
activity in primary neuronal cultures using the standard PDE assay method used 
throughout the thesis.  Finally, I attempted to replicate the effect of GSK3β inhibition on 




6.2.1 A wide range of cAMP PDEs are expressed in primary neuronal 
cultures 
 
DNA sequences were obtained from the NCBI nucleotide database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore&itool=toolbar) for all major 
mouse cAMP PDE isoforms (Siuciak and Strick, 2006), and cross referenced to UCSC 
genome browser (http://genome.ucsc.edu/).  Pan primers were designed for each of the 
following multiply spliced genes: PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, 
PDE4D, PDE7A, PDE7B, PDE8A, PDE8B and PDE10A using the NCBI Primer Blast 
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  Primer pairs were tested on 
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cDNA prepared from whole C57BL/6 mouse brain, as there are reports in the literature 
of all of these isoforms being expressed in at least one region of the brain (Kobayashi et 
al., 2003, Omori and Kotera, 2007, Degerman et al., 1997, Pérez-Torres and Mengod, 
2003, Bender and Beavo, 2006).  PCR products were run on a 1.5% agarose gel, and 
product size visualised with the use of the Invitrogen 50bp DNA ladder.  All primer 
pairs produced a product of the expected size at 35 PCR cycles (Figure 6.1).   
 
35 cycles of PCR as detailed in 2.4.2.2 were then performed on cDNA prepared from 2 
cultures of 14 d.i.v. C57BL/6 mouse primary neuronal cultures, and the products 
visualised on agarose gels.  Clear expression of PDE3A, PDE4A, 4B and 4D, PDE7A 
and 7B, PDE8B and PDE10A was seen after 35 cycles of basic PCR.  There was 
expression of PDE2A in only the first neuron preparation.  There was a very weak 
PDE3B product observable in the second preparation.  There was no product obtained 
using PDE4C primers, and only a very weak signal from the PDE8A primer pair (Figure 
6.2).  This lack of PDE4C product is consistent with reports of PDE4C in the rat brain, 
where it is present only in the olfactory bulb (Pérez-Torres et al., 2000).  All no RT 
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Figure 6.1:  Testing of all major cAMP PDE isoform primer pairs on brain cDNA.  
Three cDNA preparations were produced from a single brain, roughly 
corresponding to anterior, mid and posterior sections (1,2 and 3 respectively).  A 
no RT control is included as the fourth column.  Expected product sizes were: 
PDE2A 205bp, PDE3A 230bp, PDE3b 216bp, PDE4A 240bp, PDE4B 235bp, 
PDE4C 232bp, PDE4D 250bp, PDE7A 200bp, PDE7B 238bp, PDE8A 229bp, 
PDE8B 219bp and PDE10A 200bp.  At 35 cycles, all primer pairs produced a 
clearly visible PCR product of the correct size.   
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Figure 6.2: PCR products obtained from 35 cycles of basic PCR on 2 
preparations of cDNA from 14 d.i.v C57BL/6 cortical neurons.  A no RT control is 
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6.2.2 Using specific inhibitors to assess which PDEs are active in 
primary cortical neurons 
It is difficult to get an idea of the relative expression of each PDE by using basic PCR, 
and running the product on a gel.  To try and further assess which PDEs were primarily 
active in these cells, specific inhibitors were applied to four sets of neuron lysates in an 
adapted form of the PDE assay.   
 
The inherent difficulty in designing specific inhibitors for a set of proteins that retain 
rather a large amount of sequence similarity (Bender and Beavo, 2006) means that for 
many of the inhibitors, use at a level that inhibits the majority of the activity from their 
targeted PDE also has residual inhibitory effects on other PDEs.  In other words, they 
are selective rather than specific.  For example, the IC50 of papaverine for PDE10A is 
36nM, but it is also relatively potent in inhibiting PDE2, 3 and 4, with IC50s ranging 
from 320nM to 2.5µM (Siuciak et al., 2006).  Rolipram appears to be the exception to 
this general principle, with an IC50 of less than 2µM for all PDE4 isoforms, but over 
16µM for other cAMP PDEs (Chambers et al., 2006).  For this reason, inhibitors were 
used at their IC50, which should block 50% of the activity of the required PDE, without a 
large amount of residual activity at other PDEs.  It is important to remember that IC50s 
also vary between experiments, but are a generally useful guide.  The concentrations of 
inhibitors used are detailed in Table 6.1. 
 
Compound Primary PDE Final concentration (nM)




Dipyridamole A 8 & 10 4500
B 10 450
Papaverine 10 36  
Table 6.1 shows the concentration of PDE inhibitors used in experiment 6.2.2.  
All compounds are used at the IC50 for their primary PDE, except for 
dipyridamole, which inhibits both PDE8 at high doses (with an IC50 of 4.5µM) 
and is more selective for PDE10 at low doses (an  IC50 of 450nM).  In all cases 
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except Papaverine, IC50 values are obtained from the supplier, Tocris 
Biosciences (http://www.tocris.com/).  Information on the selectivity of 
Papaverine, supplied by Sigma, was supplied by Pfizer (Siuciak et al., 2006, A 
Stillman et al., 2009). 
 
The results obtained from this method are rather difficult to interpret.  Use of each 
inhibitor causes a measurable decrease in total PDE activity of primary neuron lysates, 
suggesting that all cAMP PDEs were active (Figure 6.3).  It is unclear from this 
experiment whether the small increase in inhibition seen at the higher concentration of 
dipyridamole (A) is due to inhibition of PDE8 and 10, or simply further inhibition of 
PDE10.  The two PDE10 inhibitors, dipyramidole (at the low concentration) and 
papaverine inhibit PDE activity to the same extent, suggesting that the PDE10 activity of 
the neurons is relatively accurately estimated by this method.  None of the percentage 
inhibition values are significantly different from those obtained from the other inhibitors 
(Figure 6.3).  This agrees with experiments performed on unstimulated rat cortical slices 
in culture, where application of PDE2, PDE3 and PDE4 specific inhibitors resulted in a 
small but significant increase in cAMP levels of approximately the same magnitude 
(Suvarna and O'Donnell, 2002). 
 
What is apparent from the raw results, and can be seen in the size of the error bars in 
Figure 6.3, is that the inhibition resulting from each compound can be highly variable 
between the four primary neuron cultures tested.  For example, anagrelide, the PDE3 
inhibitor inhibited 13, 22, 23, and 40% of measurable activity.  EHNA HCl, the PDE2 
inhibitor showed 25, 43 and 45% inhibition in three experiments, then failed to have an 
inhibitory effect at all in the fourth.  This is consistent with PCR observations, when 
only one of the cDNA preparations produced a PDE2A product.  The potential reasons 
for this variation, and the implications for the use of primary neurons in experiments 
such as these will be discussed at the end of this chapter.  This high variability between 
cultures, and the selectivity, but not specificity, of the compounds used, explains why 
the total activity reduced by these compounds used at their IC50 values, is significantly 
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greater than 100% of total measurable activity.  Although this makes comparisons 
between the activity of different isoforms difficult to make, it does show clear 
measurable activity from all cAMP PDE isoforms except PDE8, which this experiment 
was unable to resolve.  It may have been advisable to use an IBMX control to eliminate 
all PDE activity in this experiment. 
 
 
Figure 6.3:  A graph detailing the percentage inhibition of PDE activity resulting 
from the use of a series of selective inhibitors on primary cultured neuron lysate.  
None of the differences in activity seen are significant after 4 experiments.  
There was a large amount of variability observed between neuron cultures, as 
can be seen in the large error bars.   
6.2.3 Endogenous PDE4B and PDE4D colocalise with DRD1 and NR1 
in dendritic spines of primary cortical neurons 
As all neuronal cultures tested showed significant inhibition of PDE activity in response 
to treatment with rolipram, immunocytochemistry was performed to examine the 
localisation of PDE4B and PDE4D, to discover if they are located close to the receptors 
of interest: dopamine type I and NMDA.  Primary antibodies were pan PDE4B and pan 
PDE4D raised in sheep, a kind gift from Miles Houslay, University of Glasgow, and two 
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commercial antibodies: D6692 (Dopamine Type I receptor, Sigma) and MAB363 (NR1 
subunit of NMDA receptor, Chemicon).   
 
Colocalisation of both PDE4B and PDE4D was observed with DRD1 and NR1.  While 
there is some colocalisation in the cell body, most of the signal is seen along the lengths 
of the dendrites, where dendritic spines are beginning to develop (Figures 6.4-6.7).  
DISC1 has previously been observed to colocalise with PSD95 in dendritic spines of 
mature (21 D.I.V.) primary hippocampal neurons (Bradshaw et al., 2008).  Dendritic 
spines are sections of membrane which protrude from dendrites to receive an input, 
typically from a single excitatory synapse.  They are very diverse structures, containing 
a large and dynamic collection of proteins, and form the major excitatory surface of 
neurons (90% of excitatory synapses terminate on them).  Dysfunction has been 
implicated in a wide array of psychiatric and neurological disease (see Nimchinsky et 
al., 2002 for an in depth review).  The presence of PDE4B and PDE4D in the same 
dendritic spines as these two excitatory receptors suggests that phosphodiesterase 
activity changes may play a key role in downstream signalling from these receptors.  
This is to be expected, as temporal and spatial control of cAMP fluxes is key for coding 
downstream signalling (Smith and Scott, 2006).  By proxy, DISC1, due to its presence in 
spines and the changes it can cause in PDE4 activity in SHSY5Y cells, may also be an 
important mediator of downstream signalling responses. 
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Figure 6.4 A-F shows colocalisation of DRD1 and PDE4B in 14 D.I.V. primary cortical neurons.  G-I shows an 
enlargement of the highlighted area of F, which depicts a high level of colocalisation in developing dendritic spines.  
In all figures 6.4 to 6.7 scale bars show 10µm. 
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Figure 6.5 A-F shows colocalisation of DRD1 and PDE4D in 14 D.I.V. primary cortical neurons.  G-I shows an 
enlargement of the highlighted area of F, which depicts a high level of colocalisation in developing dendritic spines.   




Figure 6.6 A-F shows colocalisation of NR1 and PDE4B in 14 D.I.V. primary cortical neurons.  G-I shows an 
enlargement of the highlighted area of F, which depicts a high level of colocalisation along the exterior surface of the 
dendrites, where spines will develop.   
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Figure 6.7 A-F shows colocalisation of NR1 and PDE4D in 14 D.I.V. primary cortical neurons.  G-I shows an 
enlargement of the highlighted area of F, which depicts a high level of colocalisation in developing dendritic spines.   
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6.2.4 Treatment of 14 D.I.V. primary cultured CD1 neurons with 
NMDA causes an increase in PDE4 activity.     
The inhibition of a significant proportion of total cortical neuron PDE activity by 
rolipram, and the finding that PDE4B and D colocalise with DRD1 and NR1 in dendritic 
spines, suggests that changes in PDE4 activity may be acting downstream of receptor 
agonism to mediate downstream cellular responses.  In rat cerebral cortical cultures, 
treatment with IBMX, a non specific PDE inhibitor, and rolipram, led to 3-7.5 fold 
increase in cAMP in response to NMDA treatment (Suvarna and O'Donnell, 2002).  This 
is indirect evidence that PDE4 is the primary PDE active in breaking down cAMP 
generated by NMDA agonism.  To investigate this possibility, primary cortical neurons 
were grown in culture for 14 days, then supplement deprived for 4 hours.  An initial 
concentration curve was performed, and 15µg of protein chosen for assays of neuronal 
lysate (Figure 6.8A).  A combination of 10µM NMDA and 100µM glutamate, known to 
elicit measurable calcium transients within 7 minutes of beginning treatment in ND7 
cells (Sanchez-Martin et al., 2006), was applied to neuronal cultures for 2 or 5 minutes 
as an initial trial.  In hippocampal slice cultures as previously described, an NMDA 
mediated increase in cAMP concentration was apparent at 1 and 5 minutes of treatment, 
but had returned to baseline by 20 minutes (Chetkovich and Sweatt, 1993). Cultures 
were then lysed and PDE assayed as previously described.  To control for the potential 
that disturbance of the media or changes in temperature may alter PDE activity in these 
highly sensitive cells, I used two vehicle treated timepoint controls as a comparison, not 
a zero timepoint. 
 
Treatment of primary cortical neurons with a combination of NMDA and glutamate 
induced a significant increase in PDE4 activity at both 2 and 5 minutes of treatment 
(Figure 6.8B).  This was despite PDE4 being in the minority of measurable PDE4 
activity in these CD1 primary neurons, ranging from undetectable to 44% of measurable 
activity in vehicle treated neurons (a mean of 18% +/-4), and there being a wide variety 
of measurements obtained.  There were no significant changes observed in non-PDE4 
activity (Figure 6.8C) 
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Figure 6.8A shows a concentration curve determining PDE activity in lysate from 
primary cortical neurons.  The PDE4 component forms a smaller proportion of 
the measureable activity in these cells.  A protein concentration of 15µg was 
chosen for the following assays. 
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Figure 6.8B: Graph to show the significant increase in PDE4 activity on 
treatment of primary cortical neurons with a combination of NMDA and 
Glutamate.  In both parts of the figure, values are shown as absolute, measured 
in scintillation counts, as opposed to relative levels as in 2 cases PDE4 activity 
was undetectable in vehicle treated cells.  * n=11, p=0.04.  The mean PDE4 
activity in the vehicle treated 2 minute control is 29.9pmoles/mg/min.      
 
Figure 6.8C: Graph to show there is no change in non-PDE4 activity on 
treatment of primary cortical neurons with a combination of NMDA and 
Glutamate.  The mean non-PDE4 activity in the 2 minute vehicle treated control 
is 119.4 pmoles/mg/min. 
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6.2.5 Treatment of 14 D.I.V. primary cultured CD1 neurons with a 
DRD1 selective agonist results in an increasing trend in PDE4 
activity. 
As previously, CD1 primary neurons were grown for 14 days in vitro, before being 
supplement starved for 4 hours.  Neurons were exposed to a DRD1 agonist for 2 or 5 
minutes.  The DRD1 agonist in question was A68930, which is highly selective for type 
1 dopamine receptors at nanomolar concentrations (DeNinno et al., 1991).   A final 
concentration of 1nM was employed in this experiment.  Unfortunately, due to 
limitations in the number of mice available, only 6 cultures were available for treating 
and PDE assaying.  After six experiments, there was a trend which was approaching 
significance (p=0.08, p=0.16 for 2 and 5 minutes respectively) towards an increase in 
PDE4 activity at both timepoints (Figure 6.9A).  At both timepoints, 4 out of 6 
experiments showed an increase in PDE4 activity, 1 showed no change, and 1 a 
decrease.  Once more, there was a large amount of variation in the magnitude of the 
response to DRD1 agonism, ranging from a decrease of 5% to an increase of 30% at 2 
minutes (8% average increase +/-5), and a decrease of 8% to an increase of 56% at 5 
minutes (13% average increase +/-10).  Stimulation of PDE4 via DRD1 agonism can 
therefore not be ruled out, but certainly requires further investigation before 
confirmation.  The magnitude of the response to DRD1 agonism, which is coupled to 
and activates adenylyl cyclase, is significantly lower than that observed by direct 
activation of adenylyl cyclase by forskolin in SHSY5Y cells. 
 
Similarly, there is a trend towards a decrease in the non-PDE4 component of the 
response to A68930 (Figure 6.9B), but again this is non significant (p=0.17, p=0.1 for 2 
and 5 minutes respectively) despite this being the largest component of measurable 
activity.  It is possible that differential effects of stimulation and inhibition are occurring 
on the different PDEs that make up this component of the response, which may cloud 
changes in particular isoforms. 
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Figure 6.9A: Graph to show the trend towards an increase in PDE4 activity on 
treatment of primary cortical neurons with A68930, a DRD1 selective agonist.  
As previously, values are shown as absolute, measured in scintillation counts.   




Figure 6.9B: Graph to show the trend towards a decrease in non-PDE4 activity 
on treatment of primary cortical neurons with A68930, a DRD1 selective agonist.  
Mean non-PDE4 activity in the vehicle treated 2 minute control is 
191.0pmoles/mg/min.   Due to the high counts in this assay, readings may occur 
in the non-linear range. 
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6.2.6 Inhibition of GSK3β in primary cortical neurons has no effect 
on PDE4 activity 
As previously, primary cortical neurons were cultured for 14 days in vitro then 
supplement deprived for 4 hours.  Three cultures were treated for 30 minutes with 
vehicle, 10mM LiCl, 3µM of the GSK3β specific inhibitor SB21673, or a combination 
of the two compounds, then PDE activity assayed as previously.  Unlike observations 
made in SHSY5Y cells, there was no measurable effect of GSK3β inhibition on PDE4 
specific activity (Figure 6.10A).  Once more, PDE4 specific activity was a minor 
component (18% +/-3) of the total activity measured.  It may simply be that the PDE 
assay is not sensitive enough to detect subtle changes to such a low basal rate of activity.  
Because neurons are highly differentiated cells, there is also the potential that GSK3β 
inhibition is altering PDE4 activity, but only at specific locations within the cell.  This 
technique is likely not sensitive enough to detect such small scale, but potentially 
important changes. 
 
There was however, a trend towards inhibition of the non-PDE4 component of the 
measurable activity, which was approaching significance after 3 experiments (Figure 
6.10B).  In chapter 5 I alluded to the potential for GSK3β inhibition having an effect on 
one, or more of the other PDEs.  It would seem that this experiment also highlights this 
possibility.  The observed decrease was more variable than that observed with PDE4 in 
SHSY5Y cells (ranging from a 4-43% decrease in activity), but occurred consistently 
throughout all three experiments.  The proportion of activity inhibited by the range of 
selective PDE inhibitors in experiment 6.6.2 also varied widely between neuron cultures.  
It may be therefore, that this experiment is not detecting an inconsistent change in PDE 
activity in response to GSK3β inhibition, but varying expression of the PDE that is 
being inhibited.    Without knowing more about the mechanism of action of GSK3β on 
PDE4 – whether the effect is direct or via mediating proteins, it is difficult to speculate 
on which of the other PDEs may also be affected. 
 
 




Figure 6.10A: Treatment of primary cortical neurons with 10mM LiCl and 3µM 
SB216763 has no significant effect on PDE4 activity.  Mean PDE4 activity in the 
vehicle treated control is 23.5pmoles/mg/min. 
 
Figure 6.10B: Treatment of primary cortical neurons with 10mM LiCl and 3µM 
SB216763 causes a decrease in non-PDE4 activity which trends towards 
significance after 3 experiments.  Mean non-PDE4 activity in the vehicle treated 
control is 111.8pmoles/mg/min. 
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6.2.7 Standard PDE assays detect no difference in PDE4 activity in 
DISC1 missense mutant mice 
In his 2007 paper, Clapcote describes two missense DISC1 mutant mice, one with a 
“depressive like” phenotype (Q31L) and one with a “schizophrenic” like phenotype 
(L100P).  These are reviewed in greater detail in the introduction.  When mouse DISC1 
bearing one or other of these mutations is coexpressed with PDE4B1 in HEK293 cells, 
binding to PDE4B is reduced.  Immunoprecipitated PDE4B from Q31L mouse brain 
lysate, is 50% less active than that immunoprecipitated from wild type mouse brain 
lysate, despite there being no changes in PDE4B protein expression.  I therefore wanted 
to test whether my experimental system could detect this change in PDE4B activity in 
total lysate from primary cortical neurons, as this would allow the potential for detecting 
changes in response to compounds on a background of mutant DISC1.   
 
To prepare mice for this experiment, homozygous crosses were performed with 
genotyped wild type and mutation carrying C57BL/6 mice, to avoid the need for 
genotyping pups.  Matings were timed and primary neurons prepared as detailed in 
2.2.2.  Neurons were cultured in vitro for 14 days, supplement deprived for 4 hours to 
mimic drug treatment experiments, then lysates prepared.  Concentration curves using 5, 
10, 15 and 20µg protein per assay tube were produced, assaying matched sets of lysates, 
ie. one Q31L mutant with one WT from the Q31L breeding colony.  It was not possible 
to use wild type litter mates, as the genotype of the pups had to be known before neuron 
preparation, but mice were as closely matched as possible. 
 
There were no observable differences in PDE4 activity in either the Q31L or the L100P 
experiment (Figure 6.11 and 6.12).  PDE4 activity did not produce a clean concentration 
curve, as it formed such a small proportion of measurable activity that there was a large 
amount of error inherent in the assay.  Non-PDE4 activity was also very closely matched 
in L100P mice.  In Q31L mice, there was a trend towards increased activity in the non-
PDE4 component.  After three experiments, this trend was approaching significance.  It 
is possible that although I could not measure a difference in PDE4 activity in these mice, 
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this increase in non-PDE4 activity could be a compensatory mechanism for decreased 
PDE4B activity, as was seen in brain lysates.  There was no evidence of the specific 
50% decrease in PDE4B activity in Q31L mice reported by Clapcote et al, 2007, when 
PDE4B was immunoprecipitated and activity assayed.  It is possible that this only occurs 
in the mice as they are living behaving entities, responding to external stimuli.  Changes 
in PDE4B activity may only be revealed in response to stimulation of neurons in 
response to this activity, which is not occurring in these in vitro cultures.  It is also 
possible that activity of other PDE4s, PDE4D for example, may compensate for a 
decrease in PDE4B activity.  This experiment measuring total PDE4 activity, and not 
PDE4B specific activity from immunoprecipitated protein, would fail to detect changes 
if such compensation had occurred.  Due to the small absolute values obtained for PDE4 
activity in this assay, small decreases in activity will be difficult to detect.  However, 
this system is able to detect activation of PDE4 in response to NMDA or DRD1 
stimulation, as this process increases the proportion of measurable activity.     
 
Figure 6.11: Concentration curves showing PDE4 and non-PDE4 activity in 
L100P background and mutant mice.   
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Figure 6.12: Concentration curves showing PDE4 and non-PDE4 activity in 
Q31L background and mutant mice.  There is a trend towards an increase in 
non-PDE4 activity, but this is non-significant. 
6.3 Discussion 
 
Earlier in this thesis I defined the use of SHSY5Y cells as a model for assessing PDE4 
activity in a cultured cell line derived from a neuronal environment.  SHSY5Y cells 
were ideal for such a purpose, as their basal level of PDE activity is high, and almost 
entirely PDE4 specific, maximising the potential for detecting changes to activity 
resulting from chemical or genetic manipulations.  The aim of the experiments in this 
chapter was to further define the PDE profile of primary cultured neurons, to ascertain 
whether they could be used in similar experiments.   
 
A striking point to be taken from these experiments is the much wider variation inherent 
in using neurons when compared to a cell line.  There was a large amount of variation 
between experiments and different neuron preparations in drug treatment experiments, 
and in the PCR experiment, PDE2A and PDE3B were only present in one of the two 
cDNA preparations tested.  In the drug treatment experiments, although NMDA agonism 
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caused an increase in PDE4 activity in all but one of the cultures tested, the magnitude 
of the response varied greatly, requiring a large number of experiments to be undertaken 
before reaching significance.  Of course, this variation is not surprising, given the 
multiple levels before and during neuron preparation where variation can be introduced.  
I have tried to summarise these sources of variation, and how they may be minimised in 
table 6.2.  As one can see, the majority of these causes of variation can be completely 
negated by using a clonal cell line such as SHSY5Y to give more consistent results.   
 
While attempts were made to minimise the effect of these sources of variation as much 
as possible, as detailed in the third column of Table 6.2, it was impossible to eliminate 
all sources using the current experiment design.  It was also difficult to predict from the 
literature what the timescale of a downstream response to receptor agonism would be.  
Increasing the throughput of the assay to perform more time points or, developing a real 
time method of visualisation in single cells would be a superior approach.  Increasing the 
throughput of these experiments would be relatively difficult, as one always wishes to 
minimise the number of animals used, and major new equipment would have had to be 
bought to increase the throughput of the PDE assay (which has been successfully 
performed in a 96 well format).   
 
While the low throughput PDE assay is able to consistently detect an increase in PDE4 
activity in neurons in response to an activating treatment, it may not be sufficiently 
sensitive to detect a decrease in activity if the basal activity of a specific PDE forms a 
small proportion of measurable activity.  For example, it was unable to detect a change 
in PDE4 activity in response to lithium treatment.  Finally, this assay, and the production 
of a whole cell lysate only allows for detection of a rather large scale event across the 
cell.  It is possible that while PDE4s are being activated in close proximity to the 
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Means of introducing variation 
 
Means of minimising 
variation 
Mouse breeding There is some natural genetic 
variation between animals. 
Inbreeding of mouse lines.  
High number of biological 
replicates 
Use of primary 
culture 
The brain is a hugely heterogenous 




There are a large number of 
different types of neuron in any 
primary culture  
 
Neurons are highly differentiated 
cells with many functional 
compartments 
Use B27 supplement, 
Glutamax and Neurobasal 
medium to predispose 
towards neuron formation 
 




Not possible in this 
experiment 
Dissection It is difficult to consistently dissect 
exactly the same brain areas  
Practised dissection with 
sharp forceps.  The same 
person performs all 
dissections. 
Culture Some preparations grow better than 
others, resulting in differences in 
neuron density 
 
Differences in neuron density can 
lead to changes in the amount of 
connectivity between cells, and 
change expression profiles 
 
Stress to cells during culture and 
drug treatment 




Count cells before seeding 
them.  Practised dissection to 
reduce preparation time.  
 
 
Use a well maintained clean 
incubator.  Employ a 
standard protocol for drug 
treatment. 
PDE Assay Absolute values vary significantly 
between experiments 
Use proportional results 
where possible, carefully 
control the temperature 
throughout the experiment. 
 
Table 6.2: A summary of the different levels of an experiment involving primary 
neurons, where variation may arise from during this process, and how it can be 
minimised in my experimental design. 
 
  218 
significant activity increases I have measured in response to NMDA are real, and that 
the non-significant trend in response to the DRD1 agonist A68930 are similar, this 
experimental approach was suboptimal, but all that I was personally able to undertake in 
the time available.  For this reason, if others were to pursue this avenue of research, I 
would recommend a different approach, particularly one with greater spatial resolution, 
such as the one detailed below.  
 
Unsuccessful attempts were made to assay neurons using the AlphaScreen to increase 
throughput, but the cAMP signal obtained was highly inconsistent from well to well.  It 
is likely that plating neurons in the 384 well plates was not conducive to even growth, 
but as they were opaque white it was not possible to investigate this.  To avoid 
transfection of post mitotic primary neurons in culture, a generally quite inefficient and 
damaging process, the most elegant way to create a cAMP or PDE biosensing 
population of primary neurons is to create transgenic mice from which neurons can be 
prepared and analysed.  Calebiro et al (2009) used this approach, creating transgenic 
mice constitutively expressing an Epac based FRET cAMP sensor (YFP/CFP).  These 
mice appeared to be physiologically normal throughout development, despite expression 
of the sensor in most tissues.  Primary neurons were isolated, and stimulated with 
isoproterenol (a beta adrenergic receptor agonist), which induced a short lived decrease 
in the YFP/CFP ratio.  This response was more robust when rolipram was added to 
cultures, demonstrating that PDE4 was responsible for inactivating the cAMP flux 
resulting from isoproteronol treatment (Calebiro et al., 2009).  The beauty of a system 
such as this is that is provides spatial and temporal resolution of cAMP fluxes in single 
cells, without the need for transfection of neuron cultures.  It also enables the researcher 
to choose which cells to report from, negating some of the problems of mixed cell types 
in primary cultures.  The ratiometric read out of fluorescence allows for quantification of 
the cAMP flux, meaning that there is the potential for miniaturisation of such a system 
to a well plate format.   
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The biochemical PDE activity assay has painstakingly provided evidence for a role for 
PDE4B and 4D acting downstream of DRD1 and NR1 signalling.  To add to this 
evidence, colocalisation of endogenous PDE4B and 4D with DRD1 and NR1 was 
clearly visualised along dendrites in structures resembling developing dendritic spines.  
These structures form the major excitatory structures of neurons, and abnormalities in 
their survival and morphology have been implicated in schizophrenia, normal ageing 
and mental retardation (reviewed in Nimchinsky et al., 2002).  Post mortem studies are 
difficult however, as dendritic spines are highly plastic structures, capable of changing 
morphology in a space of minutes (Nimchinsky et al., 2002).   One DISC1 truncation 
mouse model has a decreased number of dendritic spines on granule cells in the dentate 
gyrus (Kvajo et al., 2008), while an alternative DISC1 knock down model shows 
accelerated formation of dendritic spines (Duan et al., 2007).  Thus, a role for the PDE4s 
and DISC1 in modulating cAMP fluxes in dendrites, and the downstream response to 
them is clearly possible. 
 
This functional linking of PDE4, a risk factor for schizophrenia, with two of the major 
pharmacological pathways implicated in the pathogenesis of the disease is tantalising.  
The evidence from chapter 5 that the major susceptibility gene DISC1 may act to 
modulate PDE4 fluxes downstream of increased adenylyl cyclase activity adds interest 
to this link.  Furthermore, unpublished evidence from the Millar lab suggests an 
interaction between DISC1, the Yotiao fragment of AKAP9, and the NR1 subunit of the 
NMDA receptor (Mackie et al, unpublished).  The theory of glutamatergic hypofunction 
in schizophrenia stems from two types of evidence.  Firstly, short term administration of 
the non competitive NMDA receptor antagonists PCP and ketamine to healthy humans 
results in a psychomimetic state that models aspects of the positive, negative and 
cognitive symptoms of schizophrenia (Javitt and Zukin, 1991, Lahti et al., 1995, Krystal 
et al., 1994).  Hospital departments report that it is almost impossible to distinguish a 
schizophrenic patient from a PCP drug user (Javitt and Zukin, 1991).  In schizophrenic 
patients, even those who are stable, PCP administration results in psychotic episodes that 
recapitulate the features of earlier non-drug induced psychosis.  These symptoms can 
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persist for weeks after drug administration (Javitt and Zukin, 1991).  The effects on the 
cognitive component of schizophrenia are less clear.  Deficits have been reported in the 
Wisconsin Card Sorting Test (Krystal et al., 1994) and verbal encoding paradigms, while 
spatial working memory appears to remain intact (Rowland et al., 2005).   
 
Secondly, agonists that bind the glycine modulatory site of the NMDA receptor to 
potentiate activity, such as glycine, D-serine and D-cycloserine, improve positive and 
negative symptoms when used as adjuncts to conventional antipsychotic medication 
(Tsai et al., 1998, Goff et al., 1999, Heresco-Levy et al., 1999).  More recently, a 
number of schizophrenia susceptibility genes have been highlighted that function in 
glutamate related pathways.  These include DAAO, which metabolises D-serine, G72, 
which activates DAAO, NRG1 which regulates expression of NMDA receptors through 
ErbB4 receptors, and RGS4 which acts as a negative regulator of GPCR activity, 
including metabotropic glutamate receptors (Harrison and Owen, 2003).  Glutamatergic 
neurons form the connections between the frontal cortex, limbic system, basal ganglia 
and thalamus, all brain regions which have been linked to schizophrenia (Moghaddam, 
2003), and have been strongly implicated in axon guidance, synaptic pruning and LTP 
(Meador-Woodruff and Healy, 2000).  Early trials of highly selective mGluR2/3 
receptor agonists showed inhibition of PCP induced hyperlocomotion in mice, and have 
shown promising improvements in both the negative and positive symptoms of 
schizophrenia patients (Patil et al., 2007). 
 
Despite this, evidence is weak for NMDA receptor expression changes in schizophrenic 
patients (Clinton and Meador-Woodruff, 2004), although decreased activating 
phosphorylation at Ser897 of NR1 has been found in hippocampi from schizophrenic  
patients (Emamian et al., 2004b).  One of the main criticisms of this theory is that 
glutamatergic signalling is so widespread throughout the brain that larger scale disorders 
than schizophrenia would result from disruptions to the system (Moghaddam, 2003).  If 
PDE4 and DISC1 are involved in the fine tuning of cAMP fluxes downstream of NMDA 
receptors, it may be that they only associate with a subset of receptors in specific regions 
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of the brain.  Thus if PDE4 or DISC1 are functioning sub optimally, due to presence of a 
risk SNP for example, this offers an explanation as to why symptoms may be more 
localised and mild than would be expected for a large scale glutamatergic disruption.  
 
I have also shown a trend towards PDE4 activation on agonism of DRD1 receptors.  
These receptors form the majority of dopaminergic receptors in the PFC, and are located 
on dendritic spines, particularly on distal dendrites (Weinberger and Laruelle, 2001).  
The hyperactive dopaminergic theory of schizophrenia was originally hypothesised after 
two observations, the first from studies on the targets of first generation antipsychotic 
drugs, and the second that dopamine enhancing drugs can generate psychosis (Abi-
Dargham, 2005).  First generation antipsychotics were found to inhibit release of 
dopamine from rat striatal slices, and the dose required for 50% inhibition correlated 
with clinical doses used in patients (Seeman and Lee, 1975).  This effect was attributed 
to blocking of what was then termed the “neuroleptic” receptor with an IC50 related to 
neuroleptic potency (Seeman et al., 1976).  This receptor was later defined as the type II 
dopamine receptor (DRD2), and until the trials with the mGluR2/3 agonist (Patil et al., 
2007), all licensed anti-psychotic drugs possessed activity at this receptor (Abi-
Dargham, 2005).   
 
The second strand of the evidence comes from observations that dopamine releasing 
drugs such as amphetamine and L-DOPA can lead to psychotic episodes in healthy 
individuals (for a detailed review see Abi-Dargham, 2005).  To summarise the contents 
of this review, repeated exposure to amphetamine can lead to paranoid psychosis, 
hallucinations and thought disorder.  Schizophrenic patients are also more sensitive to 
induction of psychosis by low concentrations of amphetamine than healthy individuals.  
The major criticism of this early theory however, was that while it successfully 
explained the positive symptoms of schizophrenia, it failed to explain the negative 
symptoms.  It was already known that dopaminergic tone in the PFC exerts an inhibitory 
effect on dopaminergic transmission in the striatum (Abi-Dargham, 2005, Weinberger 
and Laruelle, 2001).  Thus a dual theory was proposed of hypoactive dopaminergic tone 
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in the PFC, which leads to dysregulation and hyperactivity of striatal dopamine (Abi-
Dargham, 2005). 
 
Since this dual theory was proposed, imaging studies have strengthened the hypothesis, 
and further evidence has integrated this theory with the glutamatergic theory.  In their 
2001 meta-analysis, Weinberger and Laruelle revealed a small but significant increase of 
DRD2 receptor expression, and an increase in DOPA decarboxylase expression in the 
striatum of schizophrenic patients.  Schizophrenic patients also showed more variation 
in expression of those components then healthy controls.  They also saw a significant 
increase in dopamine release in the striatum, as inferred by studies of amphetamine 
induced radiotracer binding to DRD2.  Dopamine depletion studies revealed a higher 
DRD2 occupancy in schizophrenic patients, which was predictive of a good response to 
6 weeks of antipsychotic treatment (Weinberger and Laruelle, 2001).  Since this 
analysis, increased availability of DRD1 has been demonstrated in the dorso-lateral PFC 
(DLPFC) in schizophrenic patients, which is unrelated to antipsychotic status and 
associated with poor performance in the N-back working test of working memory and 
executive function (Abi-Dargham et al., 2002). 
 
This functional link between the PFC and striatum allows for integration of both the 
dopaminergic and glutamatergic theories of schizophrenia.  The PFC influences striatal 
dopamine through an activating glutamatergic input, and an inhibitory GABAergic input  
(Weinberger and Laruelle, 2001, Mignon, 1996).  There is currently widespread 
controversy over whether the principle deficit in schizophrenia is glutamatergic, 
dopaminergic, or indeed GABAergic.  The complexities of these arguments fall outside 
the scope of this thesis (Seeman, 2009, Kim et al., 2009a, Gaspar PA et al., 2009)but it is 
clear that dysregulation of both these components leads to symptoms that recapitulate a 
number of the symptoms of schizophrenia, and that small disturbances in local circuits 
can have more disastrous effects in downstream pathways.  If PDE4 is acting to 
modulate cAMP signalling downstream from DRD1 and NMDA receptors, then it may 
play a critical role in fine tuning of neuronal responses to stimuli, or even act to 
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compensate for small scale dysregulation in these pathways.  From the results observed 
earlier in this thesis, DISC1 may also modulate PDE4, perhaps as part of a dynamic 
signalling complex.  This evidence raises the possibility of a connection between two 
well established theories of schizophrenia pathophysiology and two genetic risk factors, 
DISC1 and PDE4.  If DISC1 and PDE4 are acting downstream of receptors to fine tune 
cAMP fluctuations, then it is easy to understand how changes in their function, such as 
those arising from non synonymous SNPs and different protein binding profiles, may 
lead to disarray in cAMP signalling.  In the paragraph below I describe evidence 
suggesting that fine control of cAMP downstream of GPCRs is critical for dendritic 
spine function, which serves as a useful paradigm for this hypothesis. 
 
The Arnsten group have previously demonstrated that elevated cAMP in the prefrontal 
cortex (PFC) of aged rats and monkeys leads to disruption of working memory, a 
process which relies on transient activation of local micro circuits (Ramos et al., 2003).  
Similarly, spatial delay related firing (relevant to working memory) was enhanced in rat 
PFC by cAMP inhibition and inhibited by treatment with etazolate, a PDE4 specific 
inhibitor.   This delay related firing was closely related to the function of 
Hyperpolarisation-activated Cyclic Nucleotide-gated (HCN) ion channels, with 
pharmacological channel blocking resulting in increased firing in control and etazolate 
treated rats.  A working model was proposed where HCN channels open in response to 
elevations in cAMP, lowering membrane resistance of dendritic spines and enabling 
gating of glutamatergic transmission.  In this model, local cAMP changes arising from 
activity of GPCRs such as the post synaptic α2A adrenoceptor and DRD1 can influence 
the excitability of axospinous inputs to cortical pyramids, with an excess of cAMP 
leading to disconnection of these circuits.  Indeed, pharmacological inhibition of HCN 
channel activity enhanced local network activity in ferret PFC slices and improved the 
performance of rats in the spatial delayed alternation task, a measure of spatial working 
memory.  HCN channels were localised to the base of emerging spines, and 
perisynaptically around excitatory synapses in spine heads in post mortem monkey PFC 
tissue (Wang et al., 2007).   It is no great leap to suggest that the PDE4s and DISC1 may 
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also be acting in these locations, to fine tune the control of cAMP fluctuations.  Indeed, 
DISC1 has been localised to dendritic spines in post mortem human tissue (Kirkpatrick 
et al., 2006), and colocalises with HCN channels in monkey PFC (Paspalas and Arnsten, 
personal communication).   
 
This model is one demonstration of how dysfunction of DISC1 or PDE4 may alter the 
physiological function of cortical circuitry, and predispose to aspects of psychiatric 
disease.  In my experiments I have shown the potential for PDE4 to be acting 
downstream of the NMDA and DRD1 receptor, both being of major interest to 
psychiatric disease.  A major criticism of both the dopamine and glutamine theories of 
schizophrenia is that schizophrenia is a relatively mild disease compared to the more 
widespread disarray you would expect from a large scale disruption in neurotransmitter 
signalling.  The presence of these two schizophrenia risk associated proteins fine tuning 
the response downstream of NMDA and DRD1 is an attractive addition to these 
theories, offering a potential means by which a more subtle and localised disease may 
result from a larger scale signalling disruption.   
 
The dendritic spines, structures which NRI, DRD1, PDE4 and DISC1 have been 
localised to (Bradshaw et al., 2008), have a small cytoplasmic volume, making them 
exquisitely sensitive to cAMP fluctuations downstream of these receptors.  Poor control 
of cAMP in these structures may lead to loss of normal neuron function (Wang et al., 
2007) through aberrant excitation and CRE related gene transcription.  Very recent 
evidence suggests one role for DISC1 in dendritic spines may be modulation of their 
size, AMPA receptor expression, and miniature Excitatory Postsynaptic Currents 
(mEPSC) activity downstream of NMDA receptor activity via interactions with Kalirin-
7 and Rac-1 (Hayashi-Takagi et al.).  Rac-1 activation has been shown to be cAMP 
responsive in growth cones of rat neuroblastoma cells, with application of the 
degradation resistant 8-bromo-cAMP resulting in Rac-1 activation (Seifert et al., 2009), 
Thus, local cAMP concentrations and PDE4 activity changes may also affect the 
functioning of this pathway to alter dendritic spine function.    
  225 
Finally, evidence from the T1:11 (DISC1) and T1:16 (PDE4B) lymphoblastoid cell lines 
suggests that both translocations result in decreased expression of the interrupted protein 
(Millar et al., 2005b).  In patients carrying these translocations, a sub optimal level of 
DISC1 and PDE4B may lead to aberrant regulation of cAMP signalling in dendritic 
spines, potentially resulting in related changes in gene expression and functional 
connectivity of neural circuits.  These changes may predispose to psychiatric disease 
such as schizophrenia and psychosis.  
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7 Chapter 7: Concluding Remarks 
 
7.1 Studying DISC1 and intracellular signalling 
Over the last ten years, DISC1 has become accepted as one of the most intensively 
studying and insightful schizophrenia susceptibility genes.  Evidence has accumulated 
on many levels, genetic, behavioural, and in vitro, linking DISC1 to psychiatric disease.  
Knowledge about DISC1 has also led to increased interest in the proteins it interacts 
with, highlighting new or “out of fashion” pathways for refocused research.  Of 
particular interest to this project is the dynamic and isoform specific interaction between 
DISC1 and the PDE4 enzymes, and the interaction between DISC1 and GSK3β.  These 
proteins are intricately involved in intracellular signalling pathways, through control of 
cAMP fluxes and phosphorylation respectively.  For this reason a hypothesis was 
formed that DISC1 may be involved in modulating intracellular signalling pathways, 
through its interaction with these two proteins. 
 
In the opening chapter, a plan was set out for investigating this hypothesis.  This plan 
had three aims, which were: to define a suitable cellular system for assessing PDE4 
activity, to assess the effect of DISC1 overexpression and knock down on PDE4 activity 
in this system, and finally, to assess the use of PDE activity assays downstream of 
receptor signalling in neurons.  To recap, each of these points will be briefly addressed 
in these concluding remarks, before speculating on the wider implications of this modest 
work.  To end this section, I will suggest future work that will begin to answer some of 
the questions posed by these experiments. 
 
7.2 Defining a suitable cellular system for assessing PDE4 activity 
SHSY5Y cells were an obvious first choice of cell line for this study, being of neuronal 
origin (neuroblastoma) and widely used by the research community.  SHSY5Y cells 
were found to possess a suitable, relatively high level of endogenous PDE4 specific 
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activity approximately three times that measurable in HEK293 cells.  Overexpression 
and knockdown of DISC1 had no effect on expression of PDE4 mRNA or protein as 
measured by quantitative RT PCR and western blot.  Overexpression of DISC1 
however, did lead to an accumulation of PDE4B and PDE4D protein in the nucleus. 
 
As expected from the literature, treatment of SHSY5Y cells with forskolin led to 
significant cAMP accumulation and a significant increase in PDE4 activity, as measured 
by the AlphaScreen and PDE activity assays respectively.  Perhaps unexpectedly, 
treatment with lithium chloride and the GSK3β specific inhibitor SB216763 also 
affected PDE4, leading to a consistent and replicable reduction in activity.  This suggests 
a previously undescribed tonic activating effect of GSK3β on PDE4 activity. 
 
7.3 The effect of DISC1 on PDE4 activity 
In all but one of the experiments performed, DISC1 overexpression or knockdown had 
no effect on basal levels of PDE4 activity.  At high passage numbers, PDE4 activity 
decreased in DISC1 knockdown cells in comparison with control cells of an equal 
passage number, suggesting a long term adaptive response to DISC1 loss was occurring.  
Both DISC1 overexpression and lithium treatment prevented the forskolin stimulated 
increase in PDE4.  This suggests that lithium either blocks PDE4 activity directly, or 
that GSK3β is also necessary for the PDE4 activity increase to occur.  This response to 
forskolin has been previously described as PKA dependant, but the requirement for 
either enzyme is by no means mutually exclusive.  DISC1 may be acting in the same 
mechanism as lithium, through inhibition of GSK3β, or inhibiting the phosphorylation 
of PDE4 by PKA.  Counter-intuitively, knock down of DISC1 also partially inhibits the 
forskolin stimulated increase in PDE4 activity, suggesting the requirement for DISC1 to 
be present as part of a complex, potentially bringing other proteins together than may be 
required for increasing PDE4 activity. 
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Overexpression of DISC1 also affected the response of PDE4 to lithium treatment.  The 
presence of excess DISC1 augmented the decrease in PDE4 activity.  This may be due to 
context dependent inhibition of GSK3β by DISC1, or an indirect effect on GSK3β, via 
AKT activation for example.  Fittingly, DISC1 knockdown did not alter the magnitude 
of the PDE4 response to lithium.  Finally, localisation of overexpressed tagged GSK3β 
and PDE4B does not change with regard to DISC1 expression status. 
 
7.4 PDE4 signalling downstream of NMDA and DRD1 receptors 
The presence of all cAMP PDEs except PDE4C was established by PCR in mouse 
primary cortical neurons.  The signal obtained from the PDE3B and PDE8A primer pairs 
was weak compared to the signal obtained from a positive whole brain control.  Using 
isoform specific inhibitors, basal activity of all cAMP PDEs was also established.  
Primary cortical neurons were treated with a combination of NMDA and glutamate to 
agonise NMDA receptors, and the DRD1 specific agonist A68930.  The PDE4 responses 
to these agonists were variable in magnitude, but despite this challenge, a significant 
increase in PDE4 activity in response to 2 and 5 minutes treatment with NMDA was 
established, and a trend (limited by the number of experiments) towards an increase was 
observed upon DRD1 agonism.  Furthermore, colocalisation of PDE4B and D was 
observed with the NR1 subunit of the NMDA receptor, and DRD1 in developing 
dendritic spines.  These results suggest a critical role for PDE4, and by extension of 
earlier results presented in this thesis, DISC1, in inactivating cAMP fluctuations 
downstream of these receptors, both of which are strongly linked to pharmacological 
theories of schizophrenia.   
 
Taken together, these results suggest that DISC1, PDE4 and GSK3β may act to fine tune 
cAMP signalling downstream of extracellular signals, such as the NMDA receptor and 
GPCRs.  While DISC1 is not essential for PDE4 activity changes to occur, my results 
demonstrate that it does modulate the PDE4 response to both forskolin and lithium.  This 
opens up new and productive avenues for research that link long standing observations 
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that lithium is a potent mood stabiliser, with a potential mechanistic explanation that 
involves independently established genetic risk factors.  There is convincing evidence, 
including the dopaminergic and glutamatergic theories of schizophrenia, that the 
majority of the symptoms of schizophrenia can be explained by aberrant activity in 
connected neural circuits, probably as a result of synaptic dysfunction.  Synapses are 
immensely complex multi-protein arrangements.  The post synaptic proteome may 
comprise over 1000 proteins, including several extracellular receptors (Collins et al., 
2006).  A large number of these extracellular receptors are coupled to adenylyl cyclase, 
and thus signal via cAMP.  The presence of PDE4s allows for containment of cAMP 
fluxes downstream of these receptors, and their control by PKA and ERK allows 
integration of activity from a series of active intracellular pathways.  Fine control of 
cAMP fluxes is particularly important in dendritic spines, where small changes can 
cause large effects due to their low cytoplasmic volume.  My experiments suggest that 
DISC1 and GSK3β can also act to modulate PDE4 signalling, allowing an extra level of 
control to “fine tune” PDE4 output and thus cAMP fluxes.  To speculate, small changes 
in DISC1 and PDE4 sequences, such as the presence of non-synonymous risk SNPs, 
may result in differential expression of protein isoforms, differential localisation of 
protein, or an altered protein binding profile.  This may result in loss of cAMP fine 
tuning, leading to aberrant local gene expression or neuron excitability, resulting in a 
domino effect of inappropriate activity in connected circuits, and predisposing to 
psychiatric disease. 
 
To continue this theme, it is likely that DISC1, GSK3β and the PDE4s are acting as part 
of a multi-component and dynamic signalling complex of which PDE4 activity changes 
and cAMP control form one of multiple outputs.  Differentially localised isoforms of 
hub proteins such as DISC1 may vary their profile of binding proteins depending on 
cellular localisation, and in response to changing cellular cues.  This dynamic complex-
formation would allow for exquisitely tight control of intracellular signalling in response 
to extracellular cues, and the presence of proteins carrying risk variants may therefore 
lead to an altered protein binding profile, disrupting tightly controlled pathways and 
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predisposing to psychiatric conditions.  This hypothesis suggests an agreement with the 
genetic theory of multiple common genetic variants with small effects predisposing to 
psychiatric disease.  Possession of single risk variants may be compensated for by 
activity changes in associated pathways.  Possession of multiple risk variants in 
associated pathways however, most likely along with an environmental contribution, 
may result in dysregulation that rises above a disease threshold, in unable to be 
compensated for, and results in psychiatric disease.  While all the pathways covered in 
this thesis are closely integrated, possession of specific risk variants may dictate 
dysregulation in specific brain locations, or a subset of these central pathways, thus 
dictating the manifestation of the disease.  A small scale proof of this concept is the 
different behavioural phenotypes observed in the DISC1 ENU mutants.  This may 
eventually lead to the ability to genetically diagnose bipolar disorder or schizophrenia, 
or perhaps more likely, result in the reclassification of psychiatric disease into genetic 
subtypes, as is beginning to be done successfully with other complex diseases, such as 
breast cancer (Huber et al., 2009, Sørlie et al., 2003).  The final goal of such 
reclassification would be the development of personalised medicine, designed to target 
the pathways affected by specific risk variants. 
 
7.5 Future work 
The experimental evidence described in this thesis is tantalising, but these early proof-
of-concept experiments require further mechanistic elucidation and extra 
experimentation to assess the true biological significance of these events.  Many of the 
further experiments I will suggest require genetic manipulation of cell lines.  As 
discussed in Chapter 3, the process of transient transfection altered PDE4 activity, and 
so the use of stable cell lines should be considered.  Issues which should be addressed 
with some priority are: 
 
1. More evidence is required to confirm that lithium is acting on PDE4 through 
GSK3β.  I have shown evidence that pharmacological GSK3β inhibition 
  231 
decreases PDE4 activity to the same magnitude as lithium, but this does indicate 
a direct effect of GSK3β.  The hypothesis would be substantiated if the effect of 
lithium on PDE4 activity was ablated by knocking down GSK3β.  However, as 
there are several targets of GSK3β, knockdown may result in changes in other 
pathways, such as PKA signalling and Wnt signalling, that may further impact 
on PDE4 activity.  Such changes would need to be carefully controlled for.     
 
2. It would be interesting to assess PDE4 activity in GSK3β knockout mice, to 
determine whether compensatory long term changes in PDE4 activity occur in 
response to a lack of activation from GSK3β. 
 
3. The relationship between PKA and lithium treatment also needs further 
investigation.  Again, GSK3β knock down cells could be used to assess whether 
GSK3β is necessary for the PKA mediated increase in PDE4 activity to occur, or 
whether lithium simply blocks PDE4 activity from the outset.   
 
4. It is presently unclear whether lithium treatment affects all PDE4 isoforms.  
Isoform selective knock-downs in cells could be used to assess the effect of 
lithium on PDE4A, PDE4B or PDE4D.  However, it is perhaps more likely that 
subsets of these major isoforms are sensitive to lithium treatment.  For example, 
PKA phosphorylation only occurs on long isoforms, and ERK phosphorylation 
has different effects on long and short isoforms (MacKenzie et al., 2002, Baillie 
et al., 2000).  In Mackenzie et al, 2002, the effect of PKA on different PDE4 
isoforms was examined by overexpression of various subtypes.  A cell-line with 
low endogenous PDE4 activity, such as HEK293, would be ideal for such an 
experiment involving lithium.   
 
5. Various experiments have shown conflicting evidence for an effect of DISC1 
expression status on AKT and ERK phosphorylation.  It would therefore be 
useful to know if the drugs treatments and expression changes in these 
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experiments altered their phosphorylation status.  This could be examined by use 
of western blotting with phospho-antibodies.  This was briefly attempted as part 
of the PhD thesis, but the phospho-antibodies did not work well with lysates 
made from 3T3 buffer, and thus the experiments would have to be re-run.  
 
6. The potential for GSK3β to directly phosphorylate PDE4 should also be 
investigated.  As detailed in the conclusion of Chapter 4, this may be a difficult 
experiment to perform due to the general requirement for priming 
phosphorylation of GSK3β targets to achieve high efficiency phosphoryation.  It 
may be possible to drive phosphorylation by using high concentrations of 
recombinant GSK3β in in vitro or high-throughput array approaches. At present 
there is no clear candidate for a putative GSK3β phosphorylation site.  If only 
certain PDE4 isoforms are found to be responsive to lithium treatment (see point 
3), then this may enable candidate sites to be refined, and a traditional site 
directed mutagenesis approach to phosphorylation detection to be performed 
(Scott, 2006).     
 
7. As with lithium treatment, it may be useful to further define which PDE4 
isoforms are activated downstream of NMDA and DRD1 signalling.  This may 
be achieved by low throughput PDE assays in neurons, or indirectly through 
cAMP measurement in brain slices (Suvarna and O'Donnell, 2002).  Allosteric 
modulators which show preferential inhibition of PDE4D over PDE4A, 4B and 
4C are in development (Burgin et al., 2010), and may be useful in this paradigm.  
Alternatively, neurons from mice with isoform specific knockdown may be 
performed.  If PDE4D is the major PDE4 responsible for cAMP inactivation 
downstream of NMDA, for example, then brain slices from PDE4D knock out 
mice would show an accumulation of cAMP after NMDA treatment, similar to 
the effect seen on rolipram or IBMX application.   
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8. It was interesting to see an accumulation of PDE4B and PDE4D in the nucleus 
when DISC1 was overexpressed.  A similar effect has been observed in an 
experiment with GSK3β, which despite possessing a nuclear localisation signal is 
mostly found in the cytoplasm.  The authors of this study proposed that GSK3β 
is anchored in the cytoplasm by other proteins, which are saturated when GSK3β 
is overexpressed, resulting in a nuclear localisation of overexpressed protein 
(Meares and Jope, 2007).  It is possible that this may be occurring with DISC1 in 
my experiment.  For this reason, it would be interesting to assess the localisation 
of endogenous GSK3β with respect to the PDE4s and DISC1.  My experiment 
involving exogenous tagged protein may saturate a potential effect on protein 
localisation.   
 
9. It is highly unlikely that DISC1, PDE4 and GSK3β are the sole components of 
the functional complex.  Instead, they are likely to function as part of a dynamic, 
multi-component complex.  It would be wonderful, (if expensive, at present!) to 
be able to assess the composition of such a complex, and the changes that might 
occur in it on a large scale, in response to forskolin stimulation for example.  
Stable isotype labelling with animo acids in cell culture (SILAC) can be used in 
combination with chemical cross linking, to allow for quantitative assessment of 
non-covalent links between proteins under different cellular conditions by mass 
spectrometry (Trakselis et al., 2005, Bose et al., 2006, Guerrero et al., 2006).  In 
their 2006 paper, Bose et al use this system to assess proteins phosphorylated by 
tyrosine kinase as a result of Her2 overexpression.  In this experiment, three cell 
cultures were maintained on media containing three different weight arginine 
isotypes.  These cultures were subjected to different conditions, in this example 
Her2 overexpression and tyrosine kinase inhibition.  Cultures were then lysed, 
the lysates combined, and immunoaffinity purified using an antiphosphotyrosine 
antibody.  Purified proteins were trypsinised, then quantitatively assessed by 
liquid chromatography mass spectrometry (LC-MS).  Peptide peaks obtained by 
LC-MS are shifted by the different weight of the arginine residues.  To identify 
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the proteins involved, peptide sequences were compared with protein sequence 
databases.  A scheme for this experiment is shown in Figure 2.A of Bose et al, 
2006.      
 
Thus, one can envisage an experiment where SHSY5Y cells may be treated with 
forskolin or vehicle, then chemical cross linked, and a lysate produced.  DISC1 
interacting proteins may then be immunoaffinity purified using a DISC1 
antibody, trypsinised and quantitatively analysed by LS-MS.  These type of 
experiments could also be used to assess the effect of overexpression of full 
length or mutant proteins, or knock down of proteins, on the composition of 
complexes.   
 
On a smaller scale, the interaction between PDE4s and DISC1 has already been 
assessed by immunoprecipitation with respect to forskolin stimulation.  It would 
be interesting to add GSK3β overexpression and lithium treatment to such an 
experiment.  Unpublished work from our laboratory finds no evidence for 
competitive binding between GSK3β and PDE4B with DISC1, and moreover 
that the GSK3β-DISC1 interaction is weak (Ogawa et al, unpublished). 
 
10. Finally, as detailed in the conclusion of chapter 6, it would be beneficial to 
develop a cellular system that would measure PDE4 activity with increased 
spatial resolution.  As previously discussed, these include genetically encoded 
FRET based cAMP sensors, based on PKA and EPAC proteins and cyclic 
nucleotide gated ion channels (Houslay, 2010).  It may even be possible to 
employ optogenetic techniques to assess cAMP fluctuations and gene expression 
in DISC1 or PDE4 isoform mutant mice, in response to excitation of neurons by 
light responsive microbial opsins (Gradinaru et al., 2007).  The low throughput 
assay system was unable to detect a decrease in PDE4 activity in neurons in 
response to lithium treatment, but it remains unclear as to whether this is because 
it does not occur, because the assay is not sensitive enough to detect a decrease 
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in a low basal rate of activity, or because PDE4 activity changes are a localised 
response compensated for elsewhere in the cell. 
 
This list of potential future directions is clearly not comprehensive, and it is clear that 
this preliminary work asks many more questions than it answers.  These are the 
approaches however, that I believe would be the most informative in the short term, in 
order to direct future research down productive avenues. 
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Supplementary Material 1 - Materials 
S.1 Solutions and buffers 
Below are listed the details for making up all of the solutions for the methods described 
in Chapter 2 – Materials & Methods. 
S.1.1 Poly D-Lysine solution 
Used for coating coverslips and plates prior to primary neuron seeding. 
 25ml  0.3M Borate buffer (Sigma) 
 22.5ml  dH2O 
 2.5ml  500µg/ml Poly D-Lysine (Sigma) 
S.1.2 Dissection Buffer 
Used to dissect foetal mouse brains in primary neuron production.  All reagents from 
Gibco. 
 500ml  HBSS with CaCl2 & MgCl2 
 5ml  L-Glutamate  
 3.5ml  HEPES (cell culture standard, pH7.3-7.5)  
When trypsinising dissected brain tissue, 20mls of TrypLE is added to 30mls dissection 
buffer.  
S.1.3 Neurobasal Medium 
Growth medium for primary neuronal cultures.  All reagents from Gibco. 
 500ml  Neurobasal medium  
 10ml  B27 supplement 
 5ml  GlutaMAX-1 supplement  
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S.1.4 RIPA Lysis Buffer 
Used to lyse cultured cells in preparation for Western blotting. 
 2.5ml  1M Tris-HCL pH 7.5 (Fisher) 
 2.5ml  3M NaCl (Fisher) 
 0.5ml  IGEPAL (Sigma) 
 2.5ml  10% Sodium deoxycholate (Fisher) 
 250µl  20% SDS (Fisher) 
Make up to 50mls with dH2O.  Store at -20
o
C.  Before being used in lysis protease 
inhibitor cocktail (1 tablet dissolved in 2mls dH2O, Roche) must be added at a 
concentration of 1 in 25. 
S.1.5 3T3 Lysis buffer 
To lyse cultured cells and primary neurons for use in phosphodiesterase assays. 
 1.25ml  1M HEPES (Gibco) 
 0.5ml  5M NaCl (Fisher) 
 5ml  0.5M NaFl (Fisher) 
 5ml  Glycerol (Promega) 
 0.5ml  Triton X-100 (Sigma) 
 3ml  0.5M Sodium pyrophosphate (Fisher) 
 50µl  1M DTT (Sigma) 
 625µl  0.2M EDTA (Sigma) 
Make up to 50mls with dH2O.  Store at -20
o
C.  Before being used in lysis protease 
inhibitor cocktail (1 tablet dissolved in 2mls dH2O, Roche) must be added at a 
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S.1.6 Protein Sample Buffer 
To denature proteins and prepare lysates for Western Blotting. 
 6.25ml  1M Tris pH 6.8 (Fisher) 
 10ml  Glycerol (Promega) 
 10ml  20% SDS (Fisher) 
 13.75ml dH2O 
 0.5mg  Bromophenol blue (Sigma) 
Store at room temperature. 
S.1.7 Western blot Running buffer 
To run Western blots on Invitrogen pre poured gels. 
 20ml  20x NuPage Tris Acetate SDS Running Buffer (Invitrogen) 
Make up to 400mls with dH2O just prior to use. 
S.1.8 Western blot transfer buffer 
To transfer Western blots from Invitrogen pre poured gels onto Invitrolon PVDF 
membrane. 
 25ml  20x NuPage Transfer Buffer (Invitrogen) 
 50ml/gel Methanol (Fisher) 
Make up to 500mls with dH2O just prior to use. 
S.1.9 Western Blot Wash buffer 
Used for washing membranes during Western blotting, and for dilution of the secondary 
antibody. 
 100ml  10x PBS (Sigma) 
 900ml  dH2O 
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S.1.10 Ponceau S stain 
To visualise successful transfer of protein to the membrane during Western Blotting 
 1g  Ponceau S (Sigma) 
 4ml  Acetic Acid (Fisher) 
Make up to 200ml with dH2O.  Solution is stored at room temperature, and can be 
reused after staining if returned to an appropriate container. 
S.1.11 Membrane Blocking Buffer 
Membrane blocking buffer is use to block western blots pre staining, and also to dilute 
the primary antibody for application. 
 2.5g  Instant Milk Powder (Marvel) 
 5ml  10x PBS (Sigma) 
 100µl  TWEEN-20 (Sigma) 
Make up to 50ml with dH2O, and store overnight at 4
o
C if required.  Solution should not 
be kept for longer than this. 
S.1.12 Mowiol mounting solution 
Used to mount slides for immunocytochemistry, contains DAPI (Sigma) to visualise 
nuclei and DABCO to decrease fading of staining.  
 7.5g  Mowiol (Sigma) 
 10ml  Glycerol (Promega) 
 25ml  dH2O 
Solution left overnight at room temperature. 
 50ml  0.2M Tris-HCL pH 8.5 (Fisher) 
The resulting solution is boiled to 100
o
C for 20 minutes and left to cool. 
 1.75g  DABCO (Sigma) 
The final solution can be stored at -20
 o
C.  Working aliquots with DAPI added to a final 
concentration of 50µg/ml can be stored at 4
 o
C for up to six months. 
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S.1.13 dNTP mix 
An equal mix of PCR grade ATP, CTP, GTP and TTP (PCR grade, Sigma) were diluted 
to 5mM in 1mM Tris pH 7.5 (Fisher) for use in PCR. 
S.1.14 TBE Buffer (5x) 
Dilute to 0.5x for preparing and running agarose gels. 
 54g  Tris Base (Sigma) 
 27.5g  Boric Acid (Sigma) 
 20ml  0.5M EDTA (Sigma) 
Make up to 1 litre with dH2O.  Store at 4
o
C. 
S.1.15 Stop solution 
Used to load PCR products onto agarose gels for electrophoresis. 
 3g  Ficoll 400 (Sigma) 
 50µl  20% SDS (Fisher) 
 800µl  0.5M EDTA (Sigma) 
 25µg  Orange G (Sigma) 
Make up to 1 litre with dH2O.  Solution was stored at room temperature. 
S.1.16 2xYT medium 
Used to amplify bacterial cultures immediately post transformation. 
 16g  Tryptone (Sigma) 
 10g  Yeast Extract (Sigma) 
 5g  Sodium Chloride (Fisher) 
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S.1.17 L Agar/ampicillin 
L agar is used to prepare plates for selection of transformed E-coli bacteria. 
 50 g  Tryptone 
 25 g  Yeast Extract 
 50 g   Sodium Chloride 
Make up to 5 litres with dH2O, and adjust pH to 7.2.  Pour into a bottle and add 75g of 
Agar.  Store at 4
o
C until use.  Melt at a moderate temperature in a microwave until a 
homogenous clear brown solution is obtained.  Leave to cool until the flask is touchable 
with gloved hands.  Add ampicillin to a final concentration of 50µg/ml, and pour into  
plates immediately. 
S.1.18 L Broth/ampicillin 
L broth is used to amplify bacterial cultures after transformation and growth on L Agar 
plates. 
 50g   Tryptone 
 25g   Yeast Extract 
 25g   Sodium chloride 
Make up to 5 litres with dH2O, and adjust pH to 7.2.  Store solution at 4
o
C.  Immediately 
prior to use add ampicillin to a final concentration of 50µg/ml. 
S.1.19 PDE Assay Tris/Mg2+ buffer 
To dilute tritiated cAMP for PDE assays. 
 400µl  1M TrisHCl pH7.4 (Fisher) 
 200µl  1M MgCl2 (Sigma) 
Make up to 20mls with dH2O and add: 
 40µl  1mM cAMP (Sigma) 
 60µl  [
3
H] cAMP (Perkin Elmer) 
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S.1.20  Dowex Slurry 
The ion exchange resin used in PDE Assays 
 400g   Dowex Mesh CL (Sigma) 
 4l  1M NaOH (Fisher) 
Stir for 15 minutes, then wash 30 times with dH2O until pH7 is reached.  Add: 
 4l  1M HCl (Fisher) 
Stir for 15 minutes, then wash 5 times with dH2O until pH3 is reached.  Store as 1:1 
slurry in dH2O at 4
o
C. 
S.1.21 AlphaScreen control buffer 
Used to generate a cAMP standard curve in AlphaScreen quality control. 
 1ml  10x control buffer (Kit component: 5mM HEPES, 50mM NaCl) 
 100µl  3% Tween-20 (Kit component) 
 8.9ml  dH2O 
Make up immediately before use. 
S.1.22 AlphaScreen Stimulation Buffer 
The agonist/tested drug is diluted in this buffer in the first stage of the AlphaScreen 
assay. 
 35ml  1x indicator free HBSS (Gibco) 
 4ml  1% BSA (Sigma) 
 40µl  500mM IBMX (Sigma) 
 200µl  1M HEPES (Gibco) 
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S.1.23 AlphaScreen Lysis Buffer “Detection mix” 
To contain the donor beads in the second stage of the AlphaScreen assay. 
 17ml  dH2O 
 2ml  1% BSA (Sigma) 
 600µl  10% Tween-20 (Sigma) 
 100µl  1M HEPES (Gibco) 
Adjust to pH 7.4 with 1N NaOH (Fisher).  Prepare immediately before use. 
 
 
 
 
 
